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Summary 
Poly(ADP-ribose) polymerase 1 (PARP1) is an ubiquitously expressed chromatin-associated 
enzyme. It converts NAD+ into poly(ADP-ribose), which is then attached to PARP1 itself or 
to other proteins. Poly(ADP-ribosyl)ation of proteins by PARP1 leads to alterations of 
protein functions, mainly by the negative charge of the ADP-ribose polymers. Thus, proper 
regulation of the enzymatic activity of PARP1 is absolutely required for the cell. PARP1 is 
involved in many cellular processes, such as transcription and maintenance of the genomic 
stability.  
The aim of the thesis was to investigate whether PARP1 is sumoylated and how 
SUMO-modification would possibly influence the function of PARP1 in vitro and in vivo. 
Furthermore, we aimed to explore the ADP-ribosylation of PARP1 and other proteins, such 
as histones.  
 PARP1 was found to be modified by SUMO1 and SUMO3 in vitro, as well as in vivo. 
The sumoylation site was located within the auto-modification domain of PARP1 at lysine 
486. Interestingly, SUMO-modification of PARP1 did not affect its enzymatic activity, but 
instead inhibited the acetylation of adjacent lysines by p300. The sumoylation deficient 
PARP1 K486R mutant exhibited higher acetylation levels in vivo. Furthermore, genetic 
complementation of cells with a SUMO-deficient PARP1-mutant revealed that SUMO-
modification of PARP1 restrained transcriptional co-activator function of certain hypoxia-
inducible genes.  
In addition, the acetylation sites of PARP1, such as lysine 498, 521 and 524, were 
identified as ADP-ribose acceptor sites for the auto-modification of PARP1. This finding led 
to the investigation of ADP-ribose acceptor sites on histones. We found core histones H2A, 
H2B, H3 and H4 to be ADP-ribosylated by PARP1, as well as by PARP10. By site directed 
mutagenesis and mass spectrometry, the site of modification by PARP1 was mapped to 
specific lysines within the N-terminal tails of the core histones.  
 
Taken together, these results reveal that the co-activator function of PARP1 is regulated 
through sumoylation as well as acetylation and that lysine residues functions as ADP-ribose 
acceptor sites within the auto-modification domain of PARP1, but also in core histone tails. 
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Zusammenfassung 
Poly(ADP-ribose) polymerase 1 ist ein ubiquitär exprimiertes chromatin-assoziiertes Enzym. 
Es konvertiert NAD+ zu Poly(ADP-ribose), welche an PARP1 selbst, oder an anderen 
Proteinen gebunden wird. Die Modifikation von Proteinen mit ADP-ribose durch PARP1 führt 
zu Änderungen der Proteinfunktion, hauptsächlich verursacht durch die hohe negative 
Ladung der ADP-ribose-ketten. Für die Zelle ist es daher absolut notwendig eine fehlerlose 
Regulation der enzymatischen Aktivität von PARP1 zu gewährleisten. PARP1 ist involviert in 
vielen zellulären Prozessen, wie zum Beispiel der Transkription und der Aufrechterhaltung 
der genomischen Integrität. 
 Das Ziel dieser Arbeit war es die Rolle von Sumoylierung für die Funktion 
von PARP1 zu finden, als auch die ADP-ribosylierung von PARP1 zu erforschen. 
Es konnte gezeigt werden, dass PARP1 sowohl in vitro als auch in vivo mit SUMO1 
und mit SUMO3 modifiziert wurde. Die Sumoylierung fand an Lysin 486 statt, innerhalb der 
Automodifizierungsdomäne von PARP1. Die SUMO Modifikation hatte interessanterweise 
keinen Einfluss auf die Automodifikation von PARP1 durch ADP-ribose, aber es inhibierte 
die Azetylierung von benachbarten Lysinen von PARP1 durch p300. Ausserdem wies eine 
sumoylierungsdefiziente PARP1 Mutante einen höheren Azetylierungsstatus in vivo auf. 
Eine genetische Komplementation von Zellen mit Sumoylierungsdefizientem PARP1 ergab, 
dass die SUMO-Modifikation von PARP1 die transkriptionelle Ko-aktivatorfunktion bei 
spezifischen Hypoxie induzierten Genen behinderte. 
Weiters wurde gefunden, dass die Lysine 498, 521 und 524 von PARP1 ADP-
ribosyliert werden. Dies führte zur Untersuchung von ADP-ribose Akzeptor Aminosäuren in 
Histonen. Die Histone H2A, H2B, H3 und H4 wurden von PARP1 und PARP10 ADP-
ribosyliert. Durch den Einsatz von Punktmutationen und von Massenspektrometrie konnten 
Lysine am N-terminalen Histonende als ADP-ribose Akzeptor Aminosäuren identifiziert 
werden. 
 
Zusammenfassend zeigen diese Resultate, dass die Ko-aktivatorfunktion von PARP1 durch 
Sumoylierung and Azetylierung reguliert wird und dass Lysine, innerhalb von PARP1, als 
auch im N-terminus von Histonen, ADP-ribose Akzeptorstellen sind. 
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Abbreviations 
 
3-AB   3-amino-benzamide  
ADP   adenosine diphosphate  
ARH  ADP-ribosyl hydrolase 
ARNT  aryl hydrocarbon receptor nuclear translocator 
ASF1  anti-silencing function 1 
ATP   adenosine triphosphate  
BER   base excision repair  
bHLH   basic helix-loop-helix  
BRCT   BRCA1 C-terminus  
CAF-1  chromatin assembly factor 1 
CAIX  carbonic anhydrase 9 
CBP   CREB binding protein  
DNA  deoxynucleic acid 
E2-25K  ubiqitin-conjugating enzyme E2K 
EPO   erythropoietin  
ERK2  extracellular signal-regulated kinase 2 
FIH   factor inhibiting HIF  
HAT   histone acetyl transferase  
HDAC   histone deacteylase  
HIF-1   hypoxia inducible factor 1  
HIRA  histone regulator 1 
HMG   high mobility group  
HMG  high mobility group protein 
HRE   hypoxia response element  
HSF   heat shock factor  
Hsp   heat shock protein  
IKK   IκB kinase  
IκB   inhibitor κB  
LOXL2  lysyl oxidase like protein 2 
LPS   lipopolysaccharide  
MEF2  myocyte enhancing factor 2 
NAD   nicotinamide adenine dinucleotide  
Nap1  nucleosome assembly protein 1 
NF-κB  nuclear factor κB  
ODDD  oxygen dependent degradation domain 
PARG   poly(ADP-ribose) glycohydrolase  
PARP   poly(ADP-ribose) polymerase  
PAS   PER-ARNT-SIM  
PDK1  pyruvate dehydrogenase kinase 1 
PDSM  phosphorylation dependent sumoylation motif 
PHD   prolyl hydroxylase  
Pol II   RNA polymerase II  
PTM   post-translational modification  
RHD   Rel homology domain  
ROS   reactive oxygen species  
SIRT  sirtuin (silent mating type information regulation 2 homolog) 
SUMO  small ubiquitin like modifier 
TBP   TATA-binding protein  
VHL   von Hippel-Lindau disease or protein  
WGR   tryptophan-glycine-arginine motif  
ZF   zinc finger  
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1 Introduction 
1.1 Chromatin and transcription 
The human genome has a size of 3.2x109 nucleotide bases, which would equal 
approximately 2 m in length, if it were not tightly packed. Since each eukaryotic cell 
contains a full copy of the genome, condensation of the DNA is absolutely required. The 
compaction of the DNA is controlled by structural arrangements of the DNA with associated 
proteins, the histones and non-histone proteins, which form together the chromatin (1). 
 
1.1.1 Structural Organization of Eukaryotic Chromosomes 
The most abundant proteins in chromatin are the core histones H2A, H2B, H3, H4 and the 
linker histone H1 (1). They contain many positively charged amino acids, which allows 
them to interact with the negatively charged DNA backbone. The basic structural unit of 
chromatin is the nucleosome (2), which is made of a histone octamer that has 145-147 
base pairs of DNA wrapped around it. This nucleoprotein complex is found every 200 ± 40 
base pairs throughout the genome. The linker region between two nucleosomes can be 
bound by histone H1 and is variable in length (3). Each nucleosome core particle comprises 
a tetramer of H3 and H4 histones and two H2A-H2B dimers. Histones, which are not 
incorporated in the nucleosome, are often associated with chaperones. For example, 
unincorporated H3 is mainly found as dimeric unit with H4, associated with the histone 
chaperones CAF-1 (chromatin assembly factor 1) or HIRA (histone regulator A) within pre-
deposition complexes (4). The H3-H4 heterodimeric complex associates also with the 
histone chaperone ASF1 (anti-silencing function 1) and promotes the nucleosome formation 
in synergy with CAF-1. When chromatin is extracted from nuclei at low salt concentrations, 
isolated chromatin resembles a “beads on a string” conformation. In this extended form, 
the string is composed of free linker DNA, which connects the nucleosomes. At 
physiological salt conditions, nucleosomes fold further into a chromatin fibre of 30 nm 
diameter (1). During cell division this structure can be additionally compacted by 
interaction with scaffolding proteins, to form the characteristic metaphase chromosome 
(5). 
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Although chromatin is highly heterogenous, it can be devided into the relatively 
uncondensed euchromatin, which includes most transcriptionally active regions, and the 
densely packaged heterochromatin. In heterochromatin, histone H1 stabilizes the higher 
order structure and compacts linear DNA overall by a factor of 30-40 (3). Chromatin 
structure imposes significant obstacles to all DNA-related metabolic processes including 
DNA-repair, recombination, replication, transcription and so forth. The dynamics of 
chromatin structure is tightly regulated through multiple mechanisms including chromatin 
remodeling (see chapter 1.1.2), histone modification (chapter 1.1.3) and histone variant 
incorporation (1.1.4).  
 
1.1.2 Chromatin remodeling 
Protein complexes that utilize ATP hydrolysis to alter histone-DNA contacts are generally 
referred to as chromatin-remodeling complexes (6). Upon binding of remodeling complexes 
to the nucleosome, they either slide the nucleosome to a different position, or transiently 
unwrap the DNA from the histone-octamer that enables binding of other protein complexes 
to DNA or facilitates histone exchange. In particular, histone H2A/H2B dimers are rather 
easily removed relative to H3 and H4 (2, 7). Histone eviction was observed upon co-
operative binding of transcription factors (8), chromatin-remodeling complexes such as 
Swi/Snf (9) or actively transcribing RNA Polymerase II (Pol II) (10). Since displaced 
histones can bind to free DNA again, histone chaperones such as Asf1, Nap1 and 
nucleophosmin prevent re-binding of the histones (11-14).  
 
1.1.3 Posttranslational modifications of histones 
Core histones are mainly globular, except for their unstructured N-terminal tails. At least 
eight distinct types of posttranslational modifications (PTMs) have been described for these 
tails. The small chemical modifications, which include lysine acetylation, methylation of 
lysines and arginines and phosphorylation of serines and threonines, are characterized 
best. More complex modifications include proline isomerization, deimination of arginines, 
ubiquitination and sumoylation of lysines and ADP-ribosylation (see also chapter 1.3) (15). 
These modifications influence chromatin structure by regulating the binding of histone tails 
to other less abundant chromatin-associated proteins or to the DNA. 
Given that modifications of histones by PTMs influence local chromatin structure as 
well as the recruitment of chromatin-modifying effectors, a histone code was proposed to 
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explain the correlations between histone PTMs and biological outputs (16-18). The 
hypothesis envisions that combinatorial histone PTMs encode the recruitment of specific 
chromatin-interacting components, which are determinant to a particular biological output, 
such as gene expression. Chromatin-interacting proteins are known to contain motifs which 
recognize and bind specific histone modifications. For example, bromodomains bind 
acetylated proteins and chromodomains interact with methylated proteins (19). 
 
1.1.4 Histone variants  
The general structure of chromatin has been conserved throughout evolution, which is also 
displayed in the amino acid sequence of histone proteins that are very similar between 
species. Nevertheless, in vertebrates minor histone variants have evolved, which can be 
incorporated into the nucleosome to exert specific functions (20). Histone variants differ 
from their more common counterparts only in a few amino acids. Thus, most sites of 
histone modifications are conserved (21) and may not affect nucleosome recognition by 
various chromatin-regulatory proteins. Histone variants can be divided into two major 
classes: replicative variants, which are synthesized in S-phase in a replication-coupled 
manner, whereas replacement forms are expressed either constitutively throughout the cell 
cycle or outside of the S-phase. Histone H2B and H4 are largely invariant, but Histone H2A 
and H3 are more disperse.  
Histone H2A variants can be grouped into the replicative histone variants H2A.1, 
H2A.2 and the replacement histone variants H2Av (H2A.X/H2A.Z), Htz1 (H2A.Z), macroH2A 
and H2ABbd (4). Among these, H2A.X is the best studied histone variant. Upon treatment 
with DNA-double-strand break inducing agents, this variant becomes phosphorylated at its 
C-terminal SQ(E/D) motif (22, 23) and is subsequently named γH2A.X. The phosphorylation 
of H2A.X is crucial for the recruitment of DNA-repair proteins (24). Another H2A variant, 
macroH2A, contains a non-histone macro-domain at the C-terminus and is much larger 
than the canonical H2A (16). MacroH2A-containing nucleosomes are reported to be 
refractory to chaperone-mediated histone exchange, ATP-dependent remodeling, 
transcription factor binding or transcription initiation by Pol II (16, 25). Another histone 
variant, H2A.Z, is enriched at promoters that are poised for transcriptional activation (26). 
H2A.Z containing nucleosomes are resistant to chromatin remodeling and transcription 
elongation-related modifications (27). Therefore, rapid eviction of H2A.Z is needed for full 
transcriptional activation and elongation (28). 
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 Histone H3 variants are grouped into the replicative H3.1 and H3.2 variants and the 
replacement H3.3 and CENP-A variants. CENP-A is the major H3 variant and is specific for 
centromeric chromatin and is essential for centromere function. Other H3 variants, such as 
H3.3, are involved in the regulation of transcription. For example, incorporation and 
removal of histone H3.3 is triggered by transcriptional activation (29) and is enriched in 
active chromatin (30).  
 Since higher order chromatin structure is typically repressive for transcription, the 
above described mechanisms (see 1.1.2 – 1.1.4) ensure chromatin dynamics, which is 
required to allow the transcriptional machinery to access the DNA. Transcription is a highly 
regulated process, which requires the concerted action of transcription factors (see 1.1.5) 
and their co-factors (see 1.1.6), which, in turn, are regulated by posttranslational 
modifications (see 1.3).  
 
1.1.5 Transcription factors 
Transcription factors are regulatory proteins with two basic functions, binding to DNA and 
activation or repression of transcription (31). These functions are often carried out by 
specific structural domains, which are in many cases conserved. One of these domains, the 
DNA-binding domain, is frequently used to classify transcription factors. For example, the 
transcription factor NF-κB belongs to the Rel family, which contain the conserved Rel 
homology domain (32). Another example is the transcription factor HIF-1, which binds DNA 
through a basic helix-loop-helix (bHLH) motif (33), found in a great number of DNA-binding 
proteins. 
In addition to their modular domain structure, transcription factors often form 
homo- and heterodimers (34). On the one hand this facilitates the assembly of a complex, 
which is able to encircle DNA, on the other hand it creates vast combinatorial possibilities 
to regulate the affinity of proteins to specific DNA-sequences (34). Additional regulatory 
steps were described for nuclear import and export, posttranslational modifications, access 
to the binding site and through the use of numerous co-factors that modulate the activity 
of transcription factors. 
 
1.1.6 Transcriptional co-activation and co-repression 
Depending on their function, co-factors are either referred to as co-activators or co-
repressors (31). Co-activators are proteins that dock on transcription factors and increase 
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the accessibility of chromatin-associated DNA for general transcription factors (35). Typical 
co-activators are chromatin-remodeling complexes, mediators or enzymes, which mediate 
histone modifications. Transcriptional co-factors influence transcription without necessarily 
binding DNA to exert their effect.  
The best studied transcriptional co-activators are p300 and CREB binding protein 
(CBP) (36). CBP and p300 function as global transcriptional co-activators for at least 40 
transcription factors (36). They co-activate transcription by different mechanisms. Firstly, 
they have been described as “molecular bridges” that mediate the interaction between 
sequence-specific transcription factors, Pol II and general transcription factors (37). 
Secondly, p300 and CBP serve as protein scaffold for the assembly of other chromatin 
modifying and remodeling complexes that increase the local concentration of co-factors 
around the transcription start sites (36). Thirdly, p300 and CBP acetylate themselves, 
histones and chromatin associated proteins, resulting usually in transcriptional activation 
(15). 
Co-repressors, like co-activators, are multi-protein complexes. They achieve 
repression of transcription by different ways, including competitive binding with a co-
activator to a transcription factor or inducing compaction of the chromatin-structure by 
histone deacetylation (31). A typical co-repressor is the CoREST1/HDAC2/LSD1 complex. 
This multiprotein complex directly deacetylates and demethylates histones, which 
consequently represses gene expression (38). 
 
1.2 Hypoxia 
Oxygen (O2) is essential for the survival of all aerobic organisms. Proper oxygen levels are 
critical for the cell (39). Oxygen plays a crucial role as electron acceptor in the 
mitochondrial respiratory chain, enabling the generation of adenine trisphosphate (ATP) by 
oxidative phosphorylation (39). Disturbance of oxygen homeostasis can be caused by 
several pathologies, such as pulmonary and circulatory diseases. The level of oxygen 
supply depends largely on the distance from the nearest functional blood vessel. Usually, 
cells experience an oxygen level between 2.5% – 9% oxygen within the cell (40, 41). 
Hypoxia is defined as the state of reduced O2 level below normal values (0.5% - 2.5% 
oxygen). Cells survive low levels of oxygen for several hours and only die if they are 
completely deprived of oxygen (anoxia). Hypoxia occurs at various physiological conditions, 
for example in the embryonic development, during adaptation to high altitudes and wound 
healing (40), but also in pathological conditions like ischemic diseases and cancer (42).  
10
  
 
1.2.1 The hypoxia inducible factor (HIF) family of transcription 
factors 
Although hypoxia generally inhibits transcription, a subset of genes is dramatically induced 
(33). The main transcription factor orchestrating the cellular response to low oxygen 
tension is the hypoxia inducible transcription factor (HIF) (33). HIF-1 is a heterodimer that 
consists of the HIF-1α subunit and a constitutively expressed HIF-1β subunit, which is also 
known as aryl hydrocarbon receptor nuclear translocator (ARNT) (39). Both subunits 
belong to the family of the basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domain-
containing transcription factors (43). The bHLH domain mediates the DNA-binding and the 
PAS-domain is responsible for the dimerization of HIF. In addition, HIF-1α contains an O2-
dependent degradation domain (ODDD) and two transactivation domains, including the N-
terminal transactivation domains (NAD) and C-terminal transactivation domain (CAD).  
 
1.2.2 Regulation of the transcriptional activity of HIF 
The gene of HIF-1α is constitutively expressed and can be additionally increased by 
the transcription factor NF-κB, which is induced by LPS and cytokines (41), providing a link 
between hypoxic and innate immune responses.  
The transcriptional activity of HIF-1α is mainly regulated at the posttranslational 
level. In presence of O2, the overall levels of α-subunits are low, as a consequence of their 
rapid degradation by the proteasome. This degradation is a complex process and is 
initiated by the activity of the O2-sensor prolyl hydroxylase domain protein (PHD). Proline 
hydroxylation by PHDs depends on the presence of the PHD co-factors oxygen, the co-
substrate 2-oxoglutarate from the citric acid cycle, plus the co-factors Fe(II) and ascorbate 
(44, 45). In the presence of oxygen, PHDs hydroxylate HIF-1α at proline 402 and 564. The 
hydroxylated prolines are recognized by the von Hippel-Lindau (VHL) protein. This E3-
ubiquitin ligase complex consists of elongin B, elongin C and cul2 and transfers ubiquitin to 
HIF-1α, which leads subsequently to proteasomal degradation of HIF-1α.  
Under hypoxic conditions, PHD`s are inactive due to low oxygen levels and cannot 
hydroxylate HIF-1α, which leads to the stabilization of HIF-1α. Once HIF-1 protein is 
stable, it translocates to the nucleus, where it forms a heterodimer with HIF-1β and 
subsequently binds to the hypoxia response element (HRE) of its target genes. HIF-1α 
contains a N-terminal activation domain (NAD) and a C-terminal activation domain (CAD), 
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which act synergistically. Besides the above described O2-dependent degradation 
mechanism, regulation of the HIF-1α CAD association with CBP/p300 is the second 
molecular switch controlling transcriptional activity of HIF-1 (46). The accessibility of the 
CAD for CBP/p300 is regulated through asparagine hydroxylation of HIF-1α by FIH-1 
(factor inhibiting HIF-1) (47). Additionally, competition among transcription factors for 
CBP/p300 co-activator binding can also play a role, as shown for the transcription factor 
p53, which sequesters CPB/p300 from HIF-1 (48), leading to decreased HIF-1α target gene 
expression. In addition, posttranslational modifications of HIF-1α, such as acetylation (49) 
or sumoylation (50) modify the transcriptional activity of HIF-1α at the promoter (see also 
1.3).     
 
In summary, HIF-1α dependent gene expression is a rather complex mechanism that 
involves I) the regulation of HIF-1α mRNA levels; II) the regulation of HIF-1α protein 
stability; III) the regulation of transcriptional activation of HIF-1 at the promoter through 
FIH-1; and IV) the co-activation of HIF-1α dependent gene expression through different 
co-activators, such as CPB/p300. 
 
1.2.3 Three examples for HIF-1 mediated responses to hypoxia 
Mid- and long-term adaptations to hypoxic conditions are mediated through the expression 
of genes that are induced by HIF-1α. For example, HIF-1α induces the expression of 
pyruvate dehydrogenase kinase (PDK1) (42). PDK1 phosphorylates and inactivates the 
catalytic subunit of the pyruvate dehydrogenase (PDH), which results in the preferential 
conversion of pyruvate to lactate rather than to acetyl-CoA (51, 52). This leads to a 
reduction in oxidative phosphorylation and results in decreased ATP-production, a hallmark 
of hypoxia (39). The importance of PDK1 for the survival of hypoxia was demonstrated by 
overexpression of PDK1, which was sufficient to reduce ROS levels and prevented cell 
death (42). 
Tumor cells experiencing prolonged hypoxia, decrease their pH both by production of 
lactic acid (due to the high glycolysis rates) and by CO2 hydration catalyzed by the HIF-1α 
target gene carbonic anhydrase IX (CAIX) (53). Carbonic anhydrases catalyze the 
conversion of CO2 to bicarbonate and protons and can thus be involved in the regulation of 
intracellular pH. They also secrete and export protons from cells and contribute additionally 
to acidosis, a hallmark of chronic hypoxia in solid tumors. The upregulation of CAIX is 
currently used as prognostic biomarker of tumor hypoxia (54). High expression of CAIX 
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correlates with poor survival. Increased levels of CAIX expression are seen in a high 
proportion of cervical carcinomas, kidney carcinomas and, to a lesser degree, in other 
types of human tumors, such as carcinomas of the breast, head, neck and lung, as well as 
tumors of the brain (54).  
Another poor prognosis marker for the survival is the HIF-1 mediated increased 
expression of lysyl oxidase proteins (LOX) (55). These proteins were originally discovered 
to play a key role in the biogenesis of the connective tissue by catalyzing the crosslinking-
formation in collagen and elastin (56). LOXL2 belongs to the four members of the lysyl-
oxidase like proteins and was initially found to promote the invasiveness of tumors in vivo 
and in vitro (57). LOXL2 expression was upregulated in breast, colon, oesophageal, 
pancreatic, prostatic, head and neck squamous cell carcinoma (HNSCC) cell lines (58). 
More recently, it has been shown that LOXL2 interacts with the transcription factor snail, 
which promotes epithelial-mesenchymal transition and thus promotes, at least partly, the 
malignant progression of cancer cells (59).  
 
1.3 Posttranslational modifications  
Posttranslational modifications (PTMs) occur after the translation of a protein to regulate 
the protein functions (1). PTMs can be divided into several classes. Firstly, proteins can be 
altered by the addition of small functional groups, such as acetylation, phosphorylation 
(60), various lipids (61) and carbohydrates (62). Secondly, proteins can be modified by the 
addition of other polypeptides, examples include ubiquitination, neddylation, ISGylation 
and SUMOylation (63-65). Thirdly, the amino acids of proteins can be conversed to other 
amino acids by removal of terminal groups. An example for this modification is the 
conversion of arginine to citrulline by deimination (66). Finally, PTMs can involve large 
structural changes, like racemization of proteins by prolyl isomerization. Another example 
for the induction of a structural change is the proteolytic cleavage of proteins, such as the 
maturation of insulin by cleavage of its own precursor by site-specific endopeptidases, 
allowing the generation of active insulin (67).  
 
1.3.1 Sumoylation 
SUMO (small ubiquitin like modifier) polypeptides are approximately 10 kDa in size and 
resemble the three-dimensional structure of ubiquitin (68). They share only 20% sequence 
identity to ubiquitin and differ in their overall surface-charge distribution. In contrast to 
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ubiquitin, all SUMO polypeptides contain an unstructured stretch of 10-25 amino acids at 
their N-termini. The human genome encodes four SUMO proteins (SUMO1-4). SUMO1-3 are 
ubiquitously expressed, whereas SUMO4 is expressed in a tissue specific manner (69) and 
is less well-studied (64). While the mature form of SUMO2 and SUMO3 are 97% identical, 
they share only 50% sequence homology with SUMO1 (64). Furthermore, SUMO1 is mainly 
attached as monomeric unit to substrate proteins in vivo, whereas SUMO2 and SUMO3 are 
able to form poly-SUMO chains. Based on the low sequence homology and the different 
expression patterns of SUMOs, it is not surprising that SUMO1 and SUMO2/3 are 
conjugated to different target proteins in vivo and exert distinct functions (70-72) 
The reversible cycle of SUMO conjugation and de-conjugation of target proteins is 
described in Fig. 2. It is similar to the ubiquitin conjugation and involves the activation of 
the SUMO-precursor (1), conjugation to a SUMO E1-activating enzyme (2), transfer to the 
SUMO E2-conjugating enzyme (3) and finally the transfer of SUMO to a lysine residue of a 
target protein, often with the help of a SUMO E3-ligase (4). Finally, the SUMO moiety can 
also be cleaved off from the target protein by SUMO proteases (5) (73). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: SUMO proteins undergo post-translational maturation, catalyzed by Ulp/SENPs, to reveal a C-terminal 
di-glycine motif (Step 1). Mature SUMOs undergo ATP-dependent activation, resulting in a thiolester linkage 
between the C-terminal di-glycine and their activating enzyme, Uba2/Aos1 (Step 2). The thiolester is transferred 
to their conjugating enzyme, Ubc9 (Step 3). Ubc9 acts in concert with SUMO ligases/E3 enzymes to form an 
isopeptide linkage between the SUMO C-terminus and an ε-amino group of a lysine within the target protein 
(Step 4). SUMOs can be removed from conjugated species by the action of Ulp/SENPs (Step 5). In some cases, 
SUMO chains can be formed through linkage of additional SUMO moieties to previously conjugated SUMOs (Step 
6). While it is possible that multiple Ulp/SENPs may disassemble SUMO chains (Step 7), members of the Ulp2 
family appear to be specialized for this reaction. Adapted from (73). 
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Many proteins are sumoylated at a SUMO-consensus motif, which has been shown to 
resemble the amino acid sequence ΨKxE (in which Ψ is an aliphatic branched amino acid 
and x is any amino acid) (74). The SUMO E2 enzyme Ubc9 recognizes this sequence and 
transfers the SUMO-moiety onto a lysine residue of a substrate protein. Extensions of the 
SUMO-consensus motif have been described. For example, for the phosphorylation-
dependent sumoylation motif (PDSM), the classical SUMO consensus motif is followed by a 
phosphorylated serine and a proline residue. This extended motif is found in heat shock 
factor-1 (HSF1), MEF2 and several other proteins (75). However, some SUMO acceptor 
sites have been reported not to contain any of the described motifs, such as K14 in human 
E2-25K (76). In addition, a non-covalent SUMO interacting motif (SIM) was identified, 
which contains a hydrophobic core, flanked by acidic and/or serine residues (77). The 
functional consequences of sumoylation are diverse and depend on the modified protein. In 
most cases, sumoylation creates new interaction surfaces or covers existing ones (64).  
An increasing number of papers report regulation of sumoylation by cellular 
stresses and suggest an important role for this modification in cellular response to 
environmental cues. Along this line, heat shock increases global sumoylation levels 
dramatically (70), as shown for the elevated SUMO modification of more than 700 proteins 
(78). Another cellular stress that induces global sumoylation is hypoxia. Elevated 
transcription of the SUMO1 gene starts within 4-8 hours after hypoxia and correlates with 
increased levels of protein sumoylation after hypoxia (79, 80). For example, the 
transcription factor HIF-1α is sumoylated by SUMO1 upon hypoxic induction. The 
consequences of this increase in HIF-1α sumoylation are still a matter of debate (50). In 
some reports, sumoylation of HIF-1α leads to its stabilization and increased transcriptional 
activation of target genes (81, 82). In another study, however, sumoylated HIF-1α is 
degraded by the VHL ubiquitin ligase complex and only a low level of active HIF-1α is 
maintained during hypoxia through the SUMO-deconjugation of HIF-1α by the SUMO-
protease SENP1 (83). A different mechanism of HIF-1 regulation by sumoylation was 
described recently (84). In this study, modest reactive oxygen species (ROS) levels induced 
SENP3 (Sentrin specific protease 3) translocation from the nucleolus to the nucleus (84). 
Once in the nucleus, SENP3 desumoylates p300, which enables complex formation between 
p300 and HIF-1α, thus leading to transcriptional activation of HIF-1 target genes. 
1.3.2 Acetylation 
Lysine acetylation is an ancient reversible PTM that is conserved from prokaryotes to 
humans (85). The transfer of an acetyl-group from acetyl-coenzyme A (CoA) onto the ε-
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amino-group of the target lysine neutralizes the positive charge of the lysine (Fig. 1). The 
acetylation impairs the ability of lysines to form hydrogen bonds with other amino acids, 
thereby affecting protein-protein, protein-DNA and protein-RNA interactions (86).  
 
 
 
 
 
 
 
 
 
Figure 1. ε-N-lysine acetylation. Transfer of an acetyl group from acetyl-coenzyme A (CoA) onto the ε-N-group 
of a lysine residue in protein x by histone acetyltransferases (HAT). The reverse reaction is catalyzed by histone 
deacetylases (HDAC) and removes the acetyl-group. Adapted from (60). 
 
Acetylation is known to regulate different nuclear processes, such as transcription through 
acetylation of histone proteins, which loosens the chromatin structure and thus often 
correlates with activated gene expression. Upon initiation of transcription, activators recruit 
histone acetyltransferases (HATs) to acetylate gene-specifically the chromatin and enhance 
transcription, while repressors, such as histone deacetylases (HDACs), deacetylate histones 
and inhibit transcription. Histone acetylation also regulates other nuclear processes, such 
as DNA replication, recombination and repair (15). 
Histone acetyltransferases catalyse the acetylation of lysine residues. Dozens of 
proteins with HAT activity have been described so far. HATs can be divided into two 
groups: the cytoplasmic B-type HATs and nuclear A-type HATs. In general, nuclear HATs 
are associated with transcriptional activation and are present in euchromatin. Lysine 
acetyltransferases are classified into different superfamilies, such as the superfamily of 
Gcn5/PCAF, p300/CBP and the MYST protein containing complexes. While Gcn5/PCAF and 
p300/CBP histone acetyltransferases mainly function as transcriptional co-activators, 
emerging evidence suggests that MYST proteins, such as Esa1, Sas2, MOF, TIP60, MOZ 
and MORF, play diverse roles in various nuclear processes (87). As for example, 
mammalian Tip60 plays an important role in apoptosis and DNA repair (88, 89). Most of 
the histone acetyltransferases were first shown to acetylate histones (Table 1), but later 
HATs have been shown to acetylate non-histone proteins as well.  
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Acetyltransferase Residues modified 
HAT1 H4 (K5, K12) 
CPB/p300 H3 (K14, K18), H4 (K5, K8), H2A (K5), H2B (K12, K15) 
PCAF/GCN5 H3 (K9, K14, K18) 
Tip60 H4 (K5, K8, K12, K16) 
HB01 (ScESA1, SpMST1) H4 (K5, K8, K12) 
ScSAS3 H3 (K14, K23) 
ScRTT109 H3 (K56) 
ScSAS2 (SpMST2) H4 (K16) 
Deacetylase  
SIRT2 H4 (K16) 
 
Table 1: HATs and HDACs that modify histones. Only enzymes with specificity for one or a few sites have been 
included in the table, along with the sites they modify. Human and yeast enzymes are shown. The yeast 
enzymes are distinguished by a prefix: Sc (Saccharomyces cerevisiae) or Sp (Saccharomyces pombe). Adapted 
from (15). 
 
Histone deacetylases remove the acetyl group from acetylated proteins (87). The 
activity of HDACs is tightly controlled through protein-protein interactions and 
posttranslational modifications (90). With the exception of one HDAC (HDAC8), functional 
HDACs are never found as single monomeric polypeptides, but are rather found in high 
molecular weight multi-protein complexes. They often associate with specific co-regulators 
as well as with other chromatin modifying enzymes (90). Mammalian histone deacetylases 
are divided into four classes.  
Class I HDACs consist of the members HDAC1-3 and HDAC8. They are part of the 
ubiquitously expressed mSin3A, NURD/Mi2/NRD and CoREST co-repressor complexes (91). 
Class II HDACs are further divided according to their sequence homology and 
domain organization into the subclass IIa (HDAC4, 5, 7, 9) and IIb (HDAC6, 10). Class IIa 
HDACs are characterized by tissue specific expression and stimulus-dependent nucleo-
cytoplasmic shuttling. Class IIb HDACs are distinct to class IIa due to a duplication of the 
catalytic domain (90). 
Class III HDACs are named Sir2-like proteins or SIRTs. These proteins represent 
NAD+-dependent deacetylases (SIRT1-7). They participate in a wide range of cellular 
processes including DNA-repair and determination of life span (92). SIRT1 deacetylates 
transcription factors, such as PGC-1α, FOXO1 and TORC2 (93), which are important in cell 
metabolism and implicated in aging. SIRT2 activity is necessary for proper cytokinesis and 
inhibition of SIRT2 was protective in a Drosophila model of Parkinson’s disease (93). SIRT6 
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deacetylates H3 at lysine 9, which is implicated in maintenance of the genomic integrity 
(94). Additionally, SIRT6 was shown to possess auto-ADP-ribosylation activity (95).  
Finally, class IV is represented by HDAC11, which is phylogenetically different from 
both class I and class II HDACs and is therefore regarded as separate class (90).  
 
1.3.3 Crosstalk of sumoylation with acetylation  
Since sumoylation and acetylation both target lysine residues, they might compete for the 
same residue. Modification of the same residue was observed for transcription factor Sp3 
(96) and for the transcriptional co-activator p300. Deacetylation of p300 by SIRT1 is 
required for efficient sumoylation at the same lysine residue (97). It is currently not 
known, whether lysine acetylation frequently overlaps with SUMO acceptor sites (98). 
Additionally, an interplay between acetylation, sumoylation and phosphorylation was 
observed for the transcription factor MEF2A. Dephosphorylation of serine 408 in MEF2A, 
which is located in the phosphorylation dependent SUMO-motif (PDSM), results in a switch 
from sumoylation to acetylation at lysine 403 of MEF2A (99). Consequently, sumoylation of 
MEF2A is inhibited not only by the lack of a phosphate on serine 408, but also by direct 
competition of acetylation and sumoylation for lysine 403. Surprisingly, it has been 
observed that HDAC4 enhances sumoylation of a variety of substrates (100-102), such as 
MEF2 (103). However, deacetylation of the lysine residue within the SUMO-consensus site 
of MEF2 is not catalyzed by HDAC4, but rather by SIRT1 (103).  
 
1.4 Poly(ADP-ribose) polymerase 1 (PARP1) 
1.4.1 Structure of PARP1 
PARP1 is a chromatin associated, ubiquitously expressed enzyme (104). It converts NAD+ 
into poly(ADP-ribose), which is then attached to PARP1 itself or to other proteins (105). 
PARP1 contains two zinc fingers at the N-terminus that were reported to bind to various 
DNA strand breaks (Fig. 3). Recently a third zinc finger within the DNA binding domain was 
discovered (106). The BRCT domain is named after the Breast Cancer Suppressor Protein-1 
(BRCA1) carboxy-terminal domain and is found within many DNA damage, DNA repair and 
cell cycle checkpoint proteins (107). The WGR domain belongs to the catalytic domain and 
is named after the most conserved central motif (W/G/R) of the domain. The WGR is found 
in a variety of polyA polymerases and other proteins of unknown function (108). The 
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Diphtheria toxin-related catalytic domain of PARP1 is responsible for the formation of 
poly(ADP-ribose). By site directed mutagenesis it was revealed, that glutamic acid 
residue 988 in the catalytic core of PARP1 is important for the formation of ADP-ribose 
polymers (109). Mutation of gluatamic acid 988 to a lysine severly impaired PARP1´s 
enzymatic activity. The mutant displayed only very weak mono(ADP-ribosyl)ation 
activity and completely lacked poly(ADP-ribose) formation activity (109). 
 
 
 
 
 
 
 
 
 
Figure 3: Domain structure of human PARP1. DBD: DNA-binding domain; AD: Auto-modification domain; FI-FIII: 
Zincfinger I-III; NLS: Nuclear localization signal; CAT: catalytic domain; BRCT: BRCA1 C-terminal domain; WGR: 
named after the central W/G/R motif.  
 
PARP1 is the founding member of the PARP family, which consists of PARP1-6. They are 
characterized by the presence of an active site glutamate in the catalytic core domain. In 
addition to the 6 PARP members, 11 new PARP-like genes have been identified (108), all 
sharing the characteristic catalytic domain, but not the conserved glutamate E988 of 
PARP1. Although no poly(ADP-ribosyl)ation has been described for them, some are able to 
catalyze mono(ADP-ribosyl)ation (104). 
 
1.4.2 The poly(ADP-ribosyl)ation cycle 
Poly(ADP-ribosyl)ation is observed in multicellular eukaryotes only, and is characterized by 
the formation of long chains of ADP-ribose, linked by a glycosydic bond (104). The 
enzymatic activity of PARP1 is highly activated by DNA-strand breaks (110). Furthermore, 
PARP1 was reported to be activated in a DNA-independent manner by phosphorylated ERK2 
(extracellular signal-regulated kinase 2) (111). PARP1 is able to synthesize poly(ADP-
ribose) and mainly modifies itself, but also other proteins such as histones, high-mobility-
group (HMG) proteins and several enzymes involved in DNA metabolism (104). Poly(ADP-
ribosyl)ation alters the physical properties of target proteins, since the polymers are highly 
negatively charged and very bulky.  
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At least three distinct enzymatic activities were postulated to be required for the 
synthesis of free or protein-associated linear and branched poly(ADP-ribose) (108). I) 
Initiation: covalent auto-mono(ADP-ribosyl)ation or mono(ADP-ribosyl)ation of a substrate 
protein, which serves as initiator site for poly(ADP-ribosyl)ation; II) Elongation: involves 
the catalysis of a 2’-1’’ glycosydic bond, whereby the covalently bound mono(ADP-ribose) 
from the initiation serves as acceptor site; and III) Branching: occurs on average after 20 
ADP-ribose units.  
The major fraction of PARP1-generated poly(ADP-ribose) has a half-life as low as 1 
min while the residual fraction has a half-life of 6-10 min (108). The release of the 
enzyme-bound branched poly(ADP-ribose) is either mediated through intrinsic poly(ADP-
ribosyl)protein-hydrolase activity of PARP1, or through poly(ADP-ribose) glycohydrolase 
activities, most likely mediated by poly(ADP-ribose) glycohydrolase (PARG). PARG is 
located in the nucleus and possesses both endoglycosidase and exoglycosidase activities 
(108), which are responsible for the hydrolysis of glycosydic ribose-ribose bonds within the 
polymer and at the end of the ADP-ribose chain, respectively. Branched and short polymers 
are more slowly degraded by PARG than long and linear poly(ADP-ribose) polymers.  
Mammalian cells contain several different PARG-like genes. For example, ARH1 
(ADP-ribose-arginine protein hydrolase 1) has been described to hydrolyze the ADP-ribose-
arginine bond, thus generating free mono(ADP-ribose) (112). However, the closely related 
enzyme ARH3 possesses no arginine-ADP-ribose hydrolyzing activity, but instead displays 
PARG like activity, which leads to the degradation of poly(ADP-ribose) (113, 114). Of note, 
ARH1 and ARH3 are mainly located in the cytoplasma and on the cell surface and are 
therefore postulated not to be responsible for degradation of PARP1-generated poly(ADP-
ribose).  
 
1.4.3 PARP1 knockout mice 
Several PARP1 knockout (PARP1-/-) mouse models have been generated (115, 116).  
PARP1-/- mice are viable and fertile and show some interesting stress-phenotypes (117). 
Among these, PARP1-/- mice are protected against cerebral ischemia (118). Cerebral 
ischemia is characterized by insufficient blood flow in the brain, which causes brain 
damage. In mouse models of ischemia-reperfusion, which is characterized by tissue 
damage through restricted blood flow and subsequent reperfusion of the tissue (119), 
PARP1-/- mice showed a protected phenotype (120). PARP-/- mice were also reported to be 
protected against streptozotocin induced diabetes (121, 122). Streptozotocin is a toxic 
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substance that induces pancreatic beta cell death and is used to mimic type-1 diabetes in 
animal models (123). Another protective phenotype was observed when PARP1-/- mice were 
treated with high doses of lipopolysaccharides (LPS). Most of the PARP1-/- mice survived, 
whereas their wild-type counterparts died of a septic shock (124, 125).  
 
1.4.4 PARP1 and transcription 
PARP1 is localized in the nucleus and specifically enriched in MCF-7 cells at the promoters 
of approximately 90% of Pol II transcribed genes (126). The accumulation of PARP1 to 
actively transcribed promoters may occur as a consequence of the transcription process, 
for example recruitment of PARP1 to histone modifications, recruitment to oxidized or 
cleaved promoter DNA or special DNA structures (127, 128). Based on this localization, 
PARP1 could exert stimulatory or inhibitory effects on transcription. Global transcription 
analysis by microarray techniques of PARP1-/- mice compared to wild-type mice revealed 
that approximately 3.5% of the transcriptome in embryonic cells is regulated by PARP1, 
with approximately 60-70% of the genes being positively regulated (129). These genes 
encode for proteins involved in metabolism, stress response, signal transduction, cell cycle 
control and transcription. Multiple molecular modes of transcriptional regulation by PARP1 
have been proposed (reviewed in (130)). Firstly, PARP1 can modulate chromatin structure 
by binding to nucleosomes, modifying histones, or regulating the composition of chromatin 
(131-133). Secondly, PARP1 can act as an enhancer-binding factor where it may bind to 
specific sequences or structures in the DNA (134, 135). Thirdly, PARP1 can act as a 
classical co-activator or co-repressor by binding and stabilizing the general transcription 
factors, the pre-initiation complex and/or specific transcription factors, to induce gene 
expression (111, 136-139). Fourthly, PARP1 can act as a component of insulators, which 
act to limit the effects of enhancers on promoters or by preventing the spread of 
heterochromatin (140). One can imagine that all these modes act either independently, or 
work in concert with each other. In summary, all of these possibilities may contribute to 
ensure proper tissue- and signal-specific gene expression. 
The resistance of PARP1-/- mice to LPS-induced septic shock is most probably due 
the impaired induction of NF-κB dependent genes in PARP-/- mice (136). This is consistent 
with the notion that PARP1 acts as classical co-activator of NF-κB induced gene expression 
(136). Co-activation of NF-κB by PARP1 depends on the acetylation of PARP1 by p300 at 
specific lysine residues (lysines 498, 505, 508, 521 and 524). Acetylation of PARP1 
facilitates its interaction with NF-κB and enables the induction of NF-κB dependent gene 
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expression (137). In addition, HDAC1, 2 and 3 were shown to deacetylate PARP1, which 
abrogated PARP1 dependent NF-κB interaction (137, 141). 
 
1.4.5 PARP1 and DNA-repair 
Since the enzymatic activity of PARP1 has been shown to be induced 10-500 fold by 
ionizing radiation, alkylating agents or oxidative stress, it has been suggested that PARP1 
is a sensor of DNA-damage (105). Indeed, PARP1 is able to recognize DNA lesions by its 
DNA-binding domain, which initiates auto-modification of PARP1 (105, 142). It has been 
proposed that PARP1 influences DNA damage signalling by the recruitment of DNA-repair 
proteins to the DNA lesion through auto-poly(ADP-ribosyl)ation (143). In addition, PARP1 
was reported to relax chromatin through poly(ADP-ribosyl)ation of histones and thus to 
facilitate access to sites of DNA-damage (133, 144, 145). However, no direct evidence for 
the involvement of PARP1 in the execution of DNA-repair was demonstrated so far (146). 
Interestingly, PARP1-mediated poly(ADP-ribosyl)ation recruits the histone variant 
macroH2A1.1 to sites of DNA-damage, which transiently compacts chromatin and reduces 
recruitment of DNA damage factors Ku70-Ku80 (147). 
1.4.6 PARP1 and cancer 
A hallmark of cancer is the accumulation of mutations in the DNA, which can lead to 
aberrant expression of important proteins. Since PARP1 has been suggested to play a key 
role as DNA-damage sensor (see 1.4.5), it has been proposed that the activity of PARP1 
would be beneficial for the prevention of cancer. Indeed, PARP1-/- mice appear to be 
sensitive to alkylating agents (148). For example, double knockout mice for PARP1 and 
p53, but not the corresponding single knockout mice develop spontaneously brain tumors 
(149). In contrast, a different strain of PARP1-/-/p53-/- mice shows in general attenuated 
tumor formation (150). In agreement with a protective role of PARP1 for tumor formation, 
PARP inhibitor treatment of mice suppresses tumorigenesis in TPA-induced skin cancer 
model (151). These contradictions could be explained by differences between various 
cancer types and the fact that PARP1 has several cellular functions, which could differently 
contribute to cancer formation (110, 152). Several PARP inhibitors are currently evaluated 
in clinical trials (153-155). They are used, in particular, for the treatment of tumors with 
BRCA1 or BRCA2 deficiency, since PARP inhibitors were reported to induce synthetic 
lethality in these cell lines (156, 157). In addition to BRCA1/BRCA2 deficient tumor cells, 
also cell lines with mutated PTEN (phosphatase and tensin homolog) show comparable 
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sensitivity towards PARP inhibitors (158), further broadening the potential use of PARP 
inhibitors in the treatment of cancer.  
 
 
23
  
2. Aim of the thesis 
PARP1 is an ubiquitously expressed, chromatin-associated protein and involved in many 
cellular processes. Understanding the regulation of its cellular function is of particular 
interest. One possible way to regulate the function of PARP1 is through posttranslational 
modifications, such as sumoylation, acetylation or ADP-ribosylation.  
The aim of the thesis was to investigate whether PARP1 is sumoylated and how 
SUMO-modification would possibly influence the function of PARP1 in vitro and in vivo. 
Furthermore, we aimed to explore the mechanism of ADP-ribosylation by PARP1 and other 
proteins, such as histones.  
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ABSTRACT Poly(ADP-ribose) polymerase 1 (PARP1)
is a chromatin-associated nuclear protein and functions
as a molecular stress sensor. At the cellular level,
PARP1 has been implicated in a wide range of pro-
cesses, such as maintenance of genome stability, cell
death, and transcription. PARP1 functions as a tran-
scriptional coactivator of nuclear factor !B (NF-!B)
and hypoxia inducible factor 1 (HIF1). In proteomic
studies, PARP1 was found to be modified by small
ubiquitin-like modifiers (SUMOs). Here, we character-
ize PARP1 as a substrate for modification by SUMO1
and SUMO3, both in vitro and in vivo. PARP1 is
sumoylated at the single lysine residue K486 within its
automodification domain. Interestingly, modification
of PARP1 with SUMO does not affect its ADP-ribosy-
lation activity but completely abrogates p300-mediated
acetylation of PARP1, revealing an intriguing crosstalk
of sumoylation and acetylation on PARP1. Genetic
complementation of PARP1-depleted cells with wild-
type and sumoylation-deficient PARP1 revealed that
SUMO modification of PARP1 restrains its transcrip-
tional coactivator function and subsequently reduces
gene expression of distinct PARP1-regulated target
genes. Messner, S., Schuermann, D., Altmeyer, M.,
Kassner, I., Schmidt, D., Scha¨r, P., Mu¨ller, S., and
Hottiger, M. O. Sumoylation of poly(ADP-ribose) poly-
merase 1 inhibits its acetylation and restrains transcrip-
tional coactivator function. FASEB J. 23, 000–000
(2009). www.fasebj.org
Key Words: NAD ! SUMO ! hypoxia ! PARP-1
Poly(ADP-ribose) polymerase 1 (PARP1) is an abun-
dant nuclear chromatin-associated multifunctional en-
zyme found in higher eukaryotes that belongs to a
family of 5 “bona fide” PARP enzymes (1). PARP1 has an
amino-terminal DNA-binding domain (DBD) contain-
ing 3 zinc finger motifs, as well as a central automodi-
fication domain (AMD), which functions as a target of
direct covalent automodification. The carboxyl-termi-
nal catalytic domain polymerizes linear or branched
chains of ADP-ribose from the donor nicotinamide
adenine dinucleotide (NAD!). ADP-ribose is mainly
attached on PARP1, but also other proteins are modi-
fied (2). Together, the DBD and the automodification
domain allow PARP1 to interact with genomic DNA
and chromatin. Although originally characterized as a
key factor in DNA single strand-break repair, a wealth
of studies over the past decade have demonstrated a
role of PARP1 in the regulation of gene expression
under basal, signal-activated, and stress-activated condi-
tions (1, 3). Recent studies have highlighted the role of
PARP1 in distinct modes of transcriptional regulation
and provided novel insight into the cellular signaling
systems that interface with PARP1 in the nucleus (4).
The basal enzymatic activity of PARP1 is very low, but
it is stimulated dramatically under conditions of cellu-
lar stress (2, 3). Activation of PARP1 results in the
synthesis of poly(ADP-ribose) (PAR) from NAD! and
the release of nicotinamide as a reaction by-product
(1). Following PARP1 activation, intracellular PAR lev-
els can rise 10- to 500-fold (1), caused by a mechanism
that remains to be resolved. Very recently, we identified
3 lysine residues in the automodification domain of
PARP1 as acceptor sites for auto-ADP-ribosylation (5).
PARP1 is the main acceptor for poly(ADP-ribosyl)ation
in vivo, and automodification of PARP1 abolishes its
affinity for NAD! and DNA (5). Remarkably, the same
3 ribosylated lysines (K498, K521, K524) were previ-
ously identified as targets for acetylation by the histone
acetyltransferase p300 (6). Acetylation of PARP1 has
been reported to be important for its transactivation
activity (6). Recently, we also highlighted the role of
PARP1 as a transcriptional coactivator of hypoxia in-
ducible factor 1-" (HIF1-"). On hypoxic induction of
cells, PARP1 was shown to interact with HIF1-" and to
regulate the transcriptional activity of HIF1-"-depen-
dent genes (7).
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Another post-translational protein modification in
response to cellular stresses is the conjugation of small
ubiquitin-like modifiers (SUMOs) (8). SUMOs regulate
diverse cellular processes, including cell-cycle progres-
sion, genome stability, intracellular trafficking, and
transcription (9, 10). In many cases, SUMO conjuga-
tion alters localization and/or activity of the substrate
by providing a new protein-protein interaction inter-
face. However, in certain cases, SUMO modification
can also prevent distinct protein-protein interactions.
Mammalian cells express three SUMO paralogs:
SUMO2 and SUMO3, which are 96% identical and only
differ by three N-terminal residues, and SUMO1, which
is 45% identical to SUMO2/3. Moreover, SUMO2/3
proteins are able to form chains, which SUMO1 cannot
(11). Although virtually all of the SUMO1 is engaged in
conjugates, there is a free pool of the more abundant
SUMO2/3 that is utilized when cells are stressed by
heat shock or ethanol exposure (12). It is clear that
proteins can be modified selectively by SUMO1 and
SUMO2/3. Growing evidence suggests that SUMO2/3
and SUMO1 have some unique biological functions
(12–14).
SUMO family proteins are conjugated to target ly-
sines via a cascade of the E1-activating enzyme (SAE1/
SAE2), the E2-conjugating enzyme Ubc9, and E3
SUMO ligases (8, 10). The SUMO E2 protein Ubc9
often recognizes the consensus sequence #KxE/D
(where # is a large hydrophobic amino acid, such as
isoleucine or valine, and x is any amino acid) in the
target protein and catalyzes SUMO conjugation (8).
Generally, sumoylation with SAE1/SAE2 and Ubc9 only
is rather inefficient, and additional proteins known as
SUMO E3 ligases are often required to accelerate this
reaction (10). A family of deconjugation enzymes,
SENPs, is responsible for the removal of SUMO from
target lysines (15), which accounts for the transient
nature of this modification. In human cells, six mem-
bers of this family (SENP1-3 and SENP5-7) have been
identified. Importantly distinct members exhibit para-
log specificity and show a characteristic subcellular
localization, indicating that spatial control is an impor-
tant regulatory concept of SENP activity.
Several proteomic studies to identify substrates for
SUMO conjugation have been reported (16–18). In
this context, PARP1 was detected to be sumoylated in
HEK293 cells and in K562 cells. SUMO modification of
proteins that regulate transcription has been associated
with dynamic regulation of gene expression (9, 19). A
large number of transcriptional regulators, including
transcription factors, cofactors, and chromatin-modify-
ing enzymes, have been found to be substrates of
SUMO modification. Generally, a SUMO-modified fac-
tor exists in a dynamic distribution between the SUMO-
modified and unmodified forms, and although the
SUMO-modified form of a protein is often difficult to
detect, it can have a great impact on transcriptional
activation (9, 10). Sumoylation of transcription factors
has generally been correlated with transcriptional re-
pression (9, 10). The specific effects, however, have to
be determined experimentally for each case.
In this study, we characterize the modification of
PARP1 through SUMO1 and SUMO3. The modifica-
tion primarily occurs at a lysine residue within the
automodification domain of PARP1. The attachment
site is close to hotspots of other post-translational
modifications of PARP1, such as ADP-ribosylation and
acetylation. This proximity led us to investigate a po-
tential crosstalk of these modifications. Sumoylation of
PARP1 inhibits its acetylation through p300, and cor-
respondingly, a sumoylation-deficient PARP1 mutant
has a higher acetylation status than wild-type PARP1. In
addition, a PARP1 sumoylation-deficient cell line exhib-
its increased transcriptional activity of genes under the
control of transcription factor HIF1-".
MATERIALS AND METHODS
Chemicals and antibodies
Protein G sepharose and glutathione sepharose 4B were
purchased from GE Healthcare (Les Ulis, France), 32P-NAD!
and 35S-methionine were from PerkinElmer (Boston, MA,
USA). NAD!, trichostatin A (TSA), acetyl-coenzyme A, 3AB,
ATP, anti-tubulin, and anti-Flag (M2) were obtained from
Sigma-Aldrich (Milan, Italy). Anti-p300 (C20) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
anti-HA antibody 16B12 from Covance (Evansville, IL, USA).
Anti-myc antibody (9E10) was purchased from Roche (Basel,
Switzerland), SUMO2/3 (18H8) was obtained from Cell
Signaling (Beverly, MA, USA), and His antibody was from
Qiagen (Valencia, Spain). Monoclonal CAIX antibody super-
natant from hybridoma was a gift from D. Stiehl (University of
Zurich, Zurich, Switzerland). Anti-PARP1 was produced in
this laboratory; anti-acetyl-PARP1 was generated in collabora-
tion with the monoclonal antibody core facility at the EMBL
Monterotondo (Monterotondo, Italy).
Cell culture and transfection
HEK293T and K562 cells were grown under standard condi-
tions. Transfections were carried out with the calcium phos-
phate method. Whole-cell extracts were prepared as de-
scribed previously (20) with 10 mM NEM and/or HDAC
inhibitors (2 $M TSA, 5 mM NAM, 1 mM Na-butyrate).
Nuclear extracts were prepared as described previously (6).
Plasmids
The baculovirus expression vectors pQE-TriSystem (Qiagen)
and BacPak8 (Clontech, Mountain View, CA, USA) were used
for the expression of recombinant proteins in Sf21 insect
cells, as described previously (21). pcDNA-myc-SUMO1, myc-
SUMO3, and myc-Ubc9 expression plasmids were kindly
provided by R. T. Hay (University of Dundee, Dundee, UK).
PARP1 was cloned into a pCMV-HA vector with NheI/NotI
restriction enzymes. pCU vector with Ubc9 was a kind gift
from R. Niedenthal (Hannover Medical School, Hannover,
Germany). PARP1 was cloned into pCU with NheI/SmaI
restriction enzymes, generating a 15-aa linker between PARP1
and Ubc9. pCMV-Flag-p300 was used for expression in mam-
malian cells. Plasmids for SUMO proteases SENP1-6 were in
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pCI-Flag backbone. Short hairpin RNA was cloned and ex-
pressed in pSUPER vector.
Cloning, expression, and purification of recombinant
proteins
Wild-type hPARP1 (National Center for Biotechnology Infor-
mation ID: BC037545) was cloned and expressed as amino-
terminal HA-tagged and carboxyl-terminal His-tagged pro-
tein. HA-PARP1, HA-PARP1 K486R, p300, SUMO1, SUMO3,
and Ubc9 proteins were purified by 1-step affinity chromatog-
raphy using ProBond resin, according to the manufacturer‘s
recommendations (Invitrogen, Carlsbad, CA, USA). GST-
SUMO3, SUMO3, SENP2 (aa 364-569), and SENP2 (aa
364-569 C548S) were cloned in pGEX-vectors, expressed
and purified with glutathione sepharose, according to the
manufacturer‘s recommendations (GE Healthcare). The
double-tagged heterodimeric human E1-activating enzyme
was expressed from the pGEX-E1H6 vector and purified by
sequential GST beads and nickel beads; GST-cleavage was
performed through thrombin, and the recombinant pro-
tein was loaded and eluted from nickel beads using stan-
dard protocols.
In vitro sumoylation assay
The reaction was carried out in standard SUMO reaction
buffer (50 mM Tris-HCl, pH 8.0; 50 mM NaCl; 5 mM MgCl2;
10% glycerol; and 0.5 mM DTT). 5 mM ATP was added to
start the reaction. Incubation time was 30 min at 30°C, unless
otherwise indicated. The final concentration of proteins was
100 nM for SAE1/SAE2, 500 nM Ubc9, 5 $M SUMO1/
SUMO3, and 500 nM HA-PARP1.
Purification of sumoylated PARP1
The sumoylation reaction was 15% scaled up, and the incu-
bation time was increased to 120 min at 30°C. Instead of
SUMO3, a GST-tagged SUMO3 at a final concentration of 10
$M was used. After sumoylation, the sample was diluted with
2% the volume with SUMO-purification buffer (50 mM
Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; and 1 mM
DTT) and bound to glutathione sepharose beads. After 60
min of incubation on rolls at 4°C, the supernatant was washed
away with the same buffer, and 2 U of PreScission protease
was added to the beads and incubated 16 h at 4°C. The
supernatant was used for experiments with sumoylated
PARP1.
Desumoylation of PARP1 in vitro
Purified sumoylated PARP1 was subjected to active recombi-
nant SENP2 (aa 364-569) or inactive SENP2 (aa 364-569
C548S) treatment in SUMO-purification buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; and 1 mM DTT) for
15 min at 30°C with a concentration of 10 ng SENP2/$l.
32P-NAD automodification
Sumoylated or desumoylated PARP1 in SUMO-purification
buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA;
and 1 mM DTT) was supplemented with 4 mM MgCl2 and 5
pmol of annealed double-stranded oligomer (5&-GGAATTCC-
3&). The reaction was started by adding 32P-NAD! at a final
concentration of 100 nM NAD!. Automodification was al-
lowed for 5 min at 30°C. Reactions were stopped by the
addition of SDS-PAGE-loading buffer and boiling for 5 min at
95°C. Samples were subjected to SDS-PAGE, followed by
detection of automodification by autoradiography.
PAR detection by silver staining
Following synthesis of PAR in the presence of 400 $M NAD!
and 5 pmol EcoRI-linker DNA for 20 min, PAR chains were
purified and separated by modified DNA-sequencing gel
electrophoresis, as described previously (22).
Immunoprecipitation and nickel-NTA pulldown
Sumoylated or desumoylated PARP1 was bound to protein G
sepharose beads with anti-HA antibody in SUMO-purification
buffer. The beads were washed and adjusted to IP buffer (50
mM Tris-HCL, pH 8.0; 100 mM NaCl; 0.25% Nonidet P-40;
and 1 $g/ml protease inhibitors). Recombinant p300 (2 $g)
was added to the beads and incubated for 2 h at 4°C on rolls.
Washing of the beads with the same buffer removed unbound
p300. Immunoprecipitation of nuclear extracts was done with
HA antibody with IP-binding buffer (20 mM HEPES, 150 mM
NaCl, and 0.25% Nonidet P-40; 1 $g/ml), protease inhibitors,
and HDAC inhibitors (2 $M TSA, 5 mM NAM, 1 mM
Na-butyrate). The salt concentration was increased with 50
mM KCl for washing steps. Elution of bound proteins was
done with SDS-PAGE loading buffer and boiled for 5 min
at 95°C. Nickel-NTA pulldown was done as described
previously (23).
HAT Assay
Sumoylated or desumoylated PARP1 was subjected to in vitro
acetylation assay with recombinant p300 as described else-
where (24).
Knockdown and complementation of PARP1 in K562 cells
Generation of viruses and transduction of cells was done as
described earlier (25). shRNA was cloned into pRDI vector
and transduced to K562 cells. The short hairpin RNA was
designed against 5&UTR region of PARP1 mRNA. Transduced
cells were selected through puromycine resistance gene.
Complementation of cells was done with pRRL-myc-PARP1
vectors containing a blasticidine resistance marker and sub-
sequently selected with this antibiotic.
RNA preparation
Total RNA was isolated from 3 biological replicates of com-
plemented K562 cells with the Total RNA Isolation kit (Agi-
lent Technologies, Santa Clara, CA, USA). Reverse transcrip-
tion was achieved with the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA).
Quantitative PCR
Total reverse-transcribed cDNA from untreated or treated
K562 cells was used for q-PCR with primers against carbonic
anhydrase IX, LOXL2, and Pdk1. Amplification products
were analyzed by SYBR Green (Quantace, London, UK), and
ribosomal protein L28 was used to normalize for differences
in RNA input. Rotor-Gene3000A (Qiagen, Basel, Switzerland)
was used to perform the real-time PCR reactions.
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RESULTS
PARP1 is sumoylated in vivo
Because PARP1 was identified as a SUMO modification
target in proteomic studies, we aimed to confirm that
PARP1 is indeed sumoylated in vivo. HA-tagged PARP1
was coexpressed with myc-tagged SUMO1 or SUMO3 in
HEK293T cells, and extracts were analyzed by Western
blot. Ectopic expression of SUMO1 or SUMO3 per se
induced the modification of a multitude of proteins
(Fig. 1A, bottom). Expression of SUMO induced a
higher molecular form of PARP1 (depicted as Su-
PARP1), which was more prominent in the presence of
SUMO3 as compared to SUMO1, suggesting that
PARP1 is preferentially conjugated with SUMO3 (Fig.
1A). Expressing His-tagged SUMO, we could enrich an
anti-PARP1-reactive species on Ni-NTA beads, thus val-
idating that the higher molecular form corresponds,
indeed, to a covalent SUMO-PARP1 conjugate (Fig.
1B). Only one distinctive band of sumoylated PARP1
was detected, suggesting that PARP1 is monosumoy-
lated at a single lysine residue under the tested condi-
tions. Similar results were obtained when PARP1 was
expressed as fusion protein with Ubc9/E2 conjugation
protein, although the overall modification rate was
clearly enhanced (Supplemental Fig. 1A). Mutation of
the catalytic cysteine of the fused Ubc9 resulted in a
strong reduction of the modification, indicating that
the Ubc9 fused to PARP1 catalyzes the sumoylation of
PARP1 (Supplemental Fig. 1B). Immunoprecipitation
of this fusion protein in extracts of cells expressing
myc-tagged SUMO3 and subsequent Western blot anal-
ysis using an anti-myc antibody revealed SUMO moi-
eties on PARP1, providing additional evidence for
covalent modification of PARP1 with SUMO (Supple-
mental Fig. 1C). To test whether PARP1 would bind to
SUMO noncovalently via a SUMO-interacting motif
(SIM), GST pulldowns were performed with conjuga-
tion-deficient SUMO1-4 and RelA/p65 as a positive
control (Supplemental Fig. 2A–C). Although PARP1
was able to interact with RelA/p65, no interaction was
detectable with GST or all tested SUMOs. Thus, we
conclude that PARP1 is covalently modified by SUMO.
SENP1 and SENP3 are able to desumoylate PARP1
SUMO proteases are known to reverse sumoylation of
proteins. To test whether SUMO proteases act on
Figure 1. PARP1 is sumoylated in vivo. A) HA-PARP1,
myc-SUMO1, or myc-SUMO3 expression plasmids were
transfected in HEK293T. Whole-cell extracts were taken
in presence of 10 mM NEM and resolved on SDS-PAGE
and subsequently analyzed through Western blotting
with the indicated antibodies. Sumoylated PARP1 is
indicated as Su-PARP1.B) Denaturating nickel pulldown
of whole-cell extracts from transfected HEK293T cells.
Cells were transfected with SUMO2 alone or with
His-tagged SUMO2. Detection of sumoylated PARP1
was performed with anti-PARP1 antibody. C) HEK293T
cells were transfected with a mix of HA-PARP1, His-
SUMO3, and myc-Ubc9 expression plasmids and the indi-
cated plasmids for expression of SUMO proteases SENP1
and SENP3, or the catalytically inactive mutant counter-
part, respectively. Expression levels of the SENPs were
monitoredwith anti-Flag antibody.D)HEK293T cells were cotransfectedwith flag-tagged expression plasmids for SENP1 or SENP3
and pSUPER vector with shRNAs against SENPs. Knockdown efficiency after 28-h expression was examined with anti-Flag
antibody. E) Knockdown of SENP1 and SENP3 was achieved as in D, but in addition, a mix of HA-PARP1, His-SUMO3,
and myc-Ubc9 was cotransfected in HEK293T cells. Cell extracts were prepared and examined with the anti-PARP1 and
anti-His antibodies.
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SUMO-modified PARP1, we coexpressed wild-type or
catalytically inactive SENP1 and SENP3 with PARP1 and
SUMO3 in HEK293T cells (Fig. 1C). This showed that
coexpression of catalytically active SENP1 and SENP3
deconjugated SUMO3 from PARP1 (Fig. 1C). Corre-
spondingly, knockdown of SENP1 and SENP3 with
transiently transfected shRNAs (Fig. 1D) resulted in the
accumulation of sumoylated PARP1, as compared to
the control (Fig. 1E), indicating that SENP1 and SENP3
can act on PARP1-SUMO conjugates at physiological
expression levels. Taken together, our results illustrate
that PARP1 is preferably modified by SUMO3 and
desumoylated by the isopeptidases SENP1 and SENP3.
Furthermore, sumoylation of PARP1 seems thus to be a
transient and reversible modification.
PARP1 is sumoylated at K486 in vitro and in vivo
The consensus sumoylation site sequence is #KxE/D
(8). As determined by the SUMOsp analysis program
(http://sumosp.biocuckoo.org), the highest score
matched to lysine 486 in human PARP1 (Fig. 2A),
which is located in proximity to previously described
sites of acetylation and ADP ribosylation. To confirm
PARP1 sumoylation in vitro and to map the modifica-
tion site, we established an in vitro sumoylation system
reconstituted with recombinant human E1 (SAE1/
SAE2 heterodimer), E2 (Ubc9), wild-type SUMO1, or
SUMO3 and wild-type PARP1 (Fig. 2B). PARP1 sumoy-
lation was efficiently reconstituted in vitro with purified
proteins: reactions containing all components pro-
duced slower migrating PARP1 forms, consistent with
conjugated SUMO moieties. Attachment of a single
moiety was detected with low E2 concentrations (run-
ning at '140 kDa), whereas multiple SUMO moieties
were attached only at higher E2 concentrations (Fig.
2B). One additional band between 120 and 140 kDa was
observed at elevated Ubc9 concentrations and likely rep-
resents the modification of a degradation product of
PARP1 by SUMO3. To test for putative sumoylation sites
in PARP1, lysine 486 of PARP1 was substituted with
arginine (PARP1 K486R) and analyzed in vitro. Substitu-
tion did completely prevent the sumoylation of PARP1 in
vitro with SUMO1, SUMO3, or GST-tagged SUMO3, as
monitored by Western blot analysis (Fig. 2C, D), indicat-
ing that K486 is the major SUMO acceptor site of PARP1.
Figure 2. PARP1 is sumoylated at K486 in vitro and in vivo. A) Schematic
overview of human PARP1 domains. Putative sumoylation consensus
motif around lysine 486 is highlighted. Reported post-translational
modifications are shown in bold. ac, acetylation; ADPR, ADP-ribosyla-
tion. B) In vitro sumoylation assay with recombinant ATP-dependent
SUMO E1 (SAE1, SAE2)-activating enzyme, SUMO E2-conjugating
enzyme Ubc9, and SUMO3. Sumoylation reaction was carried out under
standard assay conditions for 30 min. PARP1 was detected with anti-
PARP1 antibody. C) In vitro sumoylation with purified HA-PARP1
wild-type or HA-PARP1 K486R as in B for the indicated time. D) In vitro
sumoylation assay with GST-tagged SUMO3 or with SUMO1, either with
HA-PARP1 wild-type or HA-PARP1 K486R for the indicated incubation
time. E) HEK293T cells were transfected with expression plasmids for HA-PARP1, HA-PARP1 K486R, or myc-SUMO3,
respectively. Whole-cell extracts were analyzed with anti-HA antibody and anti-myc antibody. Saturated levels of unbound
myc-SUMO3 were detected in the control Western blot.
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To verify sumoylation of PARP1 at K486 in vivo, we
coexpressed wild-type or the K486R mutant of PARP1
with myc-tagged SUMO3. Sumoylation of wild-type
PARP1 could be detected but not of the K486R mutant
(Fig. 2E), confirming K486 as the main sumoylated
residue in vivo.
Sumoylation of PARP1 does not affect its ADP
ribosylation activity
To explore a potential interplay of PARP1 sumoylation
with PARP1 function, we modified the established in
vitro sumoylation system to purify sumoylated PARP1. A
large-scale sumoylation reaction was performed with
GST-tagged SUMO3, E1–E2 enzymes, and HA-PARP1,
followed by GST affinity purification and subsequent
protease digestion to remove the GST tag and to purify
Su-PARP1, specifically modified at K486 (Fig. 3A). On
purification, only Su-PARP1 could be detected, indi-
cating that no unmodified PARP1 was in the purified
complex (Fig. 3B). Because PARP1 was described to
form a homodimer, this result suggests that both
subunits are equally accessible for SUMO-conjuga-
tion. PARP1 was also efficiently sumoylated in the
presence of double-stranded DNA ends, suggesting
that binding of PARP1 to DNA does not affect its
sumoylation in vitro (Supplemental Fig. 3A). Simi-
larly, Su-PARP1 was still able to bind specifically to
DNA fragments that mimic damaged DNA (Supple-
mental Fig. 3B).
To determine whether sumoylation regulates the
intrinsic ADP-ribosylation activity of PARP1, mono-
ADP-ribosylation of purified Su-PARP1 was measured
using an in vitro ADP-ribosylation assay in the presence
of 100 nM 32P-NAD!. Sumoylation of PARP1 still allows
its mono-ADP-ribosylation activity (Fig. 3B, lane 1). To
compare the extent of ADP ribosylation, Su-PARP1 was
either desumoylated by recombinant SENP2 (aa 364-
569) before or after ADP ribosylation took place (Fig.
3B, lanes 2 and 3). Quantification of the detected
radioactivity confirmed that both proteins were modi-
fied to the same extent. Similar experiments were
repeated with 400 $M NAD!, a concentration that
allows detection of poly(ADP-ribosyl)ation of PARP1.
PAR polymers synthesized by Su-PARP1 and desumoy-
lated PARP1 were isolated and analyzed with silver-
stained PAGE (Fig. 3C). Neither the amount nor the
distribution of freshly synthesized PAR was altered by
sumoylated PARP1, indicating that SUMOmodification
neither alters the ability of PARP1 to initiate nor to
extend PAR synthesis. In addition, overexpression of
SUMO3 in HEK293T cells per se did not stimulate PAR
formation (Supplemental Fig. 4A), although PARP1 is
sumoylated under these conditions (see Fig. 1A, last
lane). Furthermore, H2O2-treated cells showed PAR
formation (Supplemental Fig. 4B), which was indepen-
dent of SUMO3 levels, indicating that SUMO modifi-
cation of PARP1 does not enhance its poly(ADP-ribo-
syl)ation activity. To test the possibility of differential
localization of PARP1 upon sumoylation, we overex-
Figure 3. Sumoylation of PARP1 does
not affect its ADP-ribosylation activity.
A) Purification of sumoylated PARP1.
Purified HA-PARP1 from insect cells
was sumoylated in vitro with GST-
SUMO3 (a), which occurred site-spe-
cific on lysine 486. GST-SUMO3-con-
jugated PARP1 was captured on
glutathione sepharose beads (b). GST
tag was removed using a GST-tagged
PreScission protease (c), which was added to the beads. Supernatant consisted of sumoylated PARP1, which was either
incubated with active recombinant SENP2 fragment (aa 364-569) or the inactive mutant SENP2 C548S. B) Sumoylated
PARP1 (lanes 1 and 2) or desumoylated PARP1 (lane 3) was incubated with 100 nM radiolabeled 32P-NAD! and 5 pmol
EcoRI-linker DNA. Reaction was stopped with PARP-inhibitor 3AB, and active SENP2 was added to deconjugate SUMO3
from PARP1 (lane 2), thus generating free PARP1. Mono(ADP-ribosyl)ation was monitored with autoradiography.
C) Silver stain of isolated PAR generated by sumoylated PARP1 (lanes 1 and 3) or by desumoylated PARP1 (lanes 2 and
4). Reaction was carried out in the absence (lanes 1 and 2) or in the presence (lanes 3 and 4) of EcoRI-linker DNA at 400
$M NAD!. D) Mono(ADP-ribosyl)ation of PARP1 in the presence or absence of PARP-inhibitor 3AB with 100 nM NAD!.
Each sample was supplemented with E1, E2, and SUMO3 proteins. Reaction was stopped after a 5-min incubation time
with 3AB (lanes 3 and 4), and ATP was added (lanes 2 and 4). After the sumoylation reaction, proteins were separated
by SDS-PAGE and analyzed by autoradiography.
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pressed SUMO3 in cells and monitored PARP1 local-
ization by immunofluorescence. However, we did not
observe differential localization of PARP1 within the
nucleus upon ectopic SUMO3 expression (Supplemen-
tal Fig. 4C).
We recently reported that PARP1 is auto-ADP-
ribosylated at several lysines adjacent to the identi-
fied sumoylation site (26). To exclude that ADP-
ribosylation would affect sumoylation, we mono-ADP-
ribosylated PARP1 in vitro with radioactive NAD! and
subsequently sumoylated the labeled PARP1 fraction
(Fig. 3D). PARP1 was sumoylated in an ATP-depen-
dent manner independent of its ADP-ribosylation.
Consistently, in vivo treatment of cells with the PARP
inhibitor 3-amino-benzamide (3AB) did not affect
sumoylation (data not shown). Taken together, this
suggests that although the sumoylated and ADP-
ribosylated lysines are rather close within the PARP1
amino acid sequence, their modifications do not
interfere with each other.
Sumoylation counteracts p300-induced acetylation of
PARP1
As p300 is critical for PARP1 transcriptional coactiva-
tion and acetylates PARP1 at distinct lysines (6), we first
examined whether acetylated PARP1 would still be
sumoylated in vitro. Acetylation of PARP1 was moni-
tored with a specific anti-acetyl PARP1 (E4) antibody
(Supplemental Fig. 5A), while sumoylation was assessed
by the migration difference between unmodified
PARP1 and Su-PARP1. Acetylation with the indicated
control and subsequent addition of sumoylation en-
zymes, followed by the sumoylation reaction, revealed
that similar to the mono-ADP-ribosylated PARP1, acety-
lated PARP1 could also be efficiently modified with
SUMO (Fig. 4A, lane 4).
Moreover, we tested whether sumoylation of PARP1
would affect acetylation. Purified Su-PARP1 or de-
sumoylated PARP1 by recombinant SENP2 was both
incubated with p300 and acetyl-CoA in vitro. Western
blot analysis using the specific anti-acetyl PARP1 (E4)
antibody revealed that PARP1 is acetylated only when
PARP1 was desumoylated prior to acetylation (Fig. 4B,
lane 2), suggesting that the SUMO-modification inhib-
its p300-mediated PARP1 acetylation. To substantiate
this, we examined protein interactions with p300,
PARP1, or Su-PARP1. p300 could interact efficiently
with PARP1 but not with Su-PARP1, as demonstrated by
coimmunoprecipitation of p300 (Fig. 4C). Thus, the
absence of detectable acetylation of Su-PARP1 (see Fig.
4B) suggests that SUMO modification at K486 prevents
p300-mediated acetylation of PARP1, likely because of
steric hindrance of the bulky SUMO conjugate block-
ing p300 binding and acetylation at the adjacent lysine
residues. To explore whether the inhibitory effect of
PARP1 sumoylation on acetylation is also observed in
vivo, we coexpressed wild-type PARP1 or the sumoyla-
tion-deficient PARP1 mutant (K486R) with p300 and
monitored acetylation with the E4 antibody on Western
blots. This revealed lower levels of acetylation for the
wild-type PARP1 compared to the sumoylation-defi-
Figure 4. Sumoylation counteracts p300-induced acetylation of PARP1. A) In vitro
acetylation of PARP1 through p300 was done in the absence (lanes 1 and 3) or the
presence (lanes 2 and 4) of acetyl-CoA. Proteins necessary for sumoylation (E1,
E2, SUMO3) were added after the acetylation reaction. Proteins were separated
with SDS-PAGE and analyzed with anti-PARP1 and anti-acetyl-PARP1 (E4) anti-
body. B) In vitro acetylation reaction was done with p300 and sumoylated PARP1
(lane 1) or PARP1 desumoylated prior to the acetylation reaction (lane 2). After
acetylation reaction, sumoylated PARP1 was desumoylated with SENP2 (lane 1),
which allowed direct comparison of acetylation status of equal amounts of PARP1.
C) Coimmunoprecipitation of p300 with PARP1 was carried out on protein G
sepharose beads, using HA antibody to capture HA-tagged PARP1, either sumoy-
lated (Su-PARP1) or desumoylated (deSu-PARP1). As control, only the HA
antibody was bound to the matrix (no PARP1). Beads were incubated with purified p300, and the unbound fraction was
removed by extensive washing. D) HEK293T cells were transfected with either HA-PARP1 wt or HA-PARP1 K486R mutant
along with p300 expression plasmid. Cells were incubated with HDAC inhibitors 2 h prior to lysis, and HDAC inhibitors
were present at all steps of manipulation. Nuclear extracts were taken and subjected to immunoprecipitation using an HA
antibody. After SDS-PAGE, proteins were detected by anti-acetyl-PARP1 (E4), anti-HA, or anti-p300 antibody.
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cient PARP1 mutant (Fig. 4D). Together, these results
provide evidence for a crosstalk between these modifi-
cations.
The sumoylation-deficient K486R PARP1 mutant
exhibits higher coactivator function compared to
wild-type PARP1
To explore a possible mechanism by which sumoyla-
tion affects PARP1-dependent transcriptional coacti-
vator function in vivo, we first knocked down endog-
enous PARP1 protein levels in K562 cells with an
shRNA approach directed against the untranslated
region of PARP1’s mRNA and subsequently comple-
mented these cells with wild-type or sumoylation-
deficient K486R PARP1 mutant (Fig. 5A, B). The
expression levels of the complemented cells were
comparable to the endogenous wild-type counter-
part. Hypoxia treatment of these cells for 28 h and
subsequent profiling of the gene expression of de-
fined hypoxia-inducible genes revealed that certain
genes, such as CAIX, LOXL2 or Pdk1, are dependent
on PARP1, but only a subset was affected by the
sumoylation-deficient K486R mutation (Fig. 5C).
Similar results were obtained when PARP1(/( mouse
lung fibroblasts were complemented with wild-type
or sumoylation-deficient K486R PARP1 mutant and
stimulated by the hypoxia-mimicking drug ciclopir-
oxolamine (Supplemental Fig. 5B). Sumoylation-de-
ficient K486R PARP1 mutant not only enhanced
CAIX mRNA levels in K562 cells, but also CAIX
protein levels in vivo (Fig. 5D). Furthermore, hypoxia
treatment of K562 cells very strongly correlated with
protein sumoylation and enhanced SUMO modifica-
tion of PARP1 in HEK293T cells (Supplemental Fig.
5C, D). Thus, we conclude that sumoylation of PARP1
reduces its coactivator activity and thus regulates
gene expression in vivo.
Figure 5. Sumoylation-deficient K486R PARP1 mutant ex-
hibits higher coactivator function compared to wild-type
PARP1. A) Stable knockdown of PARP1 in human chronic
myelogenous leukemia cell line K562 using a lentiviral
system. shRNA against PARP1 targets the 5& untranslated
region of PARP1 mRNA. B) Stable complementation of
PARP1 with either pRRL-empty vector, myc-tagged wild-
type PARP1, and sumoylation-deficient PARP1 K486R mu-
tant. C) Hypoxic induction of complemented K562 cells at
0.2% O2 for 28 h. RNA was isolated, and the quantitative
PCR was done using primers for carbonic anhydrase IX
(CAIX), lysyl oxidase-like 2 (LOXL2), and pyruvate dehy-
drogenase kinase, isenzyme 1 (Pdk1) and normalized by
using L28 ribosomal protein. Normoxic samples were set to
1; fold induction of hypoxic samples is depicted. Three
biological replicates are shown. Statistical analysis was done with unpaired t test between biological replicates. Data are
represented as means ) se. D) Complemented K562 cells were exposed for 29 h to 0.2% O2 hypoxia. Whole-cell extracts
were prepared and Western blotted with monoclonal anti-CAIX antibody and anti-tubulin antibody.
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DISCUSSION
The aim of this study was to characterize and investigate
the role of PARP1 sumoylation in the cellular context.
We provide biochemical and cellular evidence for
SUMO modification of PARP at lysine 486 within its
automodification domain. Mutation of K486 enhances
the transcriptional activity of PARP1, suggesting that
sumoylation restrains its transcriptional activity.
PARP1 is covalently sumoylated
Noncovalent interactions of proteins can occur
through SUMO interaction motifs (SIMs) (27). Pro-
teins like the DNA repair enzyme TDG and the tumor
suppressor PML were shown to interact with SUMOs
via SIMs, and such interactions were associated with
important biological activities (28–30). Although
PARP1 exhibits several putative SIMs, we did not
observe any direct noncovalent interaction of PARP1
with SUMOs, indicating that the interaction of
PARP1 with SUMO is exclusively covalent. Pulldown
experiments of sumoylated PARP1 under denaturat-
ing conditions and site-directed mutagenesis re-
vealed that sumoylation of PARP1 is indeed a cova-
lent and site-specific modification. A possible in-
volvement of SUMO E3 ligases for the sumoylation of
PARP1 needs further investigations. Although PIAS
family members are attractive candidates, overex-
pression of different PIAS proteins did not enhance
PARP1 sumoylation (data not shown).
Notably, we observed only monosumoylation of
PARP1 in vivo, but do not exclude that under specific
conditions, PARP1 may also be polysumoylated. In
support of this idea, heat shock has been reported to
induce a pattern of PARP1 sumoylation, which would
be consistent with polysumoylation (18). Understand-
ing the balance between monosumoylation and poly-
sumoylation of PARP1, as well as their functional
differences will remain an exciting issue.
Crosstalk between sumoylation and other
post-translational modifications
The crosstalk of post-translational modification systems
is an emerging concept (31). Sumoylation of target
proteins can be regulated through crosstalks with other
post-translational modification events. Phosphoryla-
tion, for instance, was shown to regulate SUMO conju-
gation through a highly conserved motif, which is
called phosphorylation-dependent sumoylation motif
(PDSM) (32). The PDSM motif, which contains a
SUMO consensus site and an adjacent proline-directed
phosphorylation site (#KxExxSP, where # represents
large hydrophobic residue and x is any amino acid),
regulates phosphorylation-dependent sumoylation of
multiple transcription factors (33–35). Lysine residues
are targeted by several other post-translational modifi-
cations, including ubiquitination, acetylation, methyl-
ation, and ADP-ribosylation. It has been documented
that SUMO conjugation can occur on the same lysine
residue as ubiquitination or acetylation in some pro-
teins. For example, the competition between sumoyla-
tion and ubiquitination of the same lysine regulates the
stability of I*B" (36), whereas in other cases, sumoyla-
tion acts as a recognition signal for a ubiquitin ligase
(37). An interplay between sumoylation and acetylation
has been observed in the regulation of proteins, such as
MEF2, the core histones, and hypermethylation in
cancer 1 (HIC1) (38, 39). In the case of MEF2, the
sumoylation-acetylation switch is regulated by phos-
phorylation (40). These studies demonstrate the impor-
tance of signaling crosstalk in the regulation of protein
sumoylation.
Mechanisms of SUMO-mediated repression of PARP1
coactivator function
First, sumoylation may directly affect PARP1’s binding
to DNA by promoting its dissociation from specific
chromatin regions. This possibility seems unlikely,
since sumoylation of PARP1 did not alter its ability to
recognize and bind damaged DNA in vitro. Second,
SUMO modification could also affect enzymatic activi-
ties of PARP1, which is important for gene expression.
Also, this seems unlikely, since we have shown that
SUMO modification of PARP1 does not interfere with
DNA-dependent ADP-ribosylation activity in vitro. In
addition, increased SUMO3 levels do not correspond to
elevated poly(ADP-ribosyl)ation in cells on hydrogen
peroxide-induced DNA damage, suggesting that sumoy-
lation of PARP1 does not have a stimulatory effect on its
enzymatic activity. However, it was shown that poly-
(ADP-ribosyl)ation is not required for NF-*B-depen-
dent gene expression (41). Neither the enzymatic
activity of PARP1 nor its binding to DNA was required
for full activation of NF-*B in response to various
stimuli in vivo when tested on transiently transfected
reporter plasmids (21, 42). Consistently, the enzymatic
activity of PARP1 was not required for full transcrip-
tional activation of NF-*B in the presence of the
histone acetyltransferase p300 (6). Because sumoyla-
tion of PARP1 inhibits its acetylation at adjacent lysine
residues and because these residues are also targets of
ADP-ribosylation, a potential acetylation-ADP-ribosyla-
tion switch, which is controlled through sumoylation of
PARP1, is very likely. Third, the SUMO modification
could promote or inhibit protein-protein interactions
through protein complex formation. This scenario
seems to be the most relevant for PARP1, since the
interaction of PARP1 with p300 and subsequent PARP1
acetylation was impaired after sumoylation of PARP1 at
K486. This lysine residue lies within the domain of
PARP1, which contributes to most protein-protein in-
teractions such as XRCC1 (6). However, we did not
observe a general SUMO-dependent inhibition of pro-
tein interactions in this region since HIF1-" and
XRCC1 binding does not seem to be affected by
sumoylation of PARP1 (Supplemental Fig. 5E and un-
published results). In addition to the inhibition of p300
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binding, SUMO modification of PARP1 may facilitate
the recruitment of a transcriptional corepressor. Cur-
rently, several chromatin-modifying enzymes and chro-
matin-binding proteins have been implicated as effec-
tors of SUMO-mediated repression. For example,
SUMO modification of the transcription factor Elk-1
promotes recruitment of HDAC2, associated with his-
tone deacetylation and transcriptional repression of the
c-fos promoter (43). Very recently, CoREST1 and Mi2
were identified as SUMO-dependent corepressors, and
evidence was provided that CoREST1 binds directly and
noncovalently to SUMO2/3, but not to SUMO1 (44,
45). Notably, the aforementioned interaction of PARP1
with PIAS family members could contribute to gene
silencing.
Desumoylation of PARP1 by SENP1 and SENP3
We observed that SENP1 and SENP3 are able to
catalyze PARP1’s SUMO deconjugation. The nucleo-
plasmic SENP1 relieves SUMO-dependent repression
of Ets1, c-Jun, and the androgen receptor, the latter
effect being through desumoylation of histone deacety-
lase 1 (46). Recent data also implicate the nucleolus in
dynamic cycles of sumoylation and desumoylation. For
example, nucleolar SENP3 is able to catalyze desumoy-
lation of various proteins in this compartment, with
specificity to SUMO2/3 (15, 46). In addition, it seems
that SENPs regulate SUMO paralog preference of
substrate proteins by deconjugation of specific SUMOs,
as shown for RanGAP1 (47). This could also explain the
higher steady-state level of SUMO3-modified than
SUMO1-modified PARP1.
Only a subset of PARP1-dependent genes are
affected by sumoylation
Analyses of the role of SUMO in transcriptional regu-
lation have mainly relied on the use of protein overex-
pession and transiently transfected reporter genes,
which may not give a true reflection of the physiological
situation. Therefore, we have established a system
where we complement cells depleted from endogenous
PARP1 with sumoylation deficient PARP1 or wild-type
PARP1 and analyzed the expression of endogenous
target genes. Known HIF1-" dependent genes with a
high induction upon hypoxia were tested. Of these,
CAIX and LOXL2 showed increased transcript levels in
sumoylation deficient K486R mutant cell line, whereas
other genes were solely dependent on PARP1, but not
on its sumoylation. Consistent with the qPCR data, the
expression levels of CAIX were increased in cells ex-
pressing sumoylation-deficient PARP1. Previous studies
on PARP1’s coactivator function revealed that this
function is heavily dependent on its acetylation
through p300. Here, we showed that acetylation is
abrogated if the SUMO moiety is present on PARP1.
Consistently, the sumoylation-deficient mutant showed
a higher acetylation status, which corresponded to
higher gene expression status for some genes. Collec-
tively, these data support the mechanistic studies per-
formed in vitro, unraveling an important role of sumoy-
lation in regulating PARP1-dependent transcriptional
coactivation through regulation of its acetylation. It is
largely accepted that post-translational modifications
fine tune and regulate the requirement of certain
transcriptional cofactors for gene expression by tran-
scription factors and might thus influence only a subset
of genes (48).
Hypoxia-induced gene expression is affected by
PARP1 sumoylation
The role of sumoylation in the regulation of hypoxia-
induced gene expression and HIF-1" stability is
controversial (49). Hypoxia can induce the expres-
sion of SUMO1 (50) and an RWD-containing sumoy-
lation enhancer (RSUME) that functions as a promoter
of protein sumoylation (51). RSUME expression is in-
duced by hypoxia, which leads to the enhanced
sumoylation and stabilization of HIF-1". Alterna-
tively, a recent study indicates that the hypoxia-
induced sumoylation of HIF-1" targets HIF-1" for
degradation through the von Hippel–Lindau (VHL)
protein-mediated ubiquitin-proteasome pathway
(37). Clearly, further studies are needed to clarify
these controversial findings on the role of sumoyla-
tion in the regulation of HIF-1" stability during
hypoxia. In this study, we have investigated the
regulation of the known HIF1-"-dependent genes
CAIX and LOXL2 and provide novel insights to
understand the complex transcriptional regulation
of these emerging tumor markers. The expression of
these genes is restrained through SUMO modifica-
tion of the transcriptional coactivator PARP1, indi-
cating that sumoylation of PARP1 dampens HIF1-"
signaling for these genes. Thus, this pathway may
have an important regulatory role in the regulation
of intracellular pH and hypoxia-induced metastasis
(52, 53). Moreover, it remains to be elucidated
whether sumoylation of PARP1 is also affecting tran-
scription mediated by other transcription factors and
whether SUMO modification is associated with the
role of PARP1 in several pathophysiological disease
models. Further studies of the sumoylation of PARP1
will determine the role of SUMO modification/
deconjugation in these pathological states.
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Supplementary Methods: 
 
DNA binding assay 
For in vitro DNA binding assays a biotinylated oligonucleotide (5´-
GCTGTGGACCCTGCTGTGGGCTGGAGAACAAGGTGATCTGCG-3´) was annealed 
with a fully complementary oligonucleotide 5´-
CGCAGATCACCTCCAGCCCACAGCAGGGTCCACAGC-3´ (control a). To mimic 
nicked or gapped DNA the biotinylated oligonucleotide was annealed with the 
oligonucleotide 5´-CGCAGATCACCTTGTTCTCCA-3´ and either 5´-
GCGCACAGCAGGGTCCACAGC-3´ (control b, nicked fragment) or 5´-
CGCAGATCACCTTGTTCT-P (gapped fragment). Biotinylated oligonucleotides were 
captured on Streptavidin Agarose beads (Novagen). 
 
Immunofluorescence 
For detection of proteins by immunofluorescence, HEK293T cells were fixed with freshly 
prepared Methanol:Acetic acid (3:1) mix for 5 min on ice, and washed with PBS. 
Unspecific binding sites were blocked with 0.05% Tween20 and 5% non-fat dry milk in 
PBS for 30 min at room temperature prior to staining with primary and FITC-conjugated 
secondary antibodies in the presence of blocking buffer. Pictures were taken with standard 
fluorescence microscope (Olympus Mx51, 40x, NA 1.3). 
 
Reporter gene Assay 
Mouse PARP1
+/+ 
or PARP1
!/!
 mouse lung fibroblasts (MLF) cells were isolated from 
129S/EV-PARP1+/+ and 129S/EV-PARP1!/! mice (Wang, Morrison, 1997). Only cell 
passages 2 to 10 were used for experiments. MLF were grown in DMEM Glutamax-I 
(Invitrogen) containing 4.5 g/L glucose, supplemented with 10% FCS (Invitrogen), 50 
units/mL penicillin, 50 µg/mL streptomycin (Sigma), and "-naphthylacetic acid 
(Invitrogen). Cells were grown in 5% CO2 at 37°C in a humidified incubator. MLF were 
transfected with polyethylenimine as previously described. Because of differences in 
transfection efficiencies, an expression plasmid of CMV driven Renilla luceriferase was 
cotransfected as a transfection efficiency control, and luciferase activities were normalized 
based on Renilla light units. Luciferase activity was measured with the pSG5C-CA9 
reporter gene (described in Kopacek J, et al. (2005). Biochim Biophys Acta 1729: 41-49). 
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 Plasmids 
Human HIF1-! (aa 365-805) was amplified from pENTR-d hHIF1-! (aa 5-805) and cloned 
into a pGEX6P3 vector with BamHI and XhoI restriction enzymes. 
 
Protein purification 
GST-hHIF1-! (aa 365-805) was expressed in bacteria and purified according to standard 
protocols using glutathione sepharose 4B  (GE healthcare). 
 
Immunoprecipitation 
Sumoylated PARP1 was purified as described in the material and methods section. Either 
sumoylated HA-PARP1 or desumoylated HA-PARP1 was incubated on protein G 
sepharose beads (GE healthcare) together with anti-HA antibody. After 1.5 h incubation 
time, the beads were washed and 5 ug of purified GST-HIF1-! (aa 365-805) was added for 
2h. The beads were washed with IP-buffer (50 mM Tris pH 8.0, 170 mM NaCl, 0.5% NP-
40, Protease inhibitors) and subjected to SDS-PAGE, followed by western blot analysis. 
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 Supplementary Figures: 
 
Supplementary Figure 1:  
(A) HA-PARP1-Ubc9 fusion protein was ectopically expressed with either myc-SUMO1 or 
myc-SUMO3 in HEK293T. Cell extracts were examined with anti-HA and anti-myc 
antibody. (B) HA-PARP1-Ubc9 or HA-PARP1-Ubc9 C93S were transfected along with 
myc-SUMO3 into HEK293T cells. Whole cell extracts were taken and analyzed with anti-
HA antibody (C) Immunoprecipitation of ectopically expressed HA-PARP1-Ubc9 fusion 
protein, expressed in HEK293T with or without myc-SUMO3. Cell extracts were examined 
with anti-HA and anti-myc antibody. 
 
Supplementary Figure 2: 
(A) GST-pulldown with GST alone, conjugation deficient GST-SUMO-AA, or GST-p65 
against whole cell extracts from HEK293T. Detection of PARP1-binding was done with 
PARP1 western blot. GST was used as negative control, GST-p65 as positive control for 
PARP1 interaction. A coomassie stain of the western blot membrane is shown. (B) GST-
pulldown as in (A), but with purified PARP1. (C) GST-pulldown with more stringent 
conditions than in (B), but with recombinant purified TDG as positive control for non-
covalent interaction.  
 
Supplementary Figure 3:  
(A) An in vitro sumoylation assay with purified PARP1 was carried out without or with 
EcoRI-linker DNA in the reaction. (B) Three different biotin-tagged oligonucleotides were 
bound to in vitro translated 
35
S-Methionine labeled and sumoylated PARP1. Precipitation 
of the oligonucleotides was performed with Streptavidin-Agarose. Bound proteins were 
separated through SDS-PAGE and detected with autoradiography. 
 
Supplementary Figure 4:  
(A) Immunofluorescence staining of untransfected or with myc-SUMO3 transfected 
HEK293T cells. The cells were fixed 28 h after transfection and stained with the anti-
SUMO2/3 (18H8) or anti-PAR (10H) antibody. (B) Immunofluorescence staining of 
untransfected or with myc-SUMO3 transfected HEK293T cells. The cells were treated with 
0.5 mM H2O2 for 10 min, fixed and stained with the anti-SUMO2/3 (18H8) or anti-PAR 
(10H) antibody. (C) Immunofluorescence staining of untransfected or with myc-SUMO3 
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 transfected HEK293T cells. Cells were fixed 28 h after transfection and stained with anit-
PARP1 (H250) or anti-myc (9E10) antibody.  
  
Supplementary Figure 5:  
(A) In vitro acetylation assay with PARP1 wild-type or with acetylation-deficient PARP1 
KQR (K498R, K505R, K521R, K524R) mutant. Western blot was done with monoclonal 
E4 antibody and anti-PARP1 antibody. The antibody was generated against an acetylated 
peptide corresponding to residues K498, K505 and K508 in human PARP1 sequence. 
Control of equal inputs of PARP1 was done through coomassie stain of the western blot 
membrane. (B) CAIX reporter plasmid is induced with SUMOylation deficient PARP1. 
Primary mouse lung fibroblasts (MLF) were transfected with HA-PARP1 wt or HA-
PARP1 K486R along with CAIX reporter plasmids and Renilla-Luciferase for 
normalization. Cells were induced with hypoxia mimicking drug Ciclopirox-olamine for 
8h. (C) SUMO2/3 conjugation is induced after hypoxia. K562 whole cell extracts were 
examined with SUMO 2/3 antibody after hypoxic induction for 28h at 0.2% O2. (D) 
HEK293T cells were transfected with HA-PARP1 and myc-SUMO3 expression plasmids. 
20 hours after transfection, cells were exposed to hypoxia (0.2%O2) for 28 h. Whole cell 
extracts were examined by western blot using anti-myc and anti-PARP1 antibodies. (E) 
HA-PARP1 was sumoylated (Su-PARP1) or desumoylated (deSu-PARP1) in vitro as 
described in Fig. 3A, and subsequently immunoprecipitated using anti-HA antibody. As 
control, only beads with the anti-HA antibody was used (no protein). After extensive 
washing, beads were incubated with purified GST-HIF1-! (aa 365-805). Co-
immunoprecipitated GST-HIF1-! was detected by western blot using an anti-GST 
antibody. 
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Supplementary Fig. 2
A
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Supplementary Fig. 3
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Supplementary Fig. 4
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ABSTRACT
The chromatin-associated enzyme PARP1 has pre-
viously been suggested to ADP-ribosylate histones,
but the specific ADP-ribose acceptor sites have
remained enigmatic. Here, we show that PARP1 co-
valently ADP-ribosylates the amino-terminal histone
tails of all core histones. Using biochemical tools
and novel electron transfer dissociation mass spec-
trometric protocols, we identify for the first time K13
of H2A, K30 of H2B, K27 and K37 of H3, as well as
K16 of H4 as ADP-ribose acceptor sites. Multiple
explicit water molecular dynamics simulations of
the H4 tail peptide into the catalytic cleft of PARP1
indicate that two stable intermolecular salt bridges
hold the peptide in an orientation that allows K16
ADP-ribosylation. Consistent with a functional
cross-talk between ADP-ribosylation and other
histone tail modifications, acetylation of H4K16
inhibits ADP-ribosylation by PARP1. Taken
together, our computational and experimental
results provide strong evidence that PARP1
modifies important regulatory lysines of the core
histone tails.
INTRODUCTION
Histone proteins form the nucleosome, which is the fun-
damental repeating unit of chromatin (1,2). Each nucleo-
some contains two heterodimers of the core histones H2A
and H2B, one tetramer of the core histones H3 and H4,
and 146 bp of DNA (3). Dynamic chromatin structures
are governed in part by post-translational modifications
of the histones, modification of nucleotides, remodeling of
nucleosomes, and by non-coding RNAs or non-histone
DNA-binding proteins (4). The amino-terminal tails
of the core histone proteins protrude from the nucleo-
some. They appear to be unstructured and are believed
to participate in the formation of higher order chromatin
structures by mediating internucleosomal interactions
and to contact the linker DNA (3,5). A large number
of residues within the histones are modified by
post-translational modifications including acetylation,
phosphorylation, methylation, ubiquitination and ADP-
ribosylation, which occur in distinct patterns (6). Recent
work has provided compelling evidence that these modifi-
cations influence the functional properties of chromatin.
Histones have long been known as substrates for
ADP-ribosylation in vivo (7). Histones isolated from rat
liver nuclei and HeLa cells incubated with radioactive
NAD+ revealed that the linker histone H1 and all core
histones, H2A, H2B, H3 and H4, are ADP-ribosylated,
although to a variable extent (8–12). An unresolved issue
regarding the mechanism of ADP-ribosylation of histones
is whether this modification primarily occurs at the
globular histone domains or at their unstructured
amino-terminals tails. Moreover, unconfirmed ADP-
ribose acceptor amino acids have previously only been
proposed for H1 and H2B, but not for H2A, H3 and
H4 (11,13–15).
Poly(ADP-ribose) polymerase 1 (ARTD1/PARP1) is a
nuclear chromatin-associated multifunctional enzyme that
is present in most eukaryotes apart from yeast (16). The
enzyme is responsible for most of the cellular
poly(ADP-ribose) formation. Targets of PARP10s enzym-
atic activity include a variety of nuclear proteins, most
prominently PARP1 itself, as well as histone proteins
(17). Among the six PARP family members, PARP2 has
the highest similarity with PARP1 (43% sequence identity
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in the catalytic domain) (18). PARP2 displays similar
automodification properties as PARP1 and may account
for the residual poly(ADP-ribose) synthesis observed in
PARP1 knockout mice.
Recently, we showed that individual lysine residues of
PARP1 and PARP2 function as acceptor sites for
auto-ADP-ribosylation and not, as previously assumed,
glutamic acid residues (19,20). Here, we report PARP1-
mediated ADP-ribosylation of the core histone proteins.
We found that PARP1, but not PARP2, ADP-ribosylates
core histone proteins at their amino-terminal tails. Mass
spectrometry of ADP-ribosylated histone peptides
revealed that the lysine residues K13 of H2A, K30 of
H2B, K27 and K37 of H3, as well as K16 of H4, are
specifically ADP-ribosylated by PARP1. Acetylation of
H4K16 or mutation of this residue to an alanine
abrogated ADP-ribosylation. Molecular dynamics (MD)
simulations of tetra- and octapeptide segments of the
amino terminal tail of H4 indicated that two positively
charged side chains at positions n and n+1 in the
histone sequence, which point in opposite directions, are
engaged in favorable electrostatic interactions with two
acidic PARP1 residues at the positions 988 and 756,
buried in the catalytic cleft and on a loop at the
entrance of the cleft, respectively. Taken together, our
results reveal that PARP1 specifically modifies lysine
residues of the core histone tails, which are known to
control chromatin structure and function.
MATERIALS AND METHODS
Chemicals and antibodies
32P-NAD+was purchased from PerkinElmer. NAD+was
obtained from Sigma-Aldrich. Anti-PAR (LP-96-10)
antibody was from Becton Dickinson. Anti-PARP1
antibody was generated in this laboratory. PARP-
inhibitor DAM-TIQ-A was obtained from Alexis
Biochemicals, PJ34 was purchased from Enzo Life
Science, 3-amino-benzamide (3AB) was from Sigma-
Aldrich. Peptides were from PiProteomics. ProbondTM
nickel beads were from Invitrogen. Glutathione-
Sepharose 4B affinity beads were from GE-healthcare.
Plasmids
The baculovirus expression vectors pQE-TriSystem
(Qiagen) and BacPak8 (Clontech) were used for the
expression of recombinant proteins in Sf21 cells as
described (21,22). pGEX-2T vectors (GE healthcare)
were used for the cloning and expression of GST-fusion
proteins. Full-length and truncated histone proteins were
expressed in pET3a or pET3d vectors, as described (3).
Sequencing of plasmids was performed by Microsynth
(Balgach, CH).
Cloning, expression and purification of
recombinant proteins
Human PARP1 and PARP2 were cloned, expressed and
purified as described (19). Full-length histone proteins
were generated as described (3). GST-histone tail fusion
proteins were generated by PCR and cloned into
pGEX-2T vector. Truncated and mutated versions of
GST-fusion proteins were generated by cloning with
BstBI and EcoRI restriction sites. Primers for PCR and
direct cloning were obtained from Sigma-Aldrich and
Microsynth. pGEX-2T plasmids were transformed into
BL21(DE3) bacteria and expression was induced by
addition of 1mM IPTG into LB-medium for 3 h at
30C. After centrifugation and resuspension in
EBC-buffer (120mM NaCl, 50mM Tris–pH 8.0, 0.5%
NP-40, 5mM DTT, 1mM PMSF), bacteria were lysed
by the addition of lysozyme (0.5mg/ml) and the DNA
was sheared by a French Press. After centrifugation the
supernatant was taken and the proteins were bound to
GST-beads and washed extensively with EBC buffer.
The GST-beads with the bound GST-fusion proteins
were equilibrated with ADP-ribosylation buffer (50mM
Tris–HCl, pH 8.0, 4mM MgCl2, 250 mM DTT, 20mM
NaCl, 1 mg/ml protease inhibitors pepstatin, leupeptin
and bestatin) and after extensive washing eluted from
the GST-beads with 10mM reduced glutathione in
ADP-ribosylation buffer.
ADP-ribosylation assays
32P-NAD+ADP-ribosylation was performed as previously
described (19). Briefly, 20 mg histone mix from calf thymus
(Roche) were incubated with 10 pmol PARP1 or PARP2
in a 25 ml reaction, containing 5 pmol annealed
EcoRI-linker DNA and 100 nM 32P-NAD+ in
ADP-ribosylation buffer (50mM Tris–HCl, pH 8.0,
4mM MgCl2, 250 mM DTT, 20mM NaCl, 1 mg/ml
protease inhibitors pepstatin, leupeptin and bestatin) for
10min at 30C. ADP-ribosylation of full-length or
truncated single histones was performed with 3 mg
full-length or truncated histone proteins and 10 pmol
PARP1 in a 25 ml reaction. ADP-ribosylation of
GST-histone tail fusion proteins was performed with
1.5 mg purified fusion protein, together with 10 pmol of
PARP1. An amount of 5 pmol EcoRI-linker DNA was
always included into the reaction to activate PARP1 en-
zymatic activity. ADP-ribosylation assays with full-length
or truncated histones were resolved by a 10–20% acryl-
amide gradient SDS-gel of 15 cm length (Amersham).
Assays with GST-fusion proteins were resolved on
standard 12% acrylamide mini-gels (Hoefer).
Radiolabeled proteins were visualized by exposure to
X-ray films or by quantification through the phospho-
imager system (Molecular Dynamics).
For mass spectrometry, 22 nmol biotinylated H2A
(aa 3–23), H2B (aa 18–37), H3 (aa 23–42), H4 (aa 1–22)
or H4K16ac (aa 1–22) peptides were incubated with
10 pmol PARP1, 5 pmol annealed EcoRI-linker and 100
or 500 mM NAD+for 15min at 30C in ADP-ribosylation
buffer without protease inhibitors. The reaction was
stopped by the addition of 3AB to a final concentration
of 20mM and subsequently 1mg GST-ARH3 was added
to the reaction and further incubated for 1 h at 30C. The
samples were acetone precipitated and the pellet was
dissolved in distilled water.
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GST-pulldown
Glutathione–sepharose affinity beads were incubated with
a bacterial extract of the GST-fusion protein expression in
EBC-buffer. After extensive washing, the GST-beads were
equilibrated with ADP-ribosylation buffer containing
50mM NaCl. After washing, 10 pmol purified PARP1
was added to the beads in a total volume of 300 ml
ADP-ribosylation buffer. The protein mixture was
incubated for 2 h at 4C on rolls to allow for protein–
protein interaction. The samples were washed again with
ADP-ribosylation buffer and resolved on standard SDS–
PAGE and subsequent western blotting with anti-PARP1
antibody.
Microvolume C-18 reversed phase purification
An amount of 22 nmol H4-peptide (aa 1–22) was
incubated with 10 pmol PARP1, 5 pmol EcoRI-linker
DNA and 100 nM 32P-NAD+ in 25 ml ADP-ribosylation
buffer for 15min at 30C. The reaction was stopped by the
addition of 3AB to a final concentration of 20mM. The
C18 reversed phase ZipTip (Millipore) was pre-wetted
with 100% methanol and equilibrated with 3% (v/v)
acetonitrile. The peptides were bound onto the column
and subsequently washed extensively with 3% (v/v) aceto-
nitrile. Bound peptides were eluted by 60% (v/v) acetoni-
trile directly into scintillation liquid. In the control
reaction, peptides were added after the addition of 3AB
to the reaction. Scintillation counts were measured and
normalized to the control reaction and the relative
increase in scintillation counts was calculated (cpm).
Mass spectrometry
Electron transfer dissociation (ETD) experiments were
performed on a hybrid LTQ Orbitrap XL ETD mass spec-
trometer (Thermo Scientific, Bremen, Germany) coupled
to an Eksigent nano LC system (Eksigent Technologies)
and the samples were analyzed by reversed-phase liquid
chromatography nanospray tandem mass spectrometry
(LC–MS/MS).
Peptides were resuspended in 3% ACN and 0.2%
formic acid, loaded from a cooled (10C) Spark Holland
autosampler (Emmen, Holland) and separated using
an ACN/water solvent system containing 0.2% formic
acid with a flow rate of 200 nl/min. Separation of the
peptides was performed on a 10-cm long fused silica
column (75 mm i.d.; BGB Analytik) in-house packed
with 3 mm, 200 A˚ pore size C18 resin (Michrom
BioResources, CA). Elution was achieved using a
gradient of 348% ACN in 35min, 4880% ACN in
4min and 80% ACN for 7min.
One scan cycle was comprised of a survey full scan MS
spectra from m/z 300 to 2000 acquired in the FT-Orbitrap
with a resolution of R=60000 at m/z 400, followed by up
to four sequential data-dependent ETD MS/MS scans
with detection of the ETD fragment ions in the linear
ion trap. AGC target values were 5 105 for full FTMS
scans, 104 for ion trap MSn scans. Anion target value was
106 and supplementary activation was employed to
enhance the fragmentation efficiency for doubly-charged
precursors and charge state dependent ETD time was
enabled. Data dependent decision tree was used in order
to control ETD dissociation based on charge state and m/
z. The ETD reaction time was set at 100ms and the iso-
lation width was m/z 2. For all experiments dynamic ex-
clusion was used with one repeat count, 30-s repeat
duration, and 10-s exclusion duration.
The instrument was calibrated externally according to
the manufacturer’s instructions. Orbitrap mass spectra
were acquired using internal lock mass calibration on
m/z 429.088735 and 445.120025. Spectra generated by
ETD were processed using Mascot Distiller 2.2 (Matrix
Science) and data was searched against a SwissProt
human database using Mascot 2.2.0 to find best
matching sequences. Detailed spectra analysis was done
by manual evaluation.
Molecular dynamics
It is computationally prohibitive to dock the full-length
histone tails to PARP1. Therefore, only the relevant
tetra- and octapeptide segments of the histone tails
(abbreviated H-peptides hereafter) were taken into
account in the present study. A two-step procedure was
used to investigate the binding of the H-peptides to
PARP1 (PDB ID: 1A26). Preliminary binding modes of
the flexible H-peptides into the rigid structure of the cata-
lytic domain of PARP1 were obtained by an in-house de-
veloped docking program, which uses a combination of
simulated annealing and genetic algorithm optimization
of position, orientation, and rotatable bonds of the
ligand (Zhao et al., unpublished). Explicit solvent MD
simulations of the H-peptide/PARP1 complexes were
then used to investigate the structural stability of the
poses obtained by docking. In both docking and MD
simulations, the N-terminus and C-terminus of the
H-peptides were capped by neutral groups (acetyl and
N-methlyamide, respectively) to take into account the
fact that they belong to a longer polypeptide chain. To
reproduce physiological pH conditions, the side chains of
aspartates and glutamates were negatively charged, those
of lysines and arginines were positively charged, while all
other residues were considered neutral. The MD simula-
tions were performed with the program NAMD (23) using
the all-atom CHARMM PARAM27 force field (24) and
the TIP3P model of water (25). The H-peptide/PARP1
complexes were inserted into a cubic water box, with a
minimal distance of 12 A˚ between any solute atom and
the boundary of the box. Chloride and sodium ions were
added to neutralize the system and approximate a salt
concentration of 150mM. The water molecules
overlapping with the solute atoms or the ions were
removed, if the distance between the water oxygen and
any atom of the complex or any ion was smaller than
2.4 A˚. Periodic boundary conditions were applied to
avoid finite-size effects. Electrostatic interactions were
calculated within a cutoff of 12 A˚, while long-range elec-
trostatic effects were taken into account by the particle
mesh Ewald summation method (26). Van der Waals
interactions were treated with the use of a switch
function starting at 10 A˚ and turning off at 12 A˚,
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which is the default of the all-atom CHARMM force field.
The temperature was kept constant at 300K by the
Langevin temperature control with a damping coefficient
of 5 ps1, while the pressure was held constant at 1 atm by
applying a pressure piston. Before the production runs,
water molecules and ions were subjected to energy mini-
mization for 6000 steps, and a 1-ns equilibration with
harmonic constraints applied to the positions of the
C-alpha atoms. The covalent bonds involving hydrogen
atoms were constrained by means of the SHAKE algo-
rithm, and the dynamics were integrated with a time
step of 2 fs. Snapshots were saved every 2 ps for trajectory
analysis. Two MD runs with different initial distribution
of velocities were carried out for each of the H4 peptides
AKRH and AKRHRKIL for a total simulation time of
150 ns for each peptide. Analysis of the trajectories was
carried out with the programs CHARMM (27) and
WORDOM (28).
RESULTS
PARP1 modifies core histones
Recently, we reported the ADP-ribosylation of distinct
lysine residues of PARP1 and PARP2 in cis (19,20).
Since core histones were described earlier to be modified
by PARP1 in vitro and in vivo [(16) and Supplementary
Figure S1A and B], we set out to investigate which
residues of H2A, H2B, H3 and H4 would be modified
by PARP1, and possibly also by PARP2 in trans. First,
human PARP1 and PARP2 were expressed and purified
from insect cells using the baculovirus-system and were
subsequently incubated with full-length histones isolated
from calf thymus together with 100 nM radiolabeled
NAD+. Although automodification of both PARP1 and
PARP2 was easily detectable, only PARP1 displayed de-
tectable trans-ADP-ribosylation of all four core histones,
indicating a clear difference in the substrate specificity
between PARP1 and PARP2 (Figure 1A). Similar experi-
ments with bacterially expressed and purified single
histone proteins revealed that, indeed, all four histones
are modified by PARP1 (Figure 1B).
PARP1 mono- and poly(ADP-ribosyl)ates amino-terminal
tails of core histone proteins covalently
Earlier reports suggested that histones are mainly
ADP-ribosylated at their amino-terminal tails (13,29). To
test whether PARP1-mediated ADP-ribosylation occurred
at the amino-terminal tails or at the globular histone folds,
we incubated the globular domains of histones H2B, H3
and H4 together with PARP1 and compared their
ADP-ribosylation to the full-length counterpart
(Supplementary Figure S2A). ADP-ribosylation of the
globular domains was reduced in comparison to full-length
histones, implying that indeed the amino-terminal tails are
required for modification by PARP1. We then expressed
the different histone tails as GST fusion proteins in bacteria
and incubated them with purified PARP1 and radiolabeled
NAD+. PARP1 was able to modify all four histone tails;
whereas comparable PARP2-mediated ADP-ribosylation
of histone tails was not detectable (Figure 1C and
Supplementary Figure S2B). This finding suggests that
the core histone tails are substrates specifically for
PARP1 but not for PARP2 in vitro. Previous reports
indicated that histones can interact with
poly(ADP-ribose) non-covalently via a PAR-binding
motif (30). Since the tested histone tails we analyzed did
not contain this motif, it is highly unlikely that the observed
labeling represented non-covalently attached PAR. To
exclude this notion experimentally, the histone tail fusion
proteins were added to the ADP-ribosylation reaction
either together with PARP1 or after the enzymatic
reaction had been stopped by addition of the
PARP-inhibitor 3AB. The addition of the histone tails
after the reaction did not result in their modification
(Figure 1D, right panel), implying that the observed
ADP-ribosylation is a covalent modification. To test
whether the observed modification is an enzymatic
reaction, the reaction was repeated in presence of the
PARP-inhibitor PJ34. Increasing amounts of PJ34 abol-
ished trans-ADP-ribosylation of the H2B tail, as well as
automodification of PARP1 (Figure 1E). Similar results
were obtained with a second PARP-inhibitor, DAM-
TIQ-A (Figure 1E). Taken together these results indicate
that PARP1 catalyzes the covalent ADP-ribosylation of
histone tails.
PARP1 is a mono- and a poly(ADP-ribosyl) transferase
(16). To determine whether the histone tails can be mono
and/or poly(ADP-ribosyl)ated by PARP1, we incubated
the histone tails with PARP1 in the presence of increasing
amounts of NAD+. Poly(ADP-ribosyl)ation was
determined by immunoblot analysis using an anti-PAR
antibody, which recognizes only polymers of ADP-ribose
(PAR). Both automodification of PARP1 and
poly(ADP-ribosyl)ation of the histones were detected,
indicating that PARP1 can attach long polymers of
ADP-ribose onto histone tails (Figure 1F). Notably, the
length of poly(ADP-ribose) chains of the histones
increased proportionally to the amounts of NAD+, which
led to retarded migration of the modified proteins due to
an increased molecular weight (Figure 1F, filled asterisk).
ADP-ribosylation was earlier described to occur on glu-
tamates of H2B and H1 (11,15). These findings were never
directly attributed to PARP1 nor were they experimentally
confirmed by mass spectrometry or amino-acid substitu-
tions. The PARP1-mediated ADP-ribosylation we
describe here occurred on the basic amino-terminal
histone tails, most of which do not contain glutamates
(Figure 2A). One exception is the tail of histone H2B
that contains one single glutamate. Mutation of this
residue to alanine did not affect the levels of incorporated
ADP-ribose onto the H2B tail by PARP1 (Supplementary
Figure S2C), suggesting that glutamates are dispensable
and that additional residues can be efficiently
ADP-ribosylated by PARP1 in trans. Furthermore, when
we incubated poly-L-lysine or poly-L-glutamate with
purified PARP1 and measured incorporated ADP-ribose,
lysines but not glutamates were modified by PARP1
(Supplementary Figure S2D). These findings are consist-
ent with our previous reports (19,20) and provided add-
itional evidence that lysines are likely the primary target
sites for PARP1-mediated ADP-ribosylation.
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Identification of ADP-ribose acceptor sites within
histone tails
As the amino-terminal histone tails are frequently targeted
by a variety of post-translational modifications with
important physiological functions (6), we aimed at iden-
tifying the exact sites of PARP1-mediated ADP-
ribosylation. To this end, we first generated a series of
histone tail deletion mutants to test in ADP-ribosylation
Figure 1. PARP1 covalently modifies all four core histone tails. (A) PARP1 trans-ADP-ribosylates histones isolated from calf thymus. An amount of
10 pmol recombinant PARP1 or PARP2 were incubated for 15min (PARP1) or 30min (PARP2) at 30C with 5 pmol EcoRI-linker DNA, 100 nM
radiolabeled NAD+ and 20 mg extracted histones from calf thymus. The reaction was stopped by addition of SDS-lysis buffer and the proteins were
resolved on a 10–20% SDS–PAGE gradient gel. The gel was stained with Coomassie-R250 and incorporated 32P was visualized by autoradiography.
(B) Recombinant expressed and purified histones (3 mg) were ADP-ribosylated by PARP1 as in Figure 1A. (C) An amount of 1.5 mg of each purified
GST-histone tail were used in PARP1 or PARP2 mediated trans-ADP-ribosylation reactions for 5min at 30C. (D) An amount of 1.5 mg of each
purified GST-histone tail were used in PARP1 mediated trans-ADP-ribosylation reactions for 5min at 30C. Histone tails were either included during
the reaction (pre) or added after the reaction had been stopped with a 100-fold excess of 3AB over radiolabeled NAD+ (post) to exclude
non-covalent interaction of the histone tails with PAR. (E) Trans-ADP-ribosylation of the H2B tail is inhibited by the PARP-inhibitors PJ34
(0.01–100 mM) and DAM-TIQ-A (10 mM). (F) GST-histones were incubated with PARP1, EcoRI linker and increasing concentrations of NAD+
(0, 10, 100, 400mM) for 10min at 30C. Poly(ADP-ribose) formation was assessed through western blotting with anti-PAR (LP-96-10) antibody.
Unmodified GST-histone tails are marked by an empty asterisk, PARylated GST-histone tails are marked by a filled asterisk.
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assays (Figure 2A). Successive shortening of the histone
tails invariably resulted in a loss of PARP1-mediated
ADP-ribosylation and defined for each histone the
region comprising putative ADP-ribose acceptor sites
(Figure 2B–E).
To directly identify the ADP-ribosylated amino acids
within the histone tails by mass spectrometry, we used
synthetic peptides covering the regions identified by our
deletion strategy. We incubated these peptides with
PARP1 in the presence of 100–500mM NAD+, stopped
the reactions by addition of 3AB and subsequently
treated the poly(ADP-ribosyl)ated peptides with
ADP-ribosylhydrolase 3 (ARH3). ARH3 is known to
possess PARG-like ADP-ribose glycohydrolase activity,
which hydrolyzes ester linkages between ADP-ribose
units (31). Since no negatively charged amino acids
(E or D), which would allow the formation of an ester
linkage, were present in the polypeptides (except for
H2B E35), we rationalized that treatment of the
modified polypeptides with ARH3 would leave the first
ADP-ribose unit bound to the peptide. The ADP-
ribosylated peptides were acetone precipitated and
analyzed by liquid-chromatography coupled mass-
spectrometry. In the presence of PARP1 and NAD+,
the attachment of a single ADP-ribose unit resulted in
a mass shift of 541 Dalton (Figure 3A–D).
Fragmentation of ADP-ribosylated peptides with conven-
tional collision induced dissociation (CID) fragmentation
Figure 2. Confining the regions of putative ADP-ribose acceptor sites. (A) Schematic representation of the deletion strategy for GST-histone tails to
identify the minimal ADP-ribosylated domain. (B–E) Trans-ADP-ribosylation of the indicated GST-histone deletion mutants by PARP1 with 100 nM
32P-NAD+.
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technique completely removed the ADP-ribose moiety
from the peptides, not allowing the identification of
specific amino-acid acceptor sites (data not shown). In
contrast, analysis of the modified peptides by electron
transfer dissociation (ETD) resulted in an almost
complete fragmentation of the multiply charged histone
peptides, as indicated by the presence of c- and z-ions,
which represent N- or C-terminal fragment ions, respect-
ively (Figure 3A–D, Supplementary Figure S2E).
Fragmentation of the mono(ADP-ribosyl)ated H2A
peptide revealed specific ADP-ribosylation of K13, while
H2B was mainly ADP-ribosylated at K30 (Figure 3A
and B). H3 was ADP-ribosylated at K27 and K37
(Figure 3C and Supplementary Figure S2E). For H4,
mass spectrometric analysis identified K16 to be
ADP-ribosylated by PARP1 (Figure 3D). Control reac-
tions performed in the presence of 500 mM NAD+ but
without PARP1 or in the presence of 500mM
ADP-ribose and PARP1 did not result in specific
ADP-ribosylation (data not shown). The identified sites
of PARP1-mediated enzymatic ADP-ribosylation repre-
sent two known sites of frequent histone modification
(H3K27 and H4K16) as well as novel modification sites
(H2AK13, H2BK30 and H3K37). To verify the mass spec-
trometric data for one histone, the H4 tail was mutated at
K16 to alanine and tested for ADP-ribosylation by
PARP1. The mutated H4 tail showed severely reduced
ADP-ribosylation in comparison to the wild-type H4
tail (Figure 3E, filled asterisk). The reduction of
ADP-ribosylation was not due to a reduced interaction
of PARP1 with the mutated H4 tail, since wild-type and
mutated histone tail fusion proteins were able to interact
with PARP1 to comparable levels (Figure 3F).
Modeling of the histone H4 tail reveals that R17 is
critical for the interaction with the catalytic
domain of PARP1
In order to test computationally, whether the tail of H4
could enter the catalytic cleft of PARP1, automatic
docking followed by explicit solvent MD simulations
were performed with the crystal structure from chicken
PARP1 (PDB ID: 1A26), which uses the sequence num-
bering of human PARP1 (see ‘Materials and methods’
section). The MD simulations indicate that the H4
tetrapeptide segment AKRH (aa 15–18) binds in an
extended conformation to the catalytic domain of
PARP1 (Figure 4A and B). Two stable salt bridges are
observed in all MD runs: between H4K16 and PARP1
Glu988 in the catalytic cleft, and between H4R17 and
PARP1 Glu756 (Asp756 in human PARP1) on a loop at
the entrance of the cleft. These intermolecular salt bridges
lock H4 into the catalytic domain of PARP1 like two
stretched arms holding two points far away from each
other. In all MD runs, a single water molecule inserts
between the amino group of K16 and the carboxy group
of Glu988 in the first 15 ns and remains between these two
charged groups until the end of the MD simulations of the
tetrapeptide (Supplementary Figure S3). This water
molecule occupies the same position as the water
molecule that is close to Glu988 in the X-ray structure
of PARP1 (water 37 in PDB code 1A26). There are two
additional side chains interactions: a stacking interaction
between the imidazole of H18 and the amide group of
Gln759 is almost always present in all MD runs, while
the hydrogen bond between the side chains of R19 and
Asn906 is not very stable. In contrast to the aforemen-
tioned intermolecular salt bridges and hydrogen bonds,
the K20 side chain is always exposed to solvent and very
flexible. Furthermore, the backbone polar groups of the
histone do not seem to be involved in hydrogen bonds
with PARP1. Importantly, in all MD simulations both
the N-terminal and C-terminal methyl groups point
towards the solvent, which would allow the rest of
the H4 polypeptide chain to position itself close to the
surface of PARP1 without steric clashes. Moreover, the
MD runs with the H4 tetra- and octapeptide (aa 15–22)
converge towards a common extended structure of the
AKRH segment with the same side chain interactions.
The convergence of multiple MD simulations and the
agreement with the experimental results indicate that the
binding mode obtained by docking and explicit water MD
is reliable. To gain insight in the putative initiation step of
ADP-ribosylation, the 10 ns snapshot of the MD simula-
tion with the H4 tetrapeptide was used for docking NAD+
into the donor site as previously published (32,33). Before
docking, the nicotinamide was manually removed
(Figure 4C), which mimics the NADase activity of
PARP1 and creates a reactive C1-atom of the
ADP-ribose that is suggested to react with the substrate
amino acid (19,34,35). Interestingly, the C1-atom of the
ADP-ribose is only 3.7 A˚ away from the "-amino group of
H4K16 and 7.8 A˚ from the "-amino group of Lys903.
Moreover, the distance between the catalytic active
Glu988 carboxy group and the "-amino group of H4K16
is only 3.0 A˚, which would potentially allow covalent
ADP-ribosylation of H4K16 (Figure 4C).
To test experimentally whether an arginine close to
H4K16 is required for the interaction with PARP1, we
mutated R17 (H4R17A) and analyzed the association
with and the modification by PARP1. GST-pulldown ex-
periments with recombinant PARP1 revealed that the
interaction between PARP1 and the mutated H4 tail
fusion protein was reduced (Figure 4D), as well as its
ADP-ribosylation by PARP1 (Figure 4E). In agreement
with the MD simulation and the mass spectrometry data,
an H4K16A/R17A double mutant was completely defect-
ive for PARP1-mediated ADP-ribosylation (Figure 4F).
Since H4R17 was suggested by molecular modeling to
interact with Asp756 of PARP1, we mutated Asp756
into a lysine (which is the corresponding amino acid
at this position in PARP2) and tested this mutant for
its ADP-ribosylation properties. The PARP1 mutant
exhibited no defect in auto(ADP-ribosyl)ation
(Supplementary Figure S2F), indicating that Asp756 is
not essential for automodification. This is consistent
with the fact that also PARP2 is able to modify itself,
although it contains a lysine at the corresponding
position. Interestingly, however, the PARP1 mutant was
impaired in trans-ADP-ribosylation of full-length histones
(Figure 4G) and in the labeling of the H4 (1–22) peptide
(Supplementary Figure S1G), confirming the MD-based
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Figure 3. Mass spectrometric analysis of ADP-ribosylated histone peptides. (A) Extracted ion chromatogram of the biotin tagged H2A (aa 3–23)
peptide incubated with 500 mM NAD+ and PARP1. The precursor masses of unmodified H2A peptide (2395.34Da) and ADP-ribosylated H2A
peptide (2936.40Da) were plotted in a range of 10 ppm over time. ETD fragment spectrum of quintuply charged precursor ion of ADP-ribosylated
H2A peptide (638.51m/z) at K13, as indicated by the sequence plot. The spectrum shows next to the two major peaks of unfragmented charge
reduced precursor ions (M+5H)n+ an almost complete series of N-terminal and C-terminal fragment ions (c-ions, z-ions, respectively). (B) Extracted
ion chromatogram of the biotin tagged H2B (aa 18–37) peptide incubated with 500 mM NAD+ and PARP1 as in (A). ETD fragment spectrum
of ADP-ribosylated H2B peptide (797.89m/z) at K30, indicated by the sequence plot. (C) Extracted ion chromatogram of the biotin tagged H3
(aa 23–42) peptide incubated with PARP1 as in (A). ETD fragment spectrum of ADP-ribosylated H3 peptide (590.29m/z) at K27, indicated by the
sequence plot. (D) Extracted ion chromatogram of the biotin tagged H4 (aa 1–22) peptide incubated with 100mM NAD+and PARP1. ETD fragment
spectrum of ADP-ribosylated H4 peptide (621.30m/z) at K16, as indicated by the sequence plot. (E) Trans-ADP-ribosylation of the GST-H4 histone
tail wild-type or K16A mutant by PARP1. (F) GST-pulldown of wild-type and mutated GST-histone H4 tails with recombinant PARP1.
The GST-histone tails are marked by an asterisk.
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Figure 4. Histone H4 interacts with PARP1 by salt bridges with acidic residues in the catalytic domain. (A) Representative snapshot of the binding
mode saved after 10 ns MD simulation of the H4 tetrapeptide AKRH. (B) Enlarged view of the catalytic cleft for the same snapshot as in (A). Amino
acids in close proximity of the H4 peptide are highlighted. PARP1 and the H4 tetrapeptide are shown in surface render and sticks, respectively. The
surface is colored according to atomic elements with carbon, oxygen and nitrogen in green, red, and blue, respectively. Carbon atoms of the H4
tetrapeptide are in cyan. (C) ADP-ribose was docked into the donor-site of PARP1 catalytic domain after 10 ns MD simulation of the H4
tetrapeptide. Amino acids in close proximity of the H4 peptide are highlighted. The orientation is rotated by about 180C with respect to (A,B).
(D) GST-pulldown of wild-type and mutated GST-histone H4 tail with recombinant PARP1 and subsequent western blot with anti-PARP1 antibody.
GST-histone tails are indicated by an asterisk. (E and F) Trans-ADP-ribosylation of wild-type and mutated GST-H4 tails with PARP1 and
radiolabeled NAD+. Coomassie stains of the input and autoradiographies are shown. (G) Trans-ADP-ribosylation of calf-thymus extracted
histones by PARP1 wild-type or PARP1 D756K mutant as in Figure 1A.
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prediction of the importance of this residue for stabiliza-
tion of the peptide in the catalytic cleft and subsequent
trans(ADP-ribosyl)ation of H4.
Acetylation of K16 inhibits ADP-ribosylation
of histone H4
Acetylation of H4K16 occurs frequently in eukaryotic
cells and has been correlated with chromatin
decompaction (6). If H4K16 was indeed an acceptor site
for PARP1-mediated ADP-ribosylation, acetylation at
that site should impair ADP-ribosylation. In order to
test this hypothesis, we employed an H4 peptide (aa 1–
22) chemically acetylated at K16. LC-coupled mass spec-
trometry of the H4K16ac peptide revealed that PARP1
was not any longer able to induce ADP-ribosylation of
the acetylated peptide above background (Figure 5A).
Consistent with this result, PARP1 mediated
ADP-ribosylation of both peptides (unmodified and
acetylated) with radiolabeled NAD+, followed by purifi-
cation over a microvolume-C18 reversed phase column
and subsequent measurement of incorporated
radiolabeled NAD+, provided evidence that ADP-
ribosylation of the acetylated peptide was severely
reduced (Figure 5B). These results confirm that H4K16
is modified by PARP1 and show that acetylation of K16
severely impairs ADP-ribosylation of the H4 peptide.
Together, our results led to the identification of
ADP-ribose acceptor sites within the amino-terminal
tails of the four core histones (Figure 5C) and imply im-
portant cross-talks with other histone modifications such
as acetylation or methylation.
DISCUSSION
Here, we provide evidence that PARP1 covalently
modifies the tails of all four core histones. We identified
H2AK13, H2BK30, H3K27, H3K37 and H4K16 as
specific target sites for PARP1-mediated ADP-
ribosylation. Our conclusions are based on several obser-
vations: (i) mass spectrometric analyses of
PARP1-mediated ADP-ribosylated peptides, (ii) loss of
function experiments by site directed mutagenesis of the
putative acceptor sites in recombinant histone tail fusion
proteins, (iii) cross-talk of acetylation and ADP-
ribosylation at the identified acceptor site in H4 and,
finally, (iv) prediction of the interaction between the
histone H4 tail and PARP1 by MD and subsequent con-
firmation with mutated proteins.
Nearly 20 years ago, ADP-ribose acceptor sites were
found in histones by biochemical approaches. Several
laboratories identified glutamic acid residues in histone
H1 and histone H2B to be modified when they incubated
chromatin from rat liver with radioactive NAD+ (11,13–
15). At that time, no other PARP family member had been
identified yet, and no knockout- or knockdown-system
was available. Thus, it is possible that PARP1, other
PARP-family members or even unrelated NAD+
consuming enzymes were responsible for the modification
at the identified glutamates. In fact, we could show here by
mutational analyses, that E2 of H2B is dispensable for
PARP1-mediated ADP-ribosylation and that additional
amino-acid residues are acceptors for ADP-ribose
moieties. Consistent with this, we identify lysines in the
amino terminal histone tails and in particular lysine 13 of
H2A, lysine 30 of H2B, lysines 27 and 37 of histone H3, as
well as lysine 16 of histone H4 as target sites for enzymatic
ADP-ribosylation by PARP1, both by mass spectrometry
and amino-acid substitution. Therefore, we propose the
ADP-ribosylation of the "-amino group of lysines by
PARP1 as a new canonical histone tail modification.
Remarkably, explicit solvent MD revealed that the
tetra- and octapeptides of H4 interact strongly with
specific amino-acid side chains of the catalytic cleft of
PARP1, suggesting that specific binding of a relatively
short segment of H4 is sufficient to allow
poly(ADP-ribosyl)ation of the histone tail. The positively
charged amino acid at the +1 position of the
ADP-ribosylated residue formed a salt bridge with
Glu756 of chicken PARP1, which corresponds to
Asp756 in human PARP1. In contrast, the corresponding
amino acid in PARP2 is a lysine at position 312. Although
the catalytic domains of PARP1 and PARP2 are highly
similar (18), the substrate specificity of those enzymes
might be regulated by subtle differences in the catalytic
cleft. This could explain why PARP2 does not modify
histones to a detectable extent at least in vitro (Figure
1A, C and Supplementary Figure S2B).
Application of novel mass spectrometry techniques
allowed us to identify distinct amino acids as acceptors
of ADP-ribose. We took advantage of the ETD technique
(36), which allows the fragmentation of highly charged
peptides, leaving most post-translational modifications
intact. Recent publications describe the technical basis
for the fragmentation of chemically ADP-ribosylated
peptides by electron capture dissociation (ECD) (37) and
the closely related ETD (38). It is noteworthy, that, in
contrast to other reports, we observed partial fragmenta-
tion of the ADP-ribose at the phosphodiester bond by
application of ETD, as revealed by the presence of a
m/z 348 ion. However, conventional CID mass spectrom-
etry of ADP-ribosylated H4 peptide did not reveal any
ADP-ribose acceptor sites, since the ADP-ribose was
cleaved off from the peptide during fragmentation. The
commonly used CID, instead of ETD, might thus explain
why numerous efforts to identify ADP-ribosylated residues
failed in the past. Consequently, we would strongly recom-
mend ETD as standard technique to detect
ADP-ribosylated peptides. Of note, a previous study em-
ploying CID failed to detect ADP-ribosylated lysine
residues in the catalytic PARP1 mutant E988Q (39). In
summary, ETD can be expected to facilitate future inves-
tigations on ADP-ribosylated peptides, opening new
opportunities to screen for ADP-ribosylated residues in a
systems-biology setup.
Since poly(ADP-ribosyl)ated peptides cannot be
detected by MS and PARP1 mainly attaches
poly(ADP-ribose) to target proteins, we removed the
poly(ADP-ribose) with ARH3, which degrades
poly(ADP-ribose). However, this treatment was rather in-
efficient (data not shown), which could partly explain the
observed low mono(ADP-ribosyl)ation of the histone
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Figure 5. ADP-ribosylation of the H4 peptide is impaired by H4K16 acetylation. (A) Elution profile of biotinylated H4 peptide (aa 1–22) and
biotinylated H4K16ac peptide (aa 1–22) incubated with 100 mM NAD+ for 15min without PARP1 (–PARP1) or in the presence of PARP1
(+PARP1) and subsequent ARH3 treatment. Acetone precipitated peptides were analyzed by LC–MS/MS using a C18 reversed-phase column
and subsequent detection by mass spectrometry. (B) Histone H4 (aa 1–22) and acetylated H4K16ac (1–22) peptides were ADP-ribosylated with
PARP1 for 15min at 30C with 100 nM 32P-NAD+. The peptides were purified by microvolume-C18 reversed phase columns, eluted into scintillation
liquid and counted for incorporated 32P. Relative increase of counts per minutes was calculated over background (peptides added after termination of
the reaction by 3AB). (C) Overview of the identified ADP-ribose acceptor sites within the amino-terminal core histone tails.
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peptides. Moreover, we cannot exclude that PARP1
modifies additional residues, which were not identified
by these mass spectrometric analyses.
Our data provide strong evidence that PARP1-mediated
ADP-ribosylation of histones occurs as post-translational
modification at distinct lysine residues within the
amino-terminal basic tails. From a chemical perspective,
modification of a lysine residue by ADP-ribose results in
an unstable Schiff base, which can undergo an Amadori
rearrangement to form a stable ketoamine (19,40). It will
be interesting to investigate whether histone lysine
ADP-ribosylation can be reversed by a previously
identified but still poorly characterized ADP-ribosyl
protein lyase (41). Since the attachment of ADP-ribose
not only neutralizes the positive charge of the amino-acid
side chain, but instead reverses it into a negative charge,
the functional consequences of lysine ADP-ribosylation
can be assumed to be even more drastic than those of
other modifications, such as acetylation. Therefore, the
possible effects on chromatin architecture, histone
dynamics, histone degradation, and histone variant
incorporation may be dramatic. Possibly,
ADP-ribosylation of histones interferes with other
post-translational modifications of the histone tails. For
example, H3K27 is methylated by EZH2 (enhancer of
zeste homolog 2), which is in the polycomb group
complex that is involved in maintenance of the inactive
X-chromosome (42). Interestingly, PARP1 was
demonstrated to participate in the maintenance of
X-chromosome silencing as well (43). On the other
hand, the amino-terminal tail of histone H4 was shown
to be required for chromatin fiber formation, since the
positively charged stretch between K16 and K20 makes
internucleosomal contacts to two acidic patches on the
carboxy-terminal a-helices of histone H2A (44). In
addition to its function for chromatin topology, the
stretch between K16 and K20 is required for the inter-
action with various non-histone modulators. For
example, the ISWI-containing ATP dependent chromatin
remodeler ACF solely engages histone H4, but is repelled,
if H4K16 is acetylated (45,46). Furthermore, the chroma-
tin remodeler Alc1 was shown to require the K16 to K20
stretch of H4 for its activity (47). Interestingly, recent
reports provide evidence that the ATPase activity of
Alc1 is highly stimulated by binding to poly(ADP-
ribosyl)ated PARP1 (47,48). Whether ADP-ribosylated
H4 would activate Alc1, remains to be investigated.
Another intriguing possibility of how histone tail
ADP-ribosylation could affect chromatin function is
implied by a recent study showing that macrodomain-
containing histone variants specifically bind to
poly(ADP-ribose) generated after DNA damage (49).
Using biochemical, crystallographic and state-of-the-art
imaging techniques, it was shown that macroH2A1.1
senses PARP1 activation and directly binds poly
(ADP-ribose) to cause a transient compaction of the chro-
matin. It will be interesting to investigate whether
macrodomains preferentially bind to automodified
PARP1 or also function as ‘readers’ of poly
(ADP-ribosyl)ated histone tails.
Taken together, the work presented here sheds new light
on a well known but neglected histone modification and
builds the basis for future investigations exploring the
function of histone lysine ADP-ribosylation in chromatin
dynamics, transcription, DNA repair signaling and other
nuclear processes influenced by histone modifications.
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Supplementary Methods 
 
Cell culture, transfection of siRNA and overexpression of PARP1 
HEK293T cells were grown in DMEM Glutamax-1 (Invitrogen), supplemented with 10% 
(v/v) fetal calf serum (Invitrogen) and 50 units/ml penicillin and 50 µg/ml streptomycin 
(Sigma). Cells were grown in 5% CO2 and 37°C in a humidified incubator. HEK293T 
cells were transfected with RNAi-max (Invitrogen) and siRNA directed against PARP1 
(Qiagen, Cat.No. S102662989) or control siRNA (Qiagen, Cat.No. S103650318) for 48 
hours. Overexpression of PARP1 was performed by transfection of HEK293T cells by 
standard Calcium-Phosphate precipitation method with a pcDNA3-HA-PARP1 
expression vector or an empty vector control, respectively. 8 hours after transfection the 
medium was replaced and the cells were grown for another 20 hours before they were 
harvested. 
 
ADP-ribosylation of isolated nuclei 
Nuclei were isolated from 5x 106 HEK293T cells by the addition of cold hypotonic lysis 
buffer (5 mM HEPES pH 7.4, 0.5% NP-40, 85 mM KCl, 1 µg/ul Pepstatin, Leupetin, 
Bestatin). After 2 minutes of incubation, the nuclei were centrifuged for 4 min at 7000g 
and washed twice with suspension buffer (33.3 mM Tris-HCl pH 7.8, 40 mM MgCl2, 1 
µg/ul Pepstatin, Leupetin, Bestatin). The pellet was resuspended in permeabilization 
buffer (38.3 mM Tris-HCl pH 7.8, 42.1 mM MgCl2, 0.53 mM EDTA, 13.9 mM β-
Mercaptoethanol, 1 µg/ul Pepstatin, Leupetin, Bestatin), supplemented with 400 µM 
etheno-NAD+ (Sigma Aldrich) or 4 mM PJ34 (Enzo Life Science) and incubated for 20 
min at 37°C at 900 rpm in a rotator. After centrifugation the pellet was resuspended in 
SDS-lysis buffer and run on a 18% SDS-PAGE. Western blotting was performed with 
anti Ig4 antibody hybridoma serum (kindly provided by Dr. R. Santella, Columbia 
University, USA) in a vacuum blot apparatus (Millipore SNAP i.d). 
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Supplementary Figures 
 
Supplementary Figure 1: 
PARP1 poly(ADP-ribosyl)ates chromatin associated histones. (A) HEK293T cells were 
depleted of PARP1 and nuclei were prepared. The nuclei were incubated with 400 µM 
etheno-NAD+ at 37°C for 20 min and lysed in SDS-lysis buffer. Western blotting was 
performed with the Ig4 antibody, which specifically recognizes the etheno-group of 
NAD+. (B) HEK293T cells were transiently transfected with HA-PARP1 (ov. PARP1) or 
with an empty vector (control). Nuclei were prepared and incubated with 400 µM etheno-
NAD+ in presence or absence of the PARP-Inhibitor PJ34. 
 
Supplementary Figure 2: 
(A) Trans-ADP-ribosylation of histone tails by PARP1. 1.5 µg of full-length and 
truncated histones were incubated with 10 pmol PARP1 and 100 nM 32P-NAD+ for 15 
min at 30°C. His-tagged H2B (36-122) was generated by PCR and cloned into pET3a 
with NdeI and BamHI restriction enzymes. The protein was expressed in inclusion 
bodies, solubilized, purified by a nickel-column and dialyzed against water. The other 
histones were expressed and purified as in Luger K. et al, 1997, JMB, 272, 301-311. (B) 
Identical to Fig. 1C of the main manuscript. The automodification of PARP2 was 
adjusted to the automodification of PARP1 by ImageQuant-Software. (C) Trans-ADP-
ribosylation of H2B is not impaired in an H2B E2A mutant, in which the only glutamic 
acid residue is substituted by an alanine. Shown are autoradiographs and Coomassie 
stained gels. (D) Poly-L-lysine but not poly-L-glutamate are modified by hPARP1. Poly-
L-amino acids were coupled onto cyanogen-bromide activated agarose beads over night 
as suggested by the provider (Sigma-Aldrich). Excess poly-L-amino acids were washed 
away and unoccupied reactive sites were blocked over night. The beads were washed and 
equilibrated in PARP1 reaction buffer. Reactions were performed for 5 minutes at 30°C 
in the presence of 100 nM radiolabeled NAD+. The beads were washed 3 times in PARP1 
reaction buffer containing 500 mM NaCl before scintillation counts in two different 
channels were determined. (E) Extracted ion chromatogram of the biotin tagged H3 (23-
42) peptide, ADP-ribosylated by PARP1. ETD fragment spectrum of ADP-ribosylated 
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H3 peptide (590.29 m/z) at K37, indicated by the sequence plot. (F) Automodification of 
wild-type PARP1 and PARP1 D756K mutant for 10 min at 30°C in presence of 
activating DNA (EcoRI-linker) and 100 nM 32P-NAD+. Shown is an autoradiography and 
the coomassie stained gel. (G) Histone H4 (aa 1-22) peptide was ADP-ribosylated with 
PARP1 or PARP1 D756K mutant for 15 min at 30°C with 100 nM 32P-NAD+. The 
peptides were purified by microvolume-C18 reversed phase columns, eluted into 
scintillation liquid and counted for incorporated 32P. Relative increase of counts per 
minutes was calculated over background (peptides added after termination of the reaction 
by 3AB) and the counts obtained for wild-type PARP1 were set to 100. 
 
Supplementary Figure 3: 
Time evolution of intermolecular salt bridges and side chain dihedral angles of PARP1 
Tyrosine residues in the catalytic cleft. 
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ABSTRACT
Poly(ADP-ribose) polymerase 1 (PARP1) synthesizes
poly(ADP-ribose) (PAR) using nicotinamide adenine
dinucleotide (NAD) as a substrate. Despite intensive
research on the cellular functions of PARP1, the
molecular mechanism of PAR formation has not
been comprehensively understood. In this study,
we elucidate the molecular mechanisms of
poly(ADP-ribosyl)ation and identify PAR acceptor
sites. Generation of different chimera proteins
revealed that the amino-terminal domains of
PARP1, PARP2 and PARP3 cooperate tightly with
their corresponding catalytic domains. The DNA-
dependent interaction between the amino-terminal
DNA-binding domain and the catalytic domain of
PARP1 increased Vmax and decreased the Km for
NAD. Furthermore, we show that glutamic acid resi-
dues in the auto-modification domain of PARP1
are not required for PAR formation. Instead, we
identify individual lysine residues as acceptor sites
for ADP-ribosylation. Together, our findings provide
novel mechanistic insights into PAR synthesis with
significant relevance for the different biological
functions of PARP family members.
INTRODUCTION
Poly(ADP-ribose) polymerases (PARPs) use nicotinamide
adenine dinucleotide (NAD) as substrate to synthesize
poly(ADP-ribose) (PAR) (1). On the cellular level,
PAR formation has been implicated in a wide range
of processes, such as maintenance of genomic stability,
transcriptional regulation, energy metabolism and cell
death (2).
PARP1 was the first protein described to catalyze
PAR formation in response to mitogenic stimuli or geno-
toxic stress (3–7). It contains three functionally distinct
domains: an amino-terminal DNA-binding domain
(DBD), an auto-modification domain (AD) and a car-
boxyl-terminal PARP homology domain that includes
the catalytic domain (CAT) responsible for PAR forma-
tion (8). The DBD extends from the initiator methionine
to threonine 373 in human PARP1. It contains two struc-
turally and functionally unique zinc fingers (FI: aa, amino
acid, 11–89; FII: aa 115–199) (2,9). Recently, a third
and so far unrecognized zinc-binding motif was discovered
(FIII: aa 233–373) (10,11). The DBD also contains
a bipartite nuclear localization signal (NLS) of the form
KRK-X(11)-KKKSKK (aa 207–226) that targets PARP1
to the nucleus (12). The PARP1 zinc fingers FI and FII are
thought to recognize altered structures in DNA rather
than particular sequences and have also been reported to
be involved in protein–protein interactions (13). PARP1
strongly associates with DNA single and double strand
breaks generated either directly by DNA damage or indi-
rectly by the enzymatic excision of damaged bases during
DNA repair processes (2,9). Several studies indicate that
the first zinc finger is required for PARP1 activation by
both DNA single and double strand breaks, whereas the
second zinc finger may exclusively act as a DNA single
strand break sensor (2,9).
The AD of PARP1 is located in the central region of
the enzyme, between residues 373 and 525 of human
PARP1 (14,15). It was identified as the domain containing
acceptor amino acids for the covalent attachment of PAR
(16). In addition, several recent studies identified a weak
leucine-zipper motif in the amino-terminal region of the
AD, which suggests that this motif might be involved in
homo- and/or hetero-dimerization (9). The AD of PARP1
also comprises a breast cancer 1 protein (BRCA1)
C-terminus (BRCT) domain (from aa 386 to 464 in
*To whom correspondence should be addressed. Tel: +41 44 635 54 74; Fax: +41 44 635 68 40; Email: hottiger@vetbio.uzh.ch
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Abstract
Hypoxia-inducible factor 1 (HIF-1) is the key
transcription factor regulating hypoxia-dependent gene
expression. Lack of oxygen stabilizes HIF-1, which in
turn modulates the gene expression pattern to adapt
cells to the hypoxic environment. Activation of HIF-1 is
also detected in most solid tumors and supports tumor
growth through the expression of target genes that are
involved in processes like cell proliferation, energy
metabolism, and oxygen delivery. Poly(ADP-ribose)
polymerase 1 (PARP1) is a chromatin-associated
protein, which was shown to regulate transcription.
Here we report that chronic myelogenous leukemia
cells expressing small interfering RNA against PARP1,
which were injected into wild-type mice expressing
PARP1, showed tumor growth with increased levels
of necrosis, limited vascularization, and reduced
expression of GLUT-1. Of note, PARP1-deficient cells
showed a reduced HIF-1 transcriptional activation that
was dependent on PARP1 enzymatic activity. PARP1
neither influenced binding of HIF-1 to its hypoxic
response element nor changed HIF-1A protein levels
in hypoxic cells. However, PARP1 formed a complex
with HIF-1A through direct protein interaction and
coactivated HIF-1A–dependent gene expression. These
findings provide convincing evidence that wild-type
mice expressing PARP1 cannot compensate for the loss
of PARP1 in tumor cells and strengthen the importance
of the role of PARP1 as a transcriptional coactivator
of HIF-1–dependent gene expression during tumor
progression. (Mol Cancer Res 2008;6(2):282–90)
Introduction
In solid tumors, rapid cell proliferation is associated with
areas of hypoxia. Intratumoral hypoxia induces neoangio-
genesis, which is an essential switch from tumorigenesis to
tumor progression (1). Oxygen limitation regulates vascular-
ization, glucose metabolism, cell survival, and tumor spread.
The hypoxic response critically depends on the transcription
factor hypoxia-inducible factor-1 (HIF-1; ref. 2). HIF-1a was
found to be overexpressed in more than 70% of human
cancers and their metastases (3). The effect of HIF-1 on
tumor growth is complex and involves the activation of
several adaptive pathways and results in the induction of
target genes (4). In solid tumors, immunohistochemistry often
shows larger fronts of HIF nuclear expression delineating
areas of necrosis (5). Induction of HIF is therefore believed
to be supportive, if not causative, in cancer (6-8). In tumor
xenograft and orthotopic mouse models, manipulation of the
levels of either HIF-1a or HIF-2a has shown a causal link
between HIF expression and tumor progression (4). HIF
signaling has emerged as an important hypoxia-driven
response allowing tumor cells to survive, expand, and invade.
As a result, tumor hypoxia or HIF expression is strongly
associated with a diminished therapeutic response and malignant
progression (9).
HIF induction is a multistep process, which is tightly
regulated in vivo (10, 11). HIF-1 is composed of two
polypeptides: HIF-1a and HIF-1h (12). Two additional HIF-a
members, the closely related HIF-2a (13) and more distantly
related HIF-3a (14), were recently identified. HIF-1 activity is
regulated at the posttranscriptional level by protein degradation
of HIF-1a subunits after oxygen-dependent hydroxylation of
specific proline residues (15). During hypoxia, the prolyl
hydroxylases are inactive and HIF-1a is not complexed with
the ubiquitin E3 ligase complex containing von Hippel Lindau,
thereby allowing for the formation of active HIF-1 complexes
(2, 5, 12). Transactivation involves dimerization of the two
HIF-1 subunits, which bind to an enhancer element, called
hypoxia response element, in target genes. Among the most
studied promoters with regard to the recruitment of HIF-1 are
those of the EPO , GLUT-1 , and CA9 [carbonic anhydrase IX
(CAIX)] genes (16-18). The presence of hypoxia response
element sites is necessary, but not sufficient, to direct gene
expression in response to hypoxia, suggesting that HIF-1 must
interact with other transcription factors or cofactors bound
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Abstract 
Most of the published data on histone post-translational modifications focus on small 
covalent modifications such as acetylation, methylation and phosphorylation. In vitro 
ADP-ribosylation of histone proteins has been described as early as 1969 and was 
shortly after confirmed in vivo. Numerous laboratories subsequently reported histone 
ADP-ribosylation using purified cell nuclei, isolated nucleosomes or purified histones. 
ADP-ribosyltransferases belonging to two different families have been reported to ADP-
ribosylate histones. The biological significance of histone ADP-ribosylation has been 
often restricted to functions attributed to the modifying enzymes. Until recently, the 
ADP-ribose acceptor sites of histones have not been identified due to the labile nature of 
the chemical linkage. However, recent structural and enzymological characterizations of 
ADP-ribosyltransferase family members, as well as the availability of genetically 
modified proteins and cells suggest that histone ADP-ribosylation plays a fundamental 
role in chromatin regulation. This review revisits the older literature and combines it 
with recent findings to provide an overview of histone ADP-ribosylation. 
 
Protein ADP-ribosylation 
ADP-ribosylation is a post-translational modification of proteins, catalyzed by ADP-
ribosyltransferases that utilize NAD+ as substrate 1. ADP-ribosylation comprises the transfer 
of the ADP-ribose moiety from NAD+ to specific amino acid residues on substrate proteins, 
also known as mono(ADP-ribosyl)ation. Subsequent elongation of the protein-bound ADP-
ribose generates poly(ADP-ribosyl)ated proteins. Mono- and poly(ADP-ribosyl)ation of 
proteins are phylogenetically ancient, reversible post-translational modifications being 
implicated in a wide range of processes 2. These include maintenance of genomic stability, 
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 transcriptional regulation, energy metabolism and cell death, although in many instances the 
precise molecular consequences are not yet known. 
 
Mono- versus poly(ADP-ribosyl)ation  
In all eukaryotic tissues only low levels of protein-bound ADP-ribose residues are found. The 
total amount ranges from 5-60 pmols (about 3-30 ng) ADP-ribose per mg DNA 3,4. Most 
ADP-ribose residues are bound to proteins as single ADP-ribose group rather than as 
oligomeric or polymeric ADP-ribose chains 5. In mouse liver, the ratio is about 226:1 (mono- 
versus poly(ADP-ribosyl)ation), in human lymphocytes about 49:1 6. Comparison of 
chemically fractionated proteins of rat liver cells revealed that over 95% of mono(ADP-
ribose) conjugates are located in other compartments than the nucleus (e.g. mitochondria) 7. In 
contrast, most poly(ADP-ribose) chains are conjugated to nuclear proteins . The different 
subcellular distribution indicates independent functions of the ADP-ribose conjugate 
subclasses and suggests the involvement of at least two different enzyme classes, one able to 
catalyze mono(ADP-ribosyl)ation and the other additionally able to generate ADP-ribose 
polymers (see below). 
 
Methods to measure ADP-ribosylation of histones   
ADP-ribosylation (the attachment of ADP-ribose as monomer or polymer) of histones 
proteins has been investigated in the past by different in vivo and in vitro approaches. When 
radiolabeled ADP-ribose was administered intraperitoneally to rats, approximately one 
percent of the radioactivity was recovered in material of the liver nuclei 2 hours after injection 
8. Chromatography of this material revealed that the radioactivity co-eluted with the histone 
subfraction 8. Since NAD+ cannot permeate the cell membrane, no specific precursor is 
available for studies in intact tissues or in cell culture 9. Labeling of histones in permeabilized 
mouse nuclei with radiolabeled NAD+ predominantly generated mono(ADP-ribosyl)ated 
histones when a low concentration of radiolabeled NAD+ (50µM) was employed 10. At higher 
NAD+ concentration (200µM) the ratio of poly- to mono(ADP-ribosyl)ated core histones 
increased 10, indicating that the cellular NAD+ concentration is a critical factor for histone 
ADP-ribosylation. The generation of an antibody recognizing polymers of ADP-ribose (PAR) 
allowed later to confirm by immunoblot analysis that histones from whole cell extracts of 
asynchronized cells are indeed poly(ADP-ribosyl)ated in vivo 11. Experiments with pure 
recombinant purified ADP-ribosyltransferases and different histone mutations allowed to 
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 further elucidated histone ADP-ribosylation  12. 
 
Histone ADP-ribosylation patterns  
Histones isolated from rat liver nuclei and HeLa cells incubated with radiolabeled NAD+ 
revealed that all histone proteins H1, H2A, H2B, H3 and H4 were modified by a copurified 
ADP-ribosyltransferase 13-15. Also significant changes in the ADP-ribosylation pattern among 
histone variants of the same histone were observed 10. The ADP-ribosylation of histones was 
not visible upon coomassie blue staining of SDS-polyacrylamide gels, but was only visualized 
by radiolabeled NAD+, suggesting that the modified histones represent only a small fraction 
of total histones (less then 1%) 16-18. Among the histone subfractions, H1 seemed to be the 
best acceptor, followed by H2B, while H2A, H3 and H4 were only weakly modified 19. This 
order is almost comparable with those observed in isolated nuclei 15,20-22. Efforts to exactly 
quantify the best acceptor turned out to be very difficult and depended on the different 
experimental protocols, cell types employed and different cultivation conditions 20,23-25. 
Histones, especially nucleosomal core histones, were modified primarily by monomers or 
short oligomers rather than by long polymers 4,13,20,26-28. A main chain length of 2-3 ADP-
ribose units was found for histones H1 isolated from Ehrlich ascited tumor cell nuclei 29, 
whereas other labs have identified a chain length up to 15 ADP-ribose units attached to H1 
17,18,28. In native chromatin, histone H1 was the major ADP-ribose acceptor, whereas in H1-
depleted chromatin histone H2B became the major poly(ADP-ribose) histone acceptor protein 
30, suggesting that ADP-ribosylation of histone proteins depend on the chromatin 
composition.  
 
Two types of covalent chemical linkages are observed in ADP-ribosylated proteins  
Radiolabeled ADP-ribsoylated histones were traditionally isolated from tissues and cells by 
precipitation with TCA. Extraction of modified proteins from the precipitated material by HCl 
revealed that both fractions (acid soluble and acid insoluble) contain ADP-ribosylated 
histones 8. Part of the insoluble protein-bound radioactivity was rendered acid-soluble by pre-
treatment with phosphodiesterase, a protein able to degrade polymers of ADP-ribose (see 
below). These observations indicate that while mono(ADP-ribosyl)ated proteins are likely 
acid soluble, poly(ADP-ribosyl)ated histones remain rather acid-insoluble 8. Since complex 
formation was not observed when purified polymers of ADP-ribose were mixed with H1, the 
binding was suggested to be covalent 17. Further treatment of acid-soluble and acid-insoluble 
(ADP-ribosyl)ated proteins with neutral hydroxylamine and alkali, resulted in the release of 
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 free acid soluble ADP-ribose or 5’AMP respectively, indicating two types of bonds, both 
alkali-labile, but only one susceptible to neutral hydroxylamine 17,28,31. Both types of bonds 
were equally distributed among acid-soluble and acid-insoluble (ADP-ribosyl)ated proteins 
32,33. Based on the sensitivity of ADP-ribose conjugates to neutral hydroxylamine (and to 
alkali), a larger portion of poly(ADP-ribosyl)ated histone bonds have been suggested to be 
carboxylesters 34. Carboxylester bonds are predominantly found between two ADP-ribose 
units in the polymer of APD-ribose. Carboxylester bonds might potentially be found when the 
first ADP-ribose moiety would be covalently bound to an acidic amino acid, such as glutamic 
and aspartic acid residues 35 (Fig.1). The hydroxylamine-resistant but alkali-labile linkage was 
suggested to be a ketoamine bond 28,32,36. This type of bond would only be formed if 
positively charged amino acids such as lysine or arginines serve as ADP-ribose acceptor sites 
(Fig.1). Interestingly, ADP-ribosylated proteins containing ADP-ribose conjugates belonging 
to this type of linkage were also described in vivo 37. 
 
Non-covalent ADP-ribosylation of histones 
 While all histone modifications observed above are expected to be catalyzed by ADP-
ribosyltransferases, also a covalent non-enzymatic ADP-ribosylation of histones was 
described earlier 36,38. ADP-ribose is a potent histone glycation and glycoxidation agent in 
vitro 38. Glycation is the covalent binding of an ADP-ribose molecule through Schiff base 
formation to lysine and/or arginine residues, which is stable upon treatment with 
hydroxylamine. Incubation of ADP-ribose with histones H1, H2A, H2B, and H4 in vitro at 
pH 7.5 and 37°C over night resulted in the formation of ketoamines derived from a Schiff 
base by an Amadori rearrangement 38-40. Based on the long incubation time, which is 
substantially longer than common incubation times of ADP-ribosylation reactions, glycation 
needs only to be considered in vivo if an enzyme is able to generate high concentrations of 
ADP-ribose from NAD+.  
 
Enzymes described to ADP-ribosylate histone proteins 
Currently, three families of proteins have been described to ADP-ribosylate proteins 1. First, 
mammalian proteins with distant sequence homology to bacterial diphtheria toxin, called 
ARTDs (formerly known as PARPs 2,41), second proteins with sequence homology to 
bacterial clostridium toxin, called ARTCs (formerly known as membrane associated ecto-
ARTs) 42 and finally some proteins of the sirtuin family 2,43. While ARTC family members 
are found on the cell membrane, some of the ARTDs and sirtuin family members are found in 
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 the nucleus and were described to modify histones. 
 
ARTD1 (PARP1): 
The presence of a cellular enzyme that is able to synthesize poly(ADP-ribose) was already 
reported in the 1960ies 44-46. Soon this activity was assigned to ARTD1. ARTD1 is associated 
with the chromatin of eukaryotic cells and localizes within internucleosomal linker regions of 
HeLa cell chromatin 47. Poly(ADP-ribosyl)ation of histones includes first mono-modification 
of acceptor residues, subsequent elongation of the primary unit to a polymer, as well as 
branching of the polymer by α(1’-2’)ribose-ribose linkage. All enzymatic reactions are 
carried out by ARTD1 19,48. The ADP-ribose-histone linkage synthesized by ARTD1 was 
mainly, but not completely labile in neutral hydroxylamine, but both alkali-labile, indicating 
the existence of both types of bonds (ester- and ketoamine bonds) 32,49,50. Similar linkages 
were observed in crude chromatin or isolated nuclei 19,51. Purified ARTD1 from calf thymus 
was able to modify all five individual histones in vitro 12,52-56. When the concentration of 
DNA exceeds the amount of histones, the modification was lost 57-59. The length of histone 
poly(ADP-ribosyl)ation was reported to change dependent on the NAD+ concentrations 60. 
Efficient activation of ARTD1 upon genotoxic stress is widely documented 2. Two 
laboratories recently reported the activation of ARTD1 by post-translational modification or 
protein complex formation independent on DNA damage 61,62. Interestingly, high H1 
concentrations at low ionic strength and in absence of Mg2+ stimulated ARTD1 activity 56,59. 
In the presence of histones, the Km of ARTD1 for NAD+ decreased from 80 µM to 25 µM and 
the Vmax doubled 57. 
 
Other ARTDs: 
From the described ADP-ribosyltransferases only ARTD1, 2 and ARTD3 are described to be 
solely nuclear, whereas ARTD5 and 6 localize also in the cytoplasma 2. Spermatocytes from 
ARTD2 (PARP2) knockout mice were described to contain hypoacetylated H4, although the 
functional contribution of ARTD2 is not yet elucidated 63. Molecular and structural in vitro 
analysis recently revealed that ARTD2 is unable to modify free histones 12. In a proteomic 
screen, ARTD3 (PARP3) was shown to interact with histones H2B and H3. Whether ARTD3 
is able to modify histones is currently not clear 64. ARTD10 (PARP10) localizes in cytoplasm 
and nucleus and is only able to mono(ADP-ribosyl)ate core histones 65-67. The exact location 
of the other ARTD family members still needs to be investigated 67.  
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Sirtuins: 
SIRT 4 and 6 of the sirtuins can mono-ADP-ribosylate histones as well 43,68,69. The ADP-
ribosylation activity of these sirtuins is, however, five orders of magnitude slower than their 
deacetylation activity, which questions the biological significance of this reaction 70. 
 
Nuclear readers of ADP-ribose   
Three non-covalent poly(ADP-ribose) binding modules were reported so far 71. The first 
described binding motif contains of alternating hydrophobic and basic residues, which confers 
affinity for poly(ADP-ribose) 72. This motif is found in several nuclear proteins, including 
histones. The non-covalent interaction is strong enough to evict histones in vitro from 
chromatin 73,74. Evidence that this is also possible in vivo are currently missing. The second 
motif is called poly(ADP-ribose)-binding zinc finger (PBZ) and is found in a number of 
proteins involved in DNA-damage response an checkpoint activation, such as APLF 
(aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains) 
75,76. Finally, macrodomains were described to bind free and protein bound mono- and 
poly(ADP-ribose) 77-80. Macrodomain are found in several ADP-ribosyltransferases, 
chromatin-remodeling enzymes (e.g. Alc1) and in the histone variants macroH2A1 and 
macroH2A2 2,81-83. Only the macrodomains of macroH2A1.1 and Alc1 were described to bind 
to the poly(ADP-ribosyl)ated form of PARP1 in vivo and to alter chromatin compaction, 
transiently 80,83. 
 
ADP-ribosylation as transient modification 
Histone ADP-ribosylation is a reversible modification, which contributes to the dynamic 
heterogeneous entities of nucleosomes. Two classes of enzymes are able to reverse ADP-
ribosylation. ADP-ribosyl hydrolases (ARHs) and poly(ADP-ribose) glycohydrolases 
(PARGs) 42,84. The importance of these enzyme in histone poly(ADP-ribosyl)ation 
metabolism is apparent from their key role in the rate-limiting step, i.e. the removal of 
primary ADP-ribosyl groups from acceptor proteins and in the overall turnover of poly(ADP-
ribosyl) groups in the cell 85. While ARH3 and PARGs are able to hydrolyze glycosidic bonds 
(between to ADP-ribose units or a glutamic acid residue and the primary ADP-ribose), they 
are not able to reverse ketoamine-linked ADP-ribose conjugates 86. ARH3 and PARG act both 
as exo- and endoglycosidases 87. An ADP-ribosyl protein lyase with molecular mass of 
83kDA was once purified from rat liver and was able to remove the glutamic acid linked 
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 ADP-ribosyl moieties 88,89. Unfortunately, the gene for this protein was never cloned. While 
ARH2 is inactive, only ARH1 is able to specifically hydrolyze only arginine-ADP-ribose 
conjugates 90. An enzyme able to hydrolyze lysine-ADP-ribose bonds has not yet been 
described. The absence of such an enzyme would leave a mono-ADP-ribose moiety at the 
protein, which would mark the protein irreversibly. Similarly, cleavage of poly(ADP-ribose) 
by a nuclear phosphodiesterase is predicted to leave a terminal phosphate group at the 
acceptor site, which cannot further be cleaved by PARG or extended by a ARTD.  
 
Towards identifying the ADP-ribose acceptor sites in histones 
It has been shown by trypsin digestion studies that the ADP-ribosylation of core histones 
predominantly takes place at the basic amino-terminal regions of the proteins 13,91. Based on 
chemical properties of the linkages of the ADP-ribosylated tryptic fragmentation of the H1 
and H2B, glutamic acid at position 2 of histone H2B 13 and of glutamic acid residues at 
position 2, 14 and 116 of H1, as well as to the carboxy-terminal COOH of lysine residue at 
position 213 of the same histone were suggested to be ADP-ribosylated 22,26,27. The acceptor 
sites of other histone tails were never mapped, despite that they were modified 12,13,91. 
Although the modification of glutamic acid residues as acceptor residues for histones was 
never verified using purified enzymes (e.g. ARTD1) or confirmed by mutagenesis or mass 
spectrometry, many review articles in the past three decades attributed the modification of 
glutamic acid residues to ARTD family members.  
Recently the automodification sites of ARTD1 could be mapped and identified as lysine 
residues 50. Furthermore, lysine residues in the tails of H3 and H4 were identified by mass 
spectrometry as ADP-ribose acceptor sites catalyzed by ARTD1, thus identifying lysine 
residues as acceptor sites for the ARTD family and resolving the paradox, that histones 
without glutamic acid residues at their amino-terminal tail can be ADP-ribosylated 12. Since 
other ADP-ribosyltransferases (e.g. sirtuins) were described to modify only arginine residues, 
glutamic acid specific modifying enzymes remain to be identified 69,92-94. Whether the 
modified glutamic acid residue is indeed catalyzed by an enzyme or induced non-
enzymatically during the extraction procedure has to be further elucidated. Together, only 
enzymes able to modify lysine and arginine residues of histones were described so far. 
 
Crosstalk of histone ADP-ribosylation with other post-translational modifications 
Since both, lysine and arginine residues of histones were described to be modified by 
acetylation and methylation, respectively, a possible cross-talk between these two covalent 
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 modifications of chromatin can be expected. Indeed, hyperacetylated chromatin regions 
associated with the chromatin domains that are undergoing poly(ADP-ribosylation), 
suggesting a crosstalk for lysine residues 95,96. In proliferating cells or after stimulation of 
human lymphoid cells, the number of ADP-ribosyl groups equaled or exceeded by one the 
number of acetyl groups on histone H4 10,97,98. A 6 hour treatment with butyrate (a known 
histone deacetylase inhibitor) resulted in the loss of the correlation between acetylation and 
(ADP-ribosyl)ation, suggesting that acetylation might interfere with (ADP-ribosyl)ation and 
that the two modifications may share common functions 97. Alternatively, H4 acetylation may 
constitute a signal for H4 ADP-ribosylation or vice versa. A crosstalk of histone arginine 
residues being ADP-ribosylated or methylated by protein arginine methyltransferase enzymes 
has not been described so far. 
 Histones modified by phosphorylation also appear to be poly(ADP-ribosyl)ated 
96,99,100. Using a reconstituted protein kinase assay system revealed that ADP-ribosylated 
histones are poor acceptors for the phosphorylation reaction 101. In addition, phosphorylation 
of histones from calf thymus by cAMP-dependent protein kinase in vitro was markedly 
reduced when the histones were ADP ribosylated 102,103. Although the majority of these 
experiments were performed in vitro, experiments on acetylation and ADP-riboslyation 
suggest that different cross talks very likely exist in vivo, possibly also involving other 
modification such as methylation or ubiquitinylation. 
 
Several groups investigated the functional role of histone ADP-ribosylation during nuclear 
processes such as chromatin structure dynamics, replication, transcription or repair (Fig.2). 
While the influence of the histone modification is rather well established, little is know about 
the enzymes catalyzing the modification. The following sections mainly focuses articles 
investigating histone ADP-ribosylation also including the existing literature on ARTD1, while 
only little or none information is available about the other ARTD family members. 
 
ADP-ribosylation-mediated nucleosome structure dynamics  
Previous studies have shown that poly(ADP-ribose) is associated with the nucleosome 104,105. 
ADP-ribosylation was reported to be involved in the regulation of the higher order structure 
of chromatin 106. ARTD1 is the only so far described ARTD, which preferentially interacts 
with nucleosomes with a periodicity of 8-10 107. In absence of NAD+ (unphysiological 
conditions) saturating binding of ARTD1 to nucleosomes promotes chromatin compaction as 
visualized by electron microscopy, whereas a high amount of NAD+ induces ARTD1 
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 automodification and its release from nucleosomes and subsequently chromatin relaxation in 
vitro 108-112. Moreover, when these ADP-ribosylated polynucleosomes are in relaxed form, 
they cannot be condensed by increasing the ionic strength, showing a close similarity to H1 
depleted chromatin in vitro 113. Poly(ADP-ribosyl) groups on histones might thus be 
important at the replication fork 97. Interestingly, modified H1 remained associated with 
chromatin in vitro 108,110. The influence of poly(ADP-ribosyl)ation on the chromatin 
conformation was also studied in vitro by using monoclonal and polyclonal antibodies 
specific for individual histones. In poly(ADP-ribosyl)ated chromatin an increased 
accessibility of some histone tails to antibodies was observed 30. The relaxed state of 
poly(ADP-ribosyl)ated polynucleosomes was also confirmed by sedimentation velocity 
analysis. When poly(ADP-ribose) is degraded by PARG activity, the chromatin returns to the 
condensed state 109. Chromatin enriched in poly(ADP-ribosyl)ated nucleosomes appeared to 
be more nuclease sensitive than that found in the fraction of chromatin depleted of poly(ADP-
ribosyl)ation 114. In contrast to these studies, other in vitro studies suggested that poly(ADP-
ribosyl)ation leads to a condensation of chromatin through the formation of covalent histone 
H1 poly(ADP-ribosyl)ation 11,17,18,115. Whether the above described changes on the level of 
nucleosomes apply also in vivo, remains to be determined.  
 
Histone ADP-ribosylation during the cell cycle and replication 
Measurements of incorporated radiolabeled NAD+ using permeabilized cells revealed that 
ADP-ribosylation takes place throughout the cell cycle 116. Comparison of proliferating cells 
with contact-inhibited cells revealed that rates of poly(ADP-ribose) synthesis and DNA 
synthesis in permeabilized cells are highest during proliferation and especially in malignant 
cells and lowest in contact inhibited cells 117. The idea that rapidly proliferating cells exhibit 
relatively higher activities of histone poly(ADP-ribosyl)ation than quiescent cells has been 
further supported by observation on SV-40 transformed cells, mitogen-stimulated 
lymphocytes and fertilizing sea urchin eggs 10,85,118-120. Blocking cells by treatment with 
chemicals or serum depletion resulted in the synthesis of only mono- but not of poly(ADP-
ribosyl)ated histones 97. Characteristically, significantly more protein-bound poly(ADP-
ribose) was also detectable in proliferating cells by immunoblot analysis using the 10H 
antibody generated against polymers of ADP-ribose 117. Furthermore, an increase of 
poly(ADP-ribosyl)ation was observed during differentiation, suggesting that ADP-
ribosylation might also be observed in specialized non-dividing cells 121,122.  
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  In synchronized HeLa cells the amount of ADP-ribose polymers was found to increase 
from early S-phase to peak at the mid S-phase with a second, even larger increase seen at the 
S-G2 transition 14,98,116,123-127. The importance of ADP-ribosylation was further strengthened 
by the observation that inhibition of ADP-ribosylation by 5-methylnicotinamide arrested the 
growth of HeLa cells between the end of S-phase or during mitosis 128. Since not all cell lines 
are arrested by inhibition of ADP-ribosylation, a possible requirement of ADP-ribosylation 
for cell cycle progression needs to be further investigated. Recently the application of ADP-
ribosylation inhibitors pursued into clinical trials phase II, displaying promising results in 
cancer therapy 129. 
  
Histone ADP-ribosylation and transcription 
Different analyses indicated that ADP-ribosylation activity was associated primarily with 
transcriptionally active regions, whereas the transcriptionally inert chromatin fractions were 
found to contain relatively low levels of ADP-ribosylation activity 14,130. Recently, it was 
reported that histone H1 and ARTD1 exhibited a reciprocal pattern of chromatin binding at 
the promoters of actively transcribed genes 131. Furthermore, ARTD1 could exclude H1 from 
a subset of ARTD1-stimulated promoters, suggesting a functional interplay between ARTD1 
and H1 at the level of nucleosome binding 131. Whether the enzymatic activity of ARTD1 is 
required for the observed effects remains to be defined. Several reports suggested a 
transcriptional coactivator role of ARTD1 independent of its enzymatic activity or not 
through the modification of histones 132-134. ARTD1’s enzymatic activity is important in puff 
formation in Drosophila at many loci, including Hsp70 135. Whether histones are ADP-
ribosylated during puff formation was not elucidated. Through a RNAi screen of known 
coactivators, ARTD1 was recently identified as being necessary for the rapid loss of 
nucleosomes at the Hsp70 gene after heat shock 136. Addition of an ADP-ribosylation 
inhibitor only 10 minutes before heat shock was sufficient to block the nucleosome eviction, 
indicating that ADP-ribosylation is required. It has been reported earlier that poly(ADP-
ribosyl)ation of H3 and H4 results in their release from DNA 137,138. Thus, nucleosomal 
displacement or even eviction may be regulated by histone ADP-ribosylation for the 
transcription of certain genes. 
  
Histone ADP-ribosylation and DNA repair 
Upon treatment of cells with alkylating agent (e.g. dimethyl sulfate), the levels of mono- and 
poly(ADP-ribosyl)ated proteins rose by a factor of 12 and 21 respectively 139. The main non-
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 histone protein that becomes poly(ADP-ribosyl)ated in intact cells after DNA damage is 
ARTD1 itself 140. The level of modification was found to involve only 4% of the total ARTD1 
pool 21. The principal poly(ADP-ribose) acceptor of alkylation induced ADP-riboslyation of 
histones were H2B and H3 10,141. Minor amounts of other histones, especially H4 and H1 were 
also modified under these conditions 139,141,142. The preferred modification of histone H2B 
induced by DNA fragmentation may not be due to a marked acceptor specificity for a certain 
ADP-ribosyltransferase, but might more likely reflect an altered chromatin structure as caused 
by the DNA strand breaks where histone H1 is less accessible for poly(ADP-ribosyl)ation 
than histone H2B 32. The chemistry and repairability of DNA breaks induced by different 
substances as well as the cell type may affect the pattern of mono and poly(ADP-
ribosyl)ation.  
 Interestingly, induced ADP-ribosylation of histone H2B could not be removed with 
neutral hydroxylamine (but by treatment with alkali), indicating lysines and arginines as 
acceptor sites 32. Similar experiments with ADP-ribosylated histones, isolated from the slime 
mold physarum polycephalum, suggested glutamate acceptor sites for H2A and H2B, and 
lysine, arginines acceptor sites for H3 and H4 143.  
 Cleavage of the DNA with either DNase I or micrococcal nuclease to fragments of an 
average size of 10-20 kilobases dramatically induces the formation of poly(ADP-ribosyl)ated 
species of histones in nuclei 16. Histones in a subset of nucleosomes proximal to the site of 
initial attack by micrococcal nuclease were found to be extensively ADP-ribosylated 14. This 
interpretation has however, to be reconsidered, since later experiments suggested that the 
DNA strand breaks induced by micrococcal nuclease would activate ARTD1 and thus induce 
greater ADP-ribosylation of histone proteins 16.  
   
Conclusions  
Tremendous efforts have been undertaken over the last decades to decipher the physiological 
roles of ADP-ribosylation on the molecular level. ADP-ribosylation has not been included in 
the histone code, primarily because stimulation of ARTD1 activity, one of the best 
characterized nuclear ADP-ribosylating enzymes, and poly(ADP-ribosyl)ation of histones in 
vivo is best visible following the introduction of DNA strand breaks. Consequently, this has 
restricted the discussion of the biological significance to modification under genotoxic stress. 
In the light of the overwhelming amount of evidence supporting the functional role of histone 
ADP-ribosylation, we favor the view that this modification should be considered as a histone 
modification, taking place not only after DNA-damage, but also during other nuclear 
79
 processes, such as DNA-replication, transcription and chromatin remodeling, thus affecting 
chromatin function. Despite the development of genetic tools and the availability of new 
protocols for mass spectrometry, basic questions remain to be answered. Clearly, additional 
research will further improve our understanding of which enzymes are modifying distinct 
histone residues under a particular conditions and of the functions of histone ADP-
ribosylation and their implications for several nuclear processes. 
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 Figure legends: 
 
Figure 1: Two types of chemical linkages between proteins and ADP-ribose. Ketoamine 
bonds of Ω-N-(C1-ADP-ribosyl)-L-arginine and ε-N-(C1-ADP-ribosyl)-L-lysine are resistant 
to treatment with neutral hydroxylamine and partially alkali resistant. Carboxylester bonds of  
ε-O-(C1-ADP-ribosyl)-L-glutamate and􏰍δ-O-(C-1-ADP-ribosyl)-L-aspartate are highly 
sensitive to neutral hydroxylamine and alkali. 
 
 
Figure 2: Involvement of ADP-ribosylated histones in cellular processes. ADP-
ribosyltransferases catalyze the hydrolysis of NAD+ into ADP-ribose and nicotinamide. 
ARTD1, ARTD10 and possibly by other ARTD family members modify histone proteins. 
ADP-ribosylated histones are involved in regulation of the chromatin structure, regulation of 
the cell cylce and are targeted during DNA-repair and transcription.  
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3.2 Unpublished Results 
3.2.1 HDAC4 enhances PARP1 sumoylation 
Several SUMO E3 ligases were reported to enhance SUMO modification of substrate 
proteins (159). Since we were interested in proteins that enhance PARP1 sumoylation, 
several E3 ligases were tested. Although PIAS proteins enhanced PARP1 sumoylation in 
vitro (unpublished results from Dr. Stefan Müller), overexpression of PIAS1-4, as well as 
TOPORS overexpression did not enhance PARP1 sumoylation (data not shown). Recently, 
also class IIa HDACs were shown to facilitate SUMO modification of several proteins (100-
102). We tested therefore HDAC4 as a putative SUMO E3 ligase for PARP1 sumoylation 
(Fig. 4). Overexpression of Flag-HDAC4 with HA-PARP1 and myc-SUMO3 in HEK293T cells 
markedly increased the SUMO modification of PARP1 (Fig. 4A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: PARP1 sumoylation is enhanced in the presence of HDAC4 in vivo and in vitro. (A) HEK293T cells were 
transiently transfected with HA-PARP1, myc-SUMO3 and/or Flag-HDAC4. Whole cell extracts were taken 36 
hours after transfection and analyzed by western blot with anti-HA antibody. The upper band at approximately 
140 kDa corresponds to sumoylated PARP1. (B) Flag-HDAC4 was expressed by a baculovirus expression system 
in insect cells and purified with nickel beads. A standard in vitro sumoylation reaction was performed in the 
presence of HA-PARP1 and increasing amounts of Flag-HDAC4 (0.1µg, 0.5µg, 2.0µg Flag-HDAC4). The reaction 
proceeded for 30 min at 30°C. Samples were subjected to western blot with the indicated antibodies. 
 
To further validate, if this observation was due to a direct interaction of HDAC4 with 
PARP1, we incubated purified PARP1 with increasing amounts of purified HDAC4 together 
with SUMO3 in a standard in vitro sumoylation assay. Indeed, the addition of HDAC4 
increased sumoylation of PARP1 (Fig. 4B), suggesting that HDAC4 acts as a SUMO E3 
ligase in vitro and in vivo (Fig. 4). Consistent with previous reports, HDAC4 was SUMO-
modified as well (160). 
 
B 
 
 
A 
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3.2.2 HDAC4 does not directly deacetylate PARP1 
Since HDAC4 complexes were described to deacetylate proteins, we further tested, whether 
HDAC4 could deacetylate PARP1. PARP1 was acetylated in vitro by p300 and acetyl-CoA. 
The reaction (± acetyl-CoA) was split and incubated with different amounts of purified 
HDAC4. After 1 hour incubation, acetylation of PARP1 was analyzed by western blot, using 
the E4 antibody, which recognizes acetylated K498, 505 and K508 of PARP1. The presence 
of HDAC4 alone did not decrease the acetylated levels of PARP1 (Fig. 5A). To investigate 
whether cellular HDAC4 associated complexes could deacetylate PARP1, overexpressed 
Flag-HDAC4 was immunoprecipitated from HEK293T cells and subsequently incubated with 
p300-acetylated PARP1 and assessed for acetylated levels of PARP1 as described above 
(Fig. 5B). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: (A) PARP1 is not deacetylated by purified HDCAC4. Purified PARP1 was acetylated by p300 in vitro, 
without (not-ac PARP1) or in the presence of acetyl-CoA (ac PARP1). Equal amounts of the reactions were 
incubated with increasing amounts of purified Flag-HDAC4 (0.1 µg, 1.0 µg, 2.0 µg) for 2 hours at 30°C. The 
 
 
A 
B 
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samples were analyzed by western blot and probed with the indicated antibodies. (B) PARP1 is deacetylated by 
immunoprecipitated HDAC4 complex. Purified PARP1 was acetylated with p300 in vitro. Equal amounts of PARP1 
were incubated with 10 µg of immunoprecipitated nuclear extract from HEK293T, transfected with Flag-HDAC4. 
IP was performed with antibody against IgG or Flag-Epitope. HDAC-inhibitor TSA (1µM) was added to the 
indicated samples. The reaction was incubated for 1 hour at 30°C.  
 
Interestingly, immunoprecipitated HDAC4 was able to deacetylate PARP1. Addition of the 
HDAC-inhibitor trichostatin A (TSA) inhibited this activity (Fig. 5B). No deacetylation 
activity was observed for the IgG control reaction, suggesting that immunoprecipitated 
HDAC4 or HDAC4-associated proteins are able to deacetylate PARP1. 
 
3.2.3 Members of the Sir2 family deacetylate PARP1 
The Sir2 family of proteins consist of seven members (SIRT1-7). These proteins utilize 
NAD+ as co-factor to cleave the acetyl-group from modified lysines, leading to the 
generation of O-acetyl-ADP-ribose and nicotinamide. Since PARP1 and SIRTs use the same 
co-factor, an interplay between these enzymes is very likely. To test whether SIRTs could 
deacetylate PARP1, purified GST-tagged SIRT1, a SIRT1 catalytic inactive mutant, SIRT2, 
SIRT6 and SIRT7 were incubated with a catalytic inactive PARP1 fragment (aa 373-1014), 
which was beforehand acetylated by p300 (Fig. 6).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: PARP1 is deacetylated by SIRT1, SIRT2 and SIRT6 in a NAD+-dependent manner. Purified PARP1 373-
1014 E988K was acetylated by p300 in vitro. The acetylation reaction was split and incubated with 1µg purified 
GST-SIRT1, GST-SIRT1 catalytic mutant, SIRT2, SIRT6 or SIRT7 for 1 hour at 30°C. The reaction contained 
acetylated PARP1 fragment 373-1014 and 1mM NAD, where indicated. Samples were analyzed by western blot 
for acetylated PARP1 with anti-E4 antibody, which recognizes acetylated PARP1. 
 
SIRT1, 2 and SIRT6, but not SIRT7, were able to deacetylate the acetylated PARP1 
fragment (Fig. 6). Deacetylation of PARP1 was NAD+-dependent, suggesting that the 
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enzymatic activity of SIRTs was responsible for the observed effect. Indeed, a catalytic 
inactive mutant of SIRT1 was not longer able to deacetylate PARP1. Whether PARP1 can be 
deacetylated by sirtuins in vivo, remains to be investigated. 
 
3.2.4 PCAF acetylates the zinc-finger I fragment of PARP1 
Previously, it was observed that the histone acetyltransferase PCAF is able to acetylate 
PARP1 between amino acids 1-214 and 372-524, but the exact acetylation sites were not 
identified (161). In order to determine putative acceptor sites of PCAF-mediated PARP1 
acetylation, several lysine mutations in the context of the 1-112 fragment of PARP1 were 
analyzed in an acetylation assay (Fig. 7/8). Only lysines were mutated, which would be 
structurally accessible for acetylation. As positive control, wild-type PARP1 fragment 1-112 
was acetylated by PCAF (Fig. 7/8). Acetylation was furthermore observed for the 
K86/87/97R mutant fragment, but not for the K97/105/108R fragment and the K5R 
fragment, where K86/87/97/105/108 was mutated (Fig. 7/8). These results suggest that 
K105 and K108 are putative acceptor sites for PCAF mediated PARP1 acetylation. Whether 
K97 is also modified, remains to be investigated by a single PARP1 amino acid mutant or by 
other techniques, such as mass spectrometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: PARP1 is acetylated by PCAF in the region 1-112. Purified PARP1 fragments 1-112 were incubated for 
1 hour at 30°C with purified PCAF, 14C-acetyl-CoA and ethidiumbromide. Samples were resolved on SDS-PAGE 
and incorporated 14C-acetyl-CoA was visualized by autoradiography. 
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Figure 8: PARP1 is potentially acetylated by PCAF at lysines 97, 105, 108 within the PARP1 1-112 fragment. 1 g 
PCAF was incubated with mutated PARP1 1-112 fragments and acetyl-CoA for 1 hour at 30°C. The samples were 
probed by western blot with the general acetyl-recognizing antibody ACK5CI. 
 
 
3.2.5 PARP2 is sumoylated by SUMO3 
Within the PARP superfamily, PARP2 shares the highest sequence homology with PARP1. 
Therefore, we tested whether PARP2, comparable to PARP1, would be sumoylated in vitro. 
Purified PARP2 from insect cells was tested in an in vitro standard sumoylation assay 
including SUMO3 (Fig. 9). 
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Figure 9: PARP2 is sumoylated by SUMO3 in vitro. Purified human PARP2 proteins were incubated in a standard 
sumoylation reaction with SUMO3 for 30 min at 30°C. Samples were resolved on SDS-PAGE and analyzed by a 
PARP2 antibody. PARP2 K7R: K37/38/48/49/56/59/71R. 
 
PARP2 was sumoylated in vitro by SUMO3 (Fig. 9). Surprisingly, sumoylation was even 
enhanced when several lysines were mutated (K37/38/71/76/78R). Interestingly, 
sumoylation of PARP2 was completely lost, if the WGR domain was deleted (Fig. 9). Within 
this domain, only one SUMO-consensus motif around K143 is found. Thus, K143 could be a 
putative acceptor site of SUMO in PARP2. Further experiments including single amino acid 
substitution (e.g. K143R) have to be performed, to confirm this observation. 
 
3.2.6 Material and Methods 
Reagents 
The radio-labelled 14C-acetyl-CoA was purchased from Movarek Biochemicals and 
Radiochemicals. Antibodies against recombinant PARP1 and PARP2 were generated in our 
laboratory. The antibody against HA-tag was purchased from Covance, Flag (M2) antibody 
was from Sigma, ACK5CI was from Santa Cruz, anti acetyl-PARP1 E4 was generated 
together with the Monoclonal antibody core facility at the EMBL Monterotondo.  
 
Generation and purification of recombinant proteins 
Recombinant his-tagged PARP1, PARP2 proteins as well as all histone acetyltransferases 
were generated in Sf21 cells using the BacPAK (Clontech) or the pQE (Qiagen) system. 
Purification was performed in batch using Ni2+-beads/Nitrobond (Invitrogen). Recombinant 
SUMO E1 activating enzyme was expressed in BL21(DE3) cells and purified via Glutathione-
Sepharose (GE Healthcare) and Ni2+-beads/Nitrobond (Invitrogen). SUMO conjugating 
enzyme Ubc9 and SUMO3 was also expressed in BL21(DE3) and purified using Ni2+-
beads/Nitrobond (Invitrogen). 
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In vitro sumoylation assay 
The reaction was carried out in standard SUMO reaction buffer (50 mM Tris-HCl pH 8.0, 50 
mM NaCl, 5 mM MgCl2, 10% Glycerol, 0.5 mM DTT). 5 mM ATP was added to start the 
reaction. The incubation time was 30 min at 30°C, unless otherwise indicated. The final 
concentration of proteins was 100 nM for SAE1/SAE2, 500 nM Ubc9, 5 µM SUMO1/SUMO3 
and 500 nM PARP2. 
 
HAT-Assay 
0.5 µg of PARP1 fragments were acetylated in vitro by recombinant p300 (1 µg) or PCAF (1 
µg) as described elsewhere (162). 
 
Deacetylation assay by sirtuins 
Acetylated PARP1 was incubated in the same buffer as for acetylation, including 1 µg 
recombinant sirtuins and 1 mM NAD+ in total volume of 30 µl for 1 hour at 30°C.  
 
Immunoprecipitation of Flag-HDAC4 
Immunoprecipitation of nuclear extracts was performed with Flag-antibody (M2) using IP-
binding buffer (20 mM HEPES, 150 mM NaCl, 0.25% NP-40, 1 µg/ml Protease inhibitors). 
The salt concentration was increased to 50 mM KCl for washing steps. Beads were 
subsequently washed with HAT-buffer and in vitro acetylated PARP1 was incubated with 
the beads. Deacetylation reaction by HDAC4 was performed for 1 hour at 30°C. 
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4. Discussion and Perspectives 
4.1 Summary of results 
The articles described in this thesis established a regulatory role for sumoylation of PARP1 
in regard to its transcriptional co-activator function, as well as the discovery of lysine ADP-
ribosylation in the auto-modification domain of PARP1 and in histone tails. 
In the first article, sumoylation was identified as a novel posttranslational 
modification of PARP1. We reported the modification of PARP1 by SUMO1 and SUMO3 
(163). Lysine 486, within the auto-modification domain, was found to be the main 
sumoylated residue of PARP1. Neither the DNA-binding activity nor the enzymatic activity 
of PARP1 was altered by sumoylation. Instead, the acetylation of adjacent lysine residues 
by p300 was impaired of SUMO-modified PARP1. Additionally, we observed an increased 
acetylation status of the SUMO-deficient PARP1 mutant and a higher transcriptional co-
activator activity of the SUMO-deficient PARP1 mutant in genetically complemented K562 
cells. Together with the fourth article (164), which describes PARP1 as co-activator of HIF-
1α, these results provide evidence that PARP1 is a co-activator of hypoxia dependent gene 
expression and that posttranslational modifications of PARP1 regulate this activity. 
In the second article we explored, based on the third article (see below), lysine 
residues as putative ADP-ribose acceptor amino acids. The four core histone tails were 
shown to be ADP-ribosylated by PARP1 in vitro. The site of modification was mapped by 
site directed mutagenesis to specific regions within the unstructured N-terminal tail of the 
histones. Mass spectrometry of histone H3 and H4 tail peptides revealed the PARP1-
mediated ADP-ribosylation of H3K27, H3K37 and H4K16. An acetylated histone H4 peptide 
at K16 was a poor substrate for ADP-ribosylation. Furthermore, molecular dynamics of 
histone H3 and H4 tail, docked into the catalytic cleft of PARP1 revealed a stable 
interaction of H3K27 and H4K16 with the catalytically active glutamate of PARP1.  
The third article established the molecular mechanism of poly(ADP-ribosylation) by 
PARP1 (165). The earlier reported glutamic acid residues in the auto-modification domain 
of PARP1 were dispensable for the auto-modification of PARP1. Instead, site directed 
mutagenesis at different lysine residues revealed that these lysines were ADP-ribose 
acceptor sites. Interestingly, the same lysines (K498, K521 and K524) were previously 
reported to be acetylated by p300 upon inflammatory stimuli.  
The fifth article summarizes the current knowledge of ADP-ribosylation of histones 
in the form of a review. Beside PARP1, histones were the first proteins reported to be ADP-
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ribosylated. The article reviews the existing literature on ADP-ribosylation of histones in 
light of our recent findings that lysines are the acceptor sites of ADP-ribose on histones.  
 
4.2 Role of sumoylated PARP1 in the cell 
In the presented work, it was found that SUMO-modification of PARP1 increased upon 
exposure of cells to hypoxia. Investigation of the functional role of SUMO-modified PARP1 
focused on the transcriptional co-activator activity of PARP1 of hypoxia inducible 
transcription, since no effect of sumoylation was found for the DNA-binding ability of 
PARP1, Caspase 3 – mediated PARP1 cleavage or its poly(ADP-ribosyl)ation activity in vitro. 
Proteomic studies reported that PARP1 is poly-sumoylated after heat shock (78, 166). More 
specifically, Anne Dejean`s lab reported that PARP1 was poly-sumoylated at K203 and 
K486 after heat shock by the SUMO E3 ligase PIASy. Furthermore, SUMO-targeted ubiquitin 
ligase RNF4 recognized poly-sumoylated PARP1 and mediated heat-shock-inducible 
ubiquitination of PARP1, thus regulating the stability of PARP1 and the transcriptional 
function of PARP1 for heat-shock inducible genes in HeLa cells (167). In contrast to these 
reports, no poly-sumoylation of PARP1 after hypoxic induction was detected in our studies 
(163). Furthermore, we did not observe enhanced sumoylation of PARP1 upon 
overexpression of PIAS family members in HEK293T cells (data not shown). Instead, we 
reported only mono-sumoylation of PARP1, which was enhanced upon overexpression of 
HDAC4 in HEK293T cells (Fig. 4A), suggesting that HDAC4 acts as SUMO E3-ligase for 
mono-sumoylation of PARP1. Interestingly, the histone deacetylase activity of HDAC4 was 
dispensable for this effect, since enzymatically inactive, purified HDAC4 was still able to 
enhance sumoylation of PARP1 in vitro (Fig. 4B). The discrepancy between our results and 
the results from Anne Dejean`s group could be explained by the application of different 
stimuli (hypoxia vs. heat shock) and the usage of different cell lines (HEK293T vs. HeLa). 
For this work, only single genes were assayed using quantitative real-time PCR. While 
focusing on single genes allows fast and robust detection of mRNA levels, genomic 
approaches permit the observation of thousands of genes, thus enabling the researcher to 
analyze global gene expression and to find new target genes with the tested conditions. 
With the cell lines generated for this thesis, DNA-microarray studies could be carried out to 
investigate whether sumoylation deficient PARP1 mutant (K486R) only influences the 
expression of some specific hypoxia inducible genes or most of them. To investigate the 
contribution of PARP1`s SUMO-modification in a more physiological context, a knock-in 
mouse model would be of advantage. One could then compare wild-type mice with PARP1-
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sumoylation deficient mice (K486R) in mouse models of cancer formation and -progression, 
inflammation or metabolic disorders. 
Sumoylation and poly(ADP-ribosyl)ation of PARP1 can co-exist on the same PARP1 
molecule. It is therefore tempting to speculate that classical PARP1 activation by genotoxic 
stress might at the same time involve sumoylation. During initiation of base excision repair 
(BER), poly(ADP-ribosyl)ated PARP1 was described to recruit the scaffolding protein XRCC1 
to the site of DNA-damage, thus facilitating DNA-repair signalling in vivo (105). XRCC1 
possesses a SUMO-interacting motif, and is itself SUMO-modified (personal communication 
D. Schürmann and (71)). Thus, sumoylation of PARP1 could influence duration and 
strength of the PARP1 interaction with XRCC1. Additionally, upon gamma-irradiation 
poly(ADP-ribosyl)ated PARP1 was shown to recruit PIASy, IKKγ (NEMO) and ATM (168). 
Activated PARP1 and PIASy mediated IKKγ sumoylation, which in turn permitted IKK and 
NF-κB activation. Since signalosome formation depended on poly(ADP-ribosyl)ated PARP1, 
one could speculate that the signalosome formation would be facilitated, if PARP1 is 
additionally SUMO-modified and able to recruit PIASy by its SUMO-interacting motif (169) 
Posttranslational modifications of other PARP-family members, such as PARP2 are 
less well characterized. However, a proteomic screen suggested that PARP2 is poly-
sumoylated after heat shock (78). Indeed, PARP2 was sumoylated by SUMO3 in vitro also 
in our hands (Fig. 9). The SUMO-modification of PARP2 was completely abolished in the 
absence of the WGR domain of PARP2, harbouring only one putative SUMO-consensus site 
at lysine 143. One could confirm by site directed mutagenesis, whether this lysine is a real 
acceptor site for SUMO-modification in vitro and in vivo and investigate the functional role 
of sumoylation of PARP2 (e.g. after heat shock).  
 
4.3 Crosstalk of acetylation and ADP-ribosylation 
The acetylation of PARP1 by p300/CPB at different lysine residues (K498, K505, K508, 
K521, K524) was reported to be necessary for the binding of PARP1 to p50 NF-κB subunit 
and for synergistic co-activation of NF-κB dependent gene expression (137). We observed 
that the same lysines (K498, K521, K524) are ADP-ribosylated, implicating an interesting 
crosstalk between ADP-ribosylation and acetylation. Remarkably, the enzymatic activity of 
PARP1 was not required for transcriptional co-activation of NF-κB (170). Thus acetylated 
PARP1 could potentially be less active under conditions when the ADP-ribose acceptor sites 
are already occupied by an acetyl-group. Thus, it might be that deacetylating enzymes, 
such as sirtuins, regulate the activity of PARP1 through the removal of acetyl groups. A 
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cross-talk between SIRT1 and PARP1 was already reported (171). SIRT1-/- cells were reported to 
have higher PARP1 activity than wild type cells, providing a functional link between two NAD+-
dependent pathways. Along this line, it was shown that PARP1 acetylation was increased in 
SIRT1-/- cells and that acetylated recombinant PARP1 had higher enzymatic activity than 
unmodified PARP1 (172). Deacetylation of PARP1 by SIRT1 blocked the enzymatic activity 
and protected against PARP1-mediated cell death in cardiomyocytes. In the report of 
Rajamohan and co-workers most of the analysis was performed with the histone 
acetyltransferase PCAF, rather than p300. Thus, it could be that other lysine residues than 
K498, K505, K508, K521 and K524 were acetylated under the tested conditions, still 
enabling acetylated PARP1 to auto-ADP-ribosylate K498, K521 and K524. We observed 
acetylation of K105 and K108 within the first zinc finger domain of PARP1 by PCAF in vitro 
(Fig. 7 and 8). Thus, one could speculate that the acetylation of the first zinc finger 
stimulates the enzymatic activity of PARP1, which would explain the synergy between 
acetylation and PARP1 activity (172).  
Interestingly, sirtuins were able to deacetylate PARP1 in a NAD+ dependent manner in 
vitro (Fig. 6). Western blot was performed with a monoclonal anti-acetyl PARP1 antibody (anti-
E4), which recognizes acetylated K498, K505 and K508. SIRT1, SIRT2 and SIRT6, but not SIRT7 
were able to reverse p300-mediated PARP1 acetylation of the above mentioned lysines. We can 
currently not exclude that SIRTs also mediate deacetylation of other acetylated lysines of PARP1 
(e.g. in the DNA-binding domain).  
It was previously reported that HDAC1, 2 and HDAC3 mediate PARP1 deacetylation 
(137). In this work we tested, whether HDAC4 could deacetylate PARP1. Deacetylation of PARP1 
was observed only after immunoprecipitation of HDAC4 (Fig. 5B), but not by incubation of 
acetylated PARP1 with recombinant HDAC4 (Fig. 5A). Therefore, it is possible that HDAC4 is in 
complex with other histone deacetylases in vivo, which are able to deacetylate PARP1. In line 
with our own results, the enzymatic activity of HDAC4 was shown to depend on the association 
with the HDAC3/SMRT/N-CoR complex, thus suggesting that HDAC4 is not an PARP1 deacetylase, 
but operates by recruiting preexisting enzymatically active HDAC3 protein complexes (90). 
Therefore, it is possible that acetyl-groups of PARP1 are removed by the HDAC3/HDAC4/SMRT/N-
CoR complex, which abrogate the transcriptional co-activator functions of PARP1. After 
deacetylation of PARP1, HDAC4 might facilitate sumoylation of PARP1, which leads to dissociation 
of PARP1 from the promoter and “tags” the protein as an already used co-activator. During this 
time, PARP1 is ready to auto-ADP-ribosylate itself again, since sumoylated PARP1 inhibits p300-
mediated acetylation of K498, K505 and K508 (163), which are targets for auto-ADP-ribosylation 
(165). Moreover, SUMO proteases SENP1 or SENP3 might cleave off the SUMO moiety from 
PARP1 and render PARP1 ready for another cycle of transcriptional co-activation. 
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Finally, poly(ADP-ribosyl)ated PARP1 might affect the acetylation status of other 
proteins also by an indirect manner. Class III histone deacetylases (sirtuins) share NAD+ as 
substrate with PARP1. This provides a link between ADP-ribosylation and deacetylation, as 
proposed by Zhang (173). Since deacetylation of histones is thought to correlate with 
attenuation of gene expression, competition between sirtuins and activated PARP1 for the cellular 
NAD+ pool could lead to inhibition of deacetylation and thus activation of gene expression. 
4.4 Identification of ADP-ribosylated residues by mass 
spectrometry  
Novel mass spectrometric methods enabled the discoverage of lysine ADP-ribosylation (see 
2nd manuscript). Application of the electron transfer dissociation (ETD) fragmentation 
technique, which leaves unstable posttranslational modifications intact, allowed us to 
assign intact ADP-ribose to specific amino acids. Positively charged peptides are 
fragmented much better by ETD than by conventional collision-induced-decay (CID) 
technique. ETD thus facilitated the fragmentation of highly positively charged histone 
peptides with their corresponding modification. However, for the fragmentation of less 
charged peptides, this preference might be a drawback. Therefore, a combination of ETD 
and CID fragmentation techniques would be of advantage. The invention of “de-novo 
sequencing” of proteins from complex samples by the usage of the protease Lys-N, which 
cleaves the peptide backbone N-terminally of the basic residue lysine, together with the 
ETD fragmentation technology might boost our knowledge of so far unrecognized 
posttranslational modifications (174). Together with novel enrichment methods of ADP-
ribosylated proteins, ETD might allow to study protein ADP-ribosylation in a systems-
biological approach.    
 
4.5 A new letter for the histone code 
In the 1980s ADP-ribose acceptor sites were detected by biochemical approaches in 
histones (175, 176). Ogata and colleagues identified glutamic acid residues in histone H1 
and histone H2B to be modified when they incubated chromatin from rat liver with 
radioactive NAD+. The enzyme responsible for the modification was, however, never 
identified. Thus it is possible that PARP1 or other PARP-family members or even unrelated 
ADP-ribosyl-transferases are responsible for the modification of the identified glutamates. 
Moreover, the confirmation of glutamic acid residues as ADP-ribose acceptor sites by site 
directed mutagenesis or mass spectrometry is still missing. 
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In contrast, we observed that poly-L-lysine and poly-L-arginine peptides were ADP-
ribosylated by PARP1 (2nd manuscript). This led to the investigation of histones as ADP-ribose 
acceptor proteins. We found that core histone tails H2A, H2B, H3 and H4 are ADP-ribosylated. 
Of note, the histone tails of H2A, H3 and H4 do not contain a single glutamic acid residue, but 
are rich in the positively charged amino acids lysine and arginine. Importantly, we observed no 
reduction in the modification of the H2B tail by recombinant purified PARP1 when we mutated 
the single glutamate at position 2 of H2B to an alanine. We mapped subsequently the domain 
important for interaction and ADP-ribosylation for each tail and mutated different residues (see 
Dissertation Matthias Altmeyer). In summary, the most important residues for ADP-ribosylation 
of the H2A-tail were K13 and K15 and for the H2B-tail several lysine and/or arginine residues 
between K27 and K34. For the H3-tail, K23/27 and K36/37, as well as K16 and K20 for the H4-
tail were identified to be important for ADP-ribosylation. Mass spectrometric analysis confirmed 
ADP-ribosylation of H3K27 and H3K37 and H4K16. Whether ADP-ribosylation co-exists with 
other histone modifications on nucleosomes remains to be determined. The particular 
combinations of posttranslational modifications have been suggested to constitute a histone 
code that influences chromatin function by creating or removing binding sites for chromatin-
associated proteins. Therefore, the newly described lysine ADP-ribosylation could thus 
represent a novel letter in the complex language of histone modifications and extent the 
number of different PTM combinations. 
 
4.6 Histone ADP-ribosylation as a stable mark? 
In general, poly(ADP-ribosyl)ation is a transient and reversible process. Poly(ADP-ribose) is 
degraded by the nuclear PARG enzyme, as well as by the cytoplasmic ARH family of ADP-ribose 
protein hydrolases (112, 114, 177). From the nature of the chemical linkage, on would have to 
assume that lysine-(ADP-ribosyl)ation is not removed by the known ADP-ribose hydrolyzing 
enzymes. Therefore it will be important to analyse PAR degrading enzymes in regard to their 
ability to degrade poly(ADP-ribosyl)ated histone tails. It will be important to distinguish, 
whether ADP-ribosylation of lysines is fully reversible, or remains as stable mark. A stable 
histone tail mark, which could only be removed by replacing the affected histone with a non-
marked histone, could be part of a chromatin memory and may function as epigenetic 
mechanism.  
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4.7 Readers of poly(ADP-ribose) 
Posttranslational histone modifications are often recognized by histone-binding modules 
(effectors). For example, chromodomain, tudor-domain, plant homeodomain (PHD), 
malignant brain tumor motif (MBT) as well as ankyrin repeats recognize methylated lysine 
and arginine residues (16). Acetylation marks, in contrast, are read by bromodomains, and 
phosphorylation is recognized by a domain within 14-3-3 proteins (15). PARP1-generated 
poly(ADP-ribose) was already described to be recognized by at least three different protein 
motifs, basic PAR binding motif (143), a PAR binding zinc fingers (178), and by 
macrodomains (179). Interestingly, macroH2A was shown to be recruited to sites of DNA-
damage, where it interacted with poly(ADP-ribose) (147). The chromatin remodeler Alc1 
contains a macro-domain that bound to poly(ADP-ribosyl)ated PARP1 upon DNA-damage 
(180, 181). Interaction of Alc1 with poly(ADP-ribosyl)ated PARP1 activated the ATPase 
activity of Alc1 and promoted chromatin remodeling. The activity of Alc1 is dependent on 
the basic H4K16-K20 batch (180). Thus one can speculate that the ATPase activity of Alc1 
could be additionally regulated by the presence of ADP-ribosylated H4K16. However, 
whether Alc1 or other proteins, which harbour these PAR sensing domains would be 
recruited in vivo to poly(ADP-ribosyl)ated histones, was not yet tested. 
  
4.8 PARP1 and Histone H4 
Histone H4 is heavily posttranslationally modified by acetylation and methylation (15). For 
example, H4K16 is acetylated by Tip60 and by ScSAS2 (SpMST2) (15). Deacetylation of 
H4K16 is regulated by SIRT2 (182). Whether ADP-ribosylation of histones is co-inciding or 
mutually exclusive with other histone modifications is yet not clear. Some reports found 
that poly(ADP-ribosylation) of histone H4 co-incided with acetylated H4 (183, 184). 
However, we observed that acetylation of H4K16 inhibited ADP-ribosylation by PARP1 in 
vitro. Therefore, direct competition of ADP-ribosylation with acetylation for the same lysine 
residue might be also relevant in vivo. To further investigate this possibility, the generation 
of antibodies raised against ADP-ribosylated histones will certainly allow the analysis of 
histone ADP-ribosylation and the detection of putative crosstalks with other histone 
modifications in vivo. 
 One could imagine that ADP-ribosylation of H4K16 repels histone acetyl-
transferase complexes from H4K16 possibly by steric hindrance or by the highly negative 
charge of the ADP-ribose moiety. 
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The acetylation of H4K16 prevents the formation of the 30nm chromatin fiber and 
the generation of higher order chromatin structures by inhibiting internucleosomal contacts 
of the basic H4K16-K20 batch with the two acidic patches on the carboxy-terminal α-
helices of histone H2A (185). Moreover, the generation of higher order chromatin 
structures could be affected by ADP-ribosylated H4K16. Acetylation of H4K16 is often 
described as switch, altering chromatin topology but also repelling various non-histone 
modulators. For example, the ISWI-containing ATP-dependent chromatin remodeller ACF 
contributes to high-order chromatin folding by regularly spacing nucleosomes. But solely 
histones in the absence of histone H4K16 acetylation are remodelled by ACF (186). 
Therefore, it could be expected that ADP-ribosylation of H4K16 inhibits binding of ACF and 
impedes chromatin remodeling. 
In regard of charge and structure of poly(ADP-ribose) one would expect that 
poly(ADP-ribosyl)ation of histone tails leads to decompaction of heterochromatin and/or 
prevent free histones from being integrated into nucleosomes. Both processes may be 
especially important during replication, where heterochromatin needs to be decondensed 
and new nucleosomes have to be incorporated into the chromatin. 
 
In summary, ADP-ribosylation of histones by PARP1 occurs as posttranslational 
modification at distinct lysine residues. The implications for processes such as nucleosome 
formation, regulation of higher order chromatin structure, histone degradation, histone 
shuttling and epigenetics remain to be determined.  
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